Early intervention methods to prevent or ameliorate toxicity

Preemptive administration of toxicity targeting agents in immunotherapy and cell therapy mitigates severe CRS and neurotoxicity, ensuring therapy efficacy and reduced toxic outcomes.

JP2024156736AActive Publication Date: 2024-11-06SEATTLE CHILDRENS HOSPITAL (DBA SEATTLE CHILDRENS RES INST)
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2024118592
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2016-12-02
Filing Date
2024-07-24
Publication Date
2024-11-06
Estimated Expiration
2037-03-22

AI Technical Summary

Technical Problem

Existing immunotherapy and cell therapy methods face challenges in managing toxicity, particularly cytokine release syndrome (CRS) and neurotoxicity, which can be severe and life-threatening, often requiring high-dose interventions that may compromise therapy efficacy.

Method used

Administering a toxicity targeting agent preemptively, typically within 24 hours of mild symptoms or fever, to prevent the onset of severe CRS or neurotoxicity, thereby maintaining therapy efficacy and reducing the risk of severe toxic outcomes.

Benefits of technology

The preemptive approach significantly reduces the incidence and severity of CRS and neurotoxicity, allowing for sustained therapy efficacy and prolonged persistence of administered cells, with a lower dosage and frequency of interventions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024156736000010
    Figure 2024156736000010
  • Figure 2024156736000011
    Figure 2024156736000011
  • Figure 2024156736000012
    Figure 2024156736000012
Patent Text Reader

Abstract

To provide a medicine for preventing or ameliorating toxicity caused by or due to a therapy, such as an immunotherapy or a cell therapy, by pre-emptive or early administration of a toxicity-targeting agent.SOLUTION: The present invention provides a medicine for treating, preventing, delaying, or attenuating the development of a toxicity in a subject who has received adoptive cell therapy (ACT), where the medicine includes a monoclonal antibody or its antigen-binding fragment capable of binding to the IL-6 receptor or IL-6, and the medicine is administered to the subject within 24 hours after the first sign of a fever following the ACT administration.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Application No. 62 / 311,906, filed March 22, 2016, entitled "Early Intervention Methods to Prevent or Ameliorate Toxicity," U.S. Provisional Application No. 62 / 417,287, filed November 3, 2016, entitled "Early Intervention Methods to Prevent or Ameliorate Toxicity," and U.S. Provisional Application No. 62 / 429,722, filed December 2, 2016, entitled "Early Intervention Methods to Prevent or Ameliorate Toxicity," the contents of each of which are incorporated by reference in their entirety.

[0002] INCORPORATION BY REFERENCE This application is filed with a sequence listing in electronic format. The sequence listing is provided in a file named 735042005140seqlist.txt, created on March 22, 2017, which is 17.6 kilobytes in size. The information in the electronic format of the sequence listing is incorporated by reference in its entirety.

[0003] Field The present disclosure relates to a method for preventing or improving toxicity caused by or resulting from therapy, such as immunotherapy or cell therapy, by preemptive or early administration of toxic targeting agent.In some embodiments, the therapy is cell therapy, and cells generally express recombinant receptors, such as chimeric receptors, such as chimeric antigen receptors (CAR), or other transgenic receptors, such as T cell receptors (TCR).The features of the present method, including the timing of administration of active substances or treatments against toxicity, provide various advantages, such as lower toxicity while maintaining the persistence and efficacy of administered cells. [Background technology]

[0004] background A variety of immunotherapy and / or cell therapy methods are available for treating disease and condition.Improved methods are needed, for example, to reduce the risk of toxicity of such methods.Improved methods are needed, for example, to reduce the risk of toxicity to cell therapy, while maintaining the subject's exposure to administered cells by proliferation and / or persistence of administered cells.Provide methods and uses that meet such needs. Summary of the Invention

[0005] overview In some aspects, a method of treatment is provided, comprising administering to a subject an active agent or other treatment that can treat, prevent, delay, or reduce the occurrence of toxicity. In some cases, at the time of administration, the subject has previously been administered a therapy, such as a therapy including immunotherapy and / or cell therapy. In some embodiments, administration of the active agent or other treatment is less than or equal to 10, 7, 6, 5, 4, or 3 days after the start of administration of the therapy. In some embodiments, administration of the active agent or other treatment is when the subject does not show signs or symptoms of severe cytokine release syndrome (CRS) and / or does not show CRS of grade 2 or higher. In some embodiments, administration of the active agent or other treatment is when the subject does not show signs or symptoms of severe neurotoxicity and / or does not show neurotoxicity of grade 2 or higher. In some aspects, between the start of administration of the therapy and the time of administration of the active agent or other treatment, the subject does not show severe CRS and / or does not show CRS of grade 2 or higher. In some cases, between the start of administration of the cell therapy and the administration of the active agent or other treatment, the subject does not experience severe neurotoxicity and / or does not experience grade 2 or higher neurotoxicity.

[0006] In some embodiments, a method of treatment is provided that includes administering an active agent or other treatment to a subject to which a therapy, such as immunotherapy and / or cell therapy, has been administered, which can treat, prevent, delay, or reduce the occurrence of toxicity. In some cases, the administration of the active agent or other treatment is less than or equal to 10, 7, 6, 5, 4, or 3 days after the start of administration of the therapy. In some embodiments, the administration of the active agent or other treatment is when the subject does not show signs or symptoms of severe cytokine release syndrome (CRS) and / or does not show CRS of grade 2 or higher. In some aspects, between the start of administration of the cell therapy and the time of administration of the active agent or other treatment, the subject does not show CRS of severe and / or does not show CRS of grade 2 or higher. In some embodiments, the administration of the active agent or other treatment is when the subject does not show signs or symptoms of severe neurotoxicity and / or does not show neurotoxicity of grade 2 or higher. In some aspects, between the start of administration of the cell therapy and the time of administration of the active agent or other treatment, the subject does not exhibit severe neurotoxicity and / or does not exhibit grade 2 or higher neurotoxicity.

[0007] In some aspects, a method of treatment is provided, comprising administering immunotherapy or cell therapy to a subject with a disease or condition. In some cases, the method involves administering to the subject an active agent or other treatment that can treat, prevent, delay, or reduce the occurrence of toxicity. In some cases, the administration of the active agent or other treatment is less than or equal to 10, 7, 6, 5, 4, or 3 days after the start of administration of the therapy. In some embodiments, the administration of the active agent or other treatment is when the subject does not show signs or symptoms of severe cytokine release syndrome (CRS) and / or does not show CRS of grade 2 or higher. In some embodiments, between the start of administration of the therapy and the time of administration of the active agent or other treatment, the subject does not show CRS of severe and / or does not show CRS of grade 2 or higher. In some aspects, the administration of the active agent or other treatment is when the subject does not show signs or symptoms of severe neurotoxicity and / or does not show neurotoxicity of grade 2 or higher. In some cases, between the start of administration of the therapy and the administration of the active agent or other treatment, the subject does not exhibit severe neurotoxicity and / or does not exhibit neurotoxicity of grade 2 or higher. In some embodiments, the therapy includes a dose of cells expressing a recombinant receptor.

[0008] In some of any such embodiments, the active agent or other treatment is administered when the subject exhibits grade 1 CRS or within 24 hours after the subject exhibits the first sign or symptom of grade 1 CRS. In some cases, the active agent or other treatment is administered when the subject exhibits signs or symptoms of CRS and / or exhibits grade 1 CRS. In some cases, the active agent or other treatment is administered within 24 hours after the subject exhibits the first sign or symptom of grade 1 CRS following the initiation of administration of the therapy.

[0009] In some embodiments, a sign or symptom of Grade 1 CRS is fever. In some cases, the active agent or other treatment is administered within 24 hours after the first sign of fever following the initiation of administration of therapy.

[0010] In some aspects, a method of treatment is provided that includes administering to a subject previously administered a therapy, such as an immunotherapy and / or a cell therapy, an active agent or other treatment that can treat, prevent, delay, or reduce the onset of toxicity. In some cases, the active agent or other treatment is administered within 24 hours of the first symptom of fever following the start of administration of the therapy.

[0011] In some embodiments, prior to administering the active agent or other treatment, the method comprises administering to the subject a therapy for treating the disease or condition.

[0012] In some embodiments, a method of treatment is provided, comprising administering immunotherapy and / or cell therapy to a subject with a disease or condition.In some cases, the method comprises administering to the subject an active agent or other treatment that can treat, prevent, delay, or reduce the occurrence of toxicity to the administered immunotherapy and / or cell therapy within 24 hours after the first symptom of fever following the start of administration of the therapy.In some aspects, the active agent or other treatment is administered within about 16 hours, within about 12 hours, within about 8 hours, within about 2 hours, or within about 1 hour after the first symptom of fever following the start of administration of the therapy.

[0013] In some embodiments, the fever is a persistent fever. In some cases, the fever does not decrease or does not decrease by more than 1° C. after treatment with an antipyretic. In some aspects, the fever is a fever that does not decrease or does not decrease by more than 1° C. after treatment with an antipyretic. In some cases, the fever does not decrease by more than 1° C. following treatment of the subject with an antipyretic.

[0014] In some embodiments, heat includes a temperature of at least 38.0° C. or at least about 38.0° C. In some aspects, heat includes a temperature of 38.0° C. to 42.0° C., 38.0° C. to 39.0° C., 39.0° C. to 40.0° C., or 40.0° C. to 42.0° C., or about 38.0° C. to 42.0° C., about 38.0° C. to 39.0° C., about 39.0° C. to 40.0° C., or about 40.0° C. to 42.0° C., inclusive. In some embodiments, heat includes temperatures greater than or equal to about 38.5°C, 39.0°C, 39.5°C, 40.0°C, 41.0°C, 42.0°C, or greater than or equal to about 38.5°C, 39.0°C, 39.5°C, 40.0°C, 41.0°C, 42.0°C.

[0015] In some embodiments, the active agent or other treatment is administered less than 5 days after initiation of administration of therapy, less than 4 days after initiation of administration of therapy, or less than 3 days after initiation of administration of therapy.

[0016] In some embodiments, the therapy is or comprises cell therapy.In some cases, the cell therapy is or comprises adoptive cell therapy.In some aspects, the therapy is or comprises tumor infiltrating lymphocyte (TIL) therapy, transgenic TCR therapy, or recombinant receptor expressing cell therapy, and the therapy is optionally T cell therapy.In some embodiments, the therapy is chimeric antigen receptor (CAR) expressing T cell therapy.

[0017] In some cases, the active agent or other treatment is or includes a steroid or an antagonist or inhibitor of a cytokine receptor or cytokine selected from among IL-10, IL-10R, IL-6, IL-6 receptor, IFNγ, IFNGR, IL-2, IL-2R / CD25, MCP-1, CCR2, CCR4, MIP1β, CCR5, TNFα, TNFR1, IL-1, and IL-1Rα / IL-1β.

[0018] In some aspects, the antagonist or inhibitor is or comprises an active agent selected from among antibodies or antigen-binding fragments, small molecules, proteins or peptides, and nucleic acids. In some cases, the active agent or other treatment is or comprises an active agent selected from among tocilizumab, situximab, sarilumab, olokizumab (CDP6038), elcilimomab, ALD518 / BMS-945429, sirukumab (CNTO 136), CPSI-2634, ARGX-109, FE301, and FM101.

[0019] In some embodiments, the active agent or other treatment is or includes tocilizumab. In some such embodiments, tocilizumab is administered at a dosage of 1 mg / kg to 10 mg / kg, 2 mg / kg to 8 mg / kg, 2 mg / kg to 6 mg / kg, 2 mg / kg to 4 mg / kg, or 6 mg / kg to 8 mg / kg, or about 1 mg / kg to 10 mg / kg, about 2 mg / kg to 8 mg / kg, about 2 mg / kg to 6 mg / kg, about 2 mg / kg to 4 mg / kg, or about 6 mg / kg to 8 mg / kg, inclusive, or tocilizumab is administered at a dosage of at least 2 mg / kg, at least 4 mg / kg, at least 6 mg / kg, or at least 8 mg / kg, or at least about 2 mg / kg, at least about 4 mg / kg, at least about 6 mg / kg, or at least about 8 mg / kg, or about 2 mg / kg, about 4 mg / kg, about 6 mg / kg, or about 8 mg / kg.

[0020] In some aspects, the method further comprises administering a steroid to the subject. In some such aspects, the steroid is administered within 7, 8, or 9 days after administration of the therapy. In some cases, the steroid is administered within 24 hours after the first sign of hypotension following administration of the therapy. In some cases, the steroid is administered when the subject exhibits grade 2 cytokine release syndrome (CRS) following administration of the therapy, or within 24 hours after the subject exhibits the first sign of grade 2 CRS following administration of the therapy. In some embodiments, the steroid is administered when the subject exhibits grade 2 neurotoxicity following administration of the therapy, or within 24 hours after the subject exhibits the first sign or symptom of grade 2 neurotoxicity following administration of the therapy.

[0021] In some embodiments, a method of treatment is provided that includes administering steroids to a subject who has been administered a therapy, such as immunotherapy and / or cell therapy. In some embodiments, administration of steroids is initiated within 7, 8, or 9 days after the start of administration of therapy. In some embodiments, administration of steroids is initiated within 24 hours after the first sign of hypotension following the start of administration of therapy. In some embodiments, administration of steroids is initiated when the subject shows grade 2 cytokine release syndrome (CRS) following the start of administration of therapy, or within 24 hours after the subject shows the first sign of grade 2 CRS following the start of administration of therapy. In some embodiments, administration of steroids is initiated when the subject shows grade 2 neurotoxicity following the start of administration of therapy, or within 24 hours after the subject shows the first sign or symptom of grade 2 neurotoxicity following the start of administration of therapy.

[0022] In some cases, prior to administering the steroid, the method includes administering to the subject a therapy for treating the disease or condition.

[0023] In some aspects, a method of treatment is provided that includes administering a therapy, such as an immunotherapy and / or a cell therapy, to a subject with a disease or condition. In some cases, the method further involves administering a steroid to the subject. In some aspects, administration of the steroid is initiated within 7, 8, or 9 days after the start of administration of the therapy. In some aspects, administration of the steroid is initiated within 24 hours after the first sign of hypotension following the start of administration of the therapy. In some aspects, administration of the steroid is initiated when the subject shows cytokine release syndrome (CRS) of grade 2 or higher following the start of administration of the therapy, or within 24 hours after the subject shows the first sign of CRS of grade 2 or higher following the start of administration of the therapy. In some aspects, administration of the steroid is initiated when the subject shows neurotoxicity of grade 2 or higher following the start of administration of the therapy, or within 24 hours after the subject shows the first sign or symptom of neurotoxicity of grade 2 or higher following the start of administration of the therapy.

[0024] In some embodiments, upon administration of the steroid, the subject does not exhibit severe CRS, does not exhibit CRS of grade 3 or higher, or does not exhibit severe neurotoxicity or does not exhibit neurotoxicity of grade 3 or higher.

[0025] In some aspects, the steroid is administered within 24 hours after or at the first sign of hypotension following the initiation of administration of therapy. In some cases, the steroid is administered at the same time as the initiation of vasopressor therapy. In some cases, hypotension comprises a systolic blood pressure of less than or about 90 mm Hg, 80 mm Hg, or 70 mm Hg. In some cases, hypotension comprises a diastolic blood pressure of less than 60 mm Hg, 50 mm Hg, or 40 mm Hg.

[0026] In some embodiments, the active agent is or comprises a steroid, including or is a corticosteroid. In some aspects, the active agent is a steroid, including or is a glucocorticoid. In some cases, the corticosteroid is or comprises dexamethasone or prednisone. In some cases, the steroid is administered intravenously or orally.

[0027] In some cases, the steroid is administered at an equivalent dosage of 1.0 mg to 20 mg dexamethasone per day, 1.0 mg to 10 mg dexamethasone per day, or 2.0 mg to 6.0 mg dexamethasone per day, or about 1.0 mg to 20 mg dexamethasone per day, about 1.0 mg to 10 mg dexamethasone per day, or about 2.0 mg to 6.0 mg dexamethasone per day, inclusive.

[0028] In some embodiments, before administering the steroid, the method includes administering an active agent or other treatment that can treat, prevent, delay, or reduce the occurrence of toxicity. In some aspects, the active agent or other treatment is administered less than or equal to 10, 7, 6, 5, 4, or 3 days after the start of administration of the therapy. In some aspects, the active agent or other treatment is administered when the subject does not show signs or symptoms of severe cytokine release syndrome (CRS) and / or does not show CRS of grade 2 or higher. In some aspects, between the start of administration of the therapy and the time of administration of the active agent or other treatment, the subject does not show CRS of severe and / or does not show CRS of grade 2 or higher. In some aspects, the active agent or other treatment is administered when the subject does not show signs or symptoms of severe neurotoxicity and / or does not show neurotoxicity of grade 2 or higher. In some embodiments, between the start of administration of the therapy and the time of administration of the active agent or other treatment, the subject does not show neurotoxicity of severe and / or does not show neurotoxicity of grade 2 or higher.

[0029] In some embodiments, the therapy includes a dose of cells expressing the recombinant receptor.

[0030] In some aspects, the active agent or other treatment is administered when the subject shows grade 1 CRS or within 24 hours after the subject shows the first sign or symptom of grade 1 CRS. In some embodiments, the sign or symptom of grade 1 CRS is fever. In some embodiments, the first sign or symptom of CRS is fever. In some cases, the active agent or other treatment is administered within 24 hours after the first sign of fever following the start of administration of therapy.

[0031] In some aspects, prior to administering the steroid, the method includes administering an active agent or other treatment that can treat, prevent, delay, or reduce the onset of toxicity. In some cases, the active agent or other treatment is administered within 24 hours after the first symptom of fever following the start of administration of the therapy. In some aspects, the active agent or other treatment is administered within about 16 hours, about 12 hours, about 8 hours, about 2 hours, or about 1 hour after the first symptom of fever following the start of administration of the therapy.

[0032] In some embodiments, the fever is a persistent fever. In some cases, the fever does not decrease or does not decrease by more than 1° C. after treatment with an antipyretic. In some embodiments, the fever is a fever that does not decrease or does not decrease by more than 1° C. after treatment with an antipyretic. In some cases, the fever does not decrease by more than 1° C. following treatment of the subject with an antipyretic.

[0033] In some cases, the heat includes a temperature of at least 38.0° C. or at least about 38.0° C. In some embodiments, the heat includes a temperature of 38.0° C. to 42.0° C., 38.0° C. to 39.0° C., 39.0° C. to 40.0° C., or 40.0° C. to 42.0° C., or about 38.0° C. to 42.0° C., about 38.0° C. to 39.0° C., about 39.0° C. to 40.0° C., or about 40.0° C. to 42.0° C., inclusive. In some aspects, heat includes temperatures greater than or equal to about 38.5°C, 39.0°C, 39.5°C, 40.0°C, 41.0°C, 42.0°C.

[0034] In some embodiments, the active agent or other treatment is administered less than 5 days after initiation of administration of therapy, less than 4 days after initiation of administration of therapy, or less than 3 days after initiation of administration of therapy.

[0035] In any of the above embodiments, the therapy is or comprises cell therapy.In some embodiments, the cell therapy is or comprises adoptive cell therapy.In some cases, the therapy is or comprises tumor infiltrating lymphocyte (TIL) therapy, transgenic TCR therapy, or recombinant receptor expressing cell therapy, and the therapy is optionally T cell therapy.In some embodiments, the therapy is or comprises chimeric antigen receptor (CAR) expressing cell therapy.

[0036] In some embodiments, the active agent or other treatment is or comprises an antagonist or inhibitor of a cytokine receptor or cytokine selected from among IL-10, IL-10R, IL-6, IL-6 receptor, IFNγ, IFNGR, IL-2, IL-2R / CD25, MCP-1, CCR2, CCR4, MIP1β, CCR5, TNFα, TNFR1, IL-1, and IL-1Rα / IL-1β. In some embodiments, the antagonist or inhibitor is or comprises an active agent selected from among an antibody or antigen-binding fragment, a small molecule, a protein or peptide, and a nucleic acid.

[0037] In some cases, the active agent or other treatment is or includes an active agent selected from among tocilizumab, cituximab, sarilumab, olokizumab (CDP6038), ersilimomab, ALD518 / BMS-945429, sirukumab (CNTO 136), CPSI-2634, ARGX-109, FE301, and FM101.

[0038] In some aspects, the active agent or other treatment is or includes tocilizumab. In some embodiments, tocilizumab is administered at a dosage of 1 mg / kg to 10 mg / kg, 2 mg / kg to 8 mg / kg, 2 mg / kg to 6 mg / kg, 2 mg / kg to 4 mg / kg, or 6 mg / kg to 8 mg / kg, or about 1 mg / kg to 10 mg / kg, about 2 mg / kg to 8 mg / kg, about 2 mg / kg to 6 mg / kg, about 2 mg / kg to 4 mg / kg, or about 6 mg / kg to 8 mg / kg, inclusive, or tocilizumab is administered at a dosage of at least 2 mg / kg, at least 4 mg / kg, at least 6 mg / kg, or at least 8 mg / kg, or at least about 2 mg / kg, at least about 4 mg / kg, at least about 6 mg / kg, or at least about 8 mg / kg, or about 2 mg / kg, about 4 mg / kg, about 6 mg / kg, or about 8 mg / kg.

[0039] In any of the above embodiments, the therapy is or includes cell therapy, and the number of cells administered is about 0.25 x 10 6 Cells / kg (subject weight) ~5 x 10 6 cells / kg, 0.5 x 10 6 Cells / kg (subject weight) ~3 x 10 6 cells / kg, approximately 0.75 x 10 6 cells / kg~2.5 x 10 6 cells / kg or approximately 1 x 10 6 cells / kg~2 x 10 6 Cells / kg (all values ​​included).

[0040] In some embodiments, the therapy is or comprises cell therapy, and the cells are administered in a single pharmaceutical composition that contains the cells.In some cases, the therapy is or comprises cell therapy, and the dose of cells is a split dose, and the dose of cells is administered in multiple compositions that contain the dose of cells in total over a period of 3 days or less.

[0041] In some embodiments, the disease or condition is or includes a tumor or cancer. In some cases, the disease or condition is or includes a leukemia or lymphoma. In some embodiments, the disease or condition is a B-cell malignancy or a hematological disease or condition. In some aspects, the disease or condition is or includes non-Hodgkin's lymphoma (NHL) or acute lymphoblastic leukemia (ALL).

[0042] In some embodiments, the therapy is a cell therapy comprising a dose of cells expressing a recombinant receptor. In some aspects, the recombinant receptor binds to, recognizes, or targets an antigen associated with a disease or condition. In some cases, the recombinant receptor is a T cell receptor or a functional non-T cell receptor. In some cases, the recombinant receptor is a chimeric antigen receptor (CAR).

[0043] In some embodiments, the CAR contains an extracellular antigen recognition domain that specifically binds to an antigen, and an intracellular signaling domain that contains ITAM. In some cases, the antigen is CD19. In some embodiments, the intracellular signaling domain comprises the intracellular domain of CD3 zeta (CD3ζ) chain. In some embodiments, the CAR further contains a costimulatory signaling region. In some aspects, the costimulatory signaling domain contains the signaling domain of CD28 or 4-1BB.

[0044] In some embodiments, the therapy is or includes a therapy that contains a dose of cells that contain T cells. In some cases, the T cells are CD4+ or CD8+. In some embodiments, the T cells are autologous to the subject.

[0045] In some embodiments, the method further comprises administering a chemotherapeutic agent prior to administering the therapy. In some cases, the subject is pre-treated with a chemotherapeutic agent prior to the initiation of administration of the therapy. In some aspects, the chemotherapeutic agent comprises an active agent selected from the group consisting of cyclophosphamide, fludarabine, and / or combinations thereof. In some embodiments, the chemotherapeutic agent is administered 2-5 days prior to the initiation of administration of the therapy. In some cases, the chemotherapeutic agent is administered 1 min after the subject is pre-treated with a chemotherapeutic agent. 2 1g per unit or approx. 1g to 1m 2 The dosage is at or about 3 g per dose.

[0046] In some embodiments, toxicity is neurotoxicity.In some embodiments, the CNS-related outcome in subject at the 7th, 8th, 9th, 10th, 11th, 12th, 13th, 14th, 15th, 16th, 17th, 18th, 19th, 20th, 21st, 22nd, 23rd, 24th, 25th, 26th, 27th, 28th, 29th or 30th day or at the 7th, 8th, 9th, 10th, 11th, 12th, 13th, 14th, 15th, 16th, 17th, 18th, 19th, 20th, 21st, 22nd, 23rd, 24th, 25th, 26th, 27th, 28th, 29th or 30th day following administration of therapy is not detectable or is reduced when compared with the method comprising alternative treatment regimen, in which active substance or other treatment is administered to subject after the onset of severe CRS or neurotoxicity or after the onset of grade 2 or higher CRS or neurotoxicity. In some embodiments, the toxicity outcome is a symptom associated with grade 3 or higher neurotoxicity or a symptom associated with grade 2 or higher CRS. In some embodiments, the toxicity outcome is reduced by more than 50%, 60%, 70%, 80%, 90%, or more. In some cases, the toxicity outcome is a symptom associated with grade 3 or higher neurotoxicity. In some embodiments, the toxicity outcome is selected from among grade 3 or higher neurotoxicity, including confusion, delirium, expressive aphasia, obtundation, myoclonus, lethargy, mental status changes, convulsions, seizure-like activity, and seizures.

[0047] In some aspects, the therapy is a therapy in which the cells exhibit increased or longer proliferation and / or persistence in the subject compared to cells administered in a method that includes an alternative treatment regimen in which an active agent or other treatment is administered to the subject after the onset of severe CRS or neurotoxicity or after the onset of Grade 2 or higher CRS or neurotoxicity. In some cases, proliferation and / or persistence is increased by 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or 10-fold.

[0048] In some embodiments, the toxicity outcome is Grade 3 or greater CRS, including one or more symptoms selected from the following: persistent fever above or above 38°C for at least three consecutive days; hypotension requiring high doses of vasopressors or multiple vasopressors; hypoxia, optionally including, for example, a plasma oxygen (PO2) level of less than or about 90%; and respiratory failure requiring mechanical ventilation. In some embodiments, the therapy is a cell therapy comprising administration of cells, and the cells exhibit increased or prolonged proliferation and / or persistence in the subject compared to administration of the cell therapy using an alternative treatment regimen (in the subject or in a corresponding subject in an alternative cohort or treatment group), the alternative treatment regimen comprising administering the cell therapy and then administering an active agent or other treatment after the onset of severe CRS or after the onset of grade 2 or higher CRS, and optionally, the subject in the alternative treatment regimen is not administered the active agent, and optionally is not administered any other treatment designed to treat CRS or neurotoxicity after administration of the cells and prior to the onset of grade 2 or higher CRS or severe CRS. In some embodiments, the increase or prolongation of proliferation and / or persistence is 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or 10-fold.

[0049] In some embodiments, the therapy is a cell therapy comprising administration of cells, and the cells show increased or prolonged proliferation and / or persistence in the subject compared to administration of the cell therapy using an alternative treatment regimen (in the subject or in the corresponding subject in an alternative cohort or treatment group).In some cases, the alternative treatment regimen comprises administering cell therapy, and then administering an active agent or other treatment after the onset of severe CRS or neurotoxicity or after the onset of grade 2 or higher CRS or neurotoxicity.In some cases, the subject in the alternative treatment regimen is not administered the active agent.In some cases, the subject in the alternative treatment regimen is not administered any other treatment designed to treat CRS or neurotoxicity after administration of cells and before the onset of grade 2 or higher CRS or severe CRS or grade 2 or higher neurotoxicity or severe neurotoxicity.

[0050] In some embodiments, the increase or prolongation of proliferation and / or persistence is 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or 10-fold.

[0051] In some embodiments, the cells show the same or similar proliferation and / or persistence in the subject compared to the cells administered in the method comprising an alternative treatment regimen, in which the subject is administered a cell therapy, but in the absence of active substances or other treatments.In some embodiments, the proliferation and / or persistence is at most 2-fold lower or reduced compared to the method comprising an alternative treatment regimen, in which the subject is administered a cell therapy, but in the absence of active substances or other treatments.

[0052] In some embodiments, the therapy is a cell therapy comprising engineered cells and / or CAR-expressing cells. In some cases, the concentration or number of engineered cells and / or CAR-expressing cells in the subject's blood on the 30th, 60th, or 90th day following the start of administration of the therapy is at least 10 or at least about 10 engineered or CAR-expressing cells per microliter, at least 50% of the total number of peripheral blood mononuclear cells (PBMCs), at least 1 x 10 5 or at least about 1 x 10 5 In some embodiments, the CAR-expressing and / or engineered cells are detectable in the subject's blood or serum at 30, 60, or 90 days following initiation of administration of the therapy. In some cases, the subject's blood contains at least 20% CAR-expressing cells, at least 10 CAR-expressing cells per microliter, or at least 1 x 10 4 In some cases, on the 30th, 60th, or 90th day following initiation of administration of the therapy, the subject's blood contains at least 50%, 60%, 70%, 80%, or 90% of the biologically effective dose of cells. In some embodiments, on the 30th, 60th, or 90th day following initiation of administration of the therapy, the subject's blood contains at least 20% engineered cells and / or CAR-expressing cells, at least 10 engineered cells and / or CAR-expressing cells per microliter, and / or at least 1 x 10 4The subject is administered a therapeutic agent that contains a number of engineered cells and / or CAR-expressing cells. In some cases, at the 30th, 60th, or 90th day following the start of administration of the therapy, the subject shows a reduction or continued reduction in the burden of the disease or condition. In some cases, the reduction or continued reduction in the burden of the disease or condition is a 50, 60, 70, or 80% peak reduction or about 50, about 60, about 70, or about 80% peak reduction or at least 50, at least 60, at least 70, or at least 80% peak reduction or at least about 50, at least about 60, at least about 70, or at least about 80% peak reduction following administration of the therapy, or a reduction associated with an effective dose.

[0053] In some embodiments, at the 30th, 60th, or 90th day following initiation of administration of the therapy, the subject does not exhibit and / or does not exhibit severe neurotoxicity, severe CRS, CRS of Grade 2 or higher, neurotoxicity of Grade 2 or higher following cell therapy treatment, and / or does not exhibit seizures or other CNS outcomes; or, at the 30th, 60th, or 90th day following initiation of administration of the therapy, less than or about 25%, less than or about 20%, less than or about 15%, or less than or about 10% of the subjects so treated do not exhibit and / or do not exhibit severe neurotoxicity, severe CRS, CRS of Grade 2 or higher, neurotoxicity of Grade 2 or higher following cell therapy treatment, and / or does not exhibit seizures or other CNS outcomes.

[0054] In some embodiments, the therapy is a cell therapy comprising engineered cells and / or CAR-expressing cells; and the area under the curve (AUC) of blood concentrations of the engineered cells and / or CAR-expressing cells over a period of time following administration of the therapy is greater than that obtained by a method comprising an alternative dosing regimen, e.g., in which the therapy is administered to a subject and an active agent or other treatment is administered when the subject exhibits severe or Grade 2 or greater or Grade 3 or greater CRS or neurotoxicity.

[0055] In some embodiments, the present invention further provides an active agent or other treatment for use in treating, preventing, delaying or reducing the occurrence of toxicity in a subject previously administered a therapy, including immunotherapy and / or cell therapy.In some embodiments, (a) the active agent or other treatment is administered to the subject: (i) less than or equal to 10, 7, 6, 5, 4, or 3 days after the start of administering a therapy to the subject; and / or (ii) the subject does not show signs or symptoms of severe cytokine release syndrome (CRS) and / or does not show CRS of grade 2 or higher; and / or (iii) the subject does not show signs or symptoms of severe neurotoxicity and / or does not show neurotoxicity of grade 2 or higher; and / or (b) between the start of administering a therapy to the subject and the administration of the active agent or other treatment, (i) the subject does not show CRS of severe and / or does not show CRS of grade 2 or higher, and / or (ii) the subject does not show neurotoxicity of severe and / or does not show neurotoxicity of grade 2 or higher.

[0056] In some embodiments, the active agent or other treatment is administered when the subject exhibits signs or symptoms of CRS and / or exhibits grade 1 CRS, or is administered within 24 hours after the subject exhibits the first sign or symptom of grade 1 CRS following administration of the therapy. In some embodiments, the sign or symptom of grade 1 CRS is fever; and / or the active agent or other treatment is administered within 24 hours after the first sign of fever following administration of the therapy.

[0057] In some embodiments, further provided is an active agent or other treatment for use in treating, preventing, delaying or reducing the onset of toxicity in a subject who has previously been administered a therapy, including immunotherapy and / or cell therapy, wherein the active agent or other treatment is administered within 24 hours of the first symptom of fever following administration of the therapy.

[0058] In some embodiments, the present invention further provides an active agent or other treatment for use as a medicine in treating, preventing, delaying or reducing the occurrence of toxicity in a subject previously administered a therapy, including immunotherapy and / or cell therapy.In some embodiments, (a) the active agent or other treatment is administered to the subject: (i) less than or equal to 10, 7, 6, 5, 4 or 3 days after the start of administering a therapy to the subject; and / or (ii) the subject does not show signs or symptoms of severe cytokine release syndrome (CRS) and / or does not show CRS of grade 2 or higher; and / or (iii) the subject does not show signs or symptoms of severe neurotoxicity and / or does not show neurotoxicity of grade 2 or higher; and / or (b) between the start of administering a therapy to the subject and the administration of the active agent or other treatment, (i) the subject does not show severe CRS and / or does not show CRS of grade 2 or higher, and / or (ii) the subject does not show severe neurotoxicity and / or does not show neurotoxicity of grade 2 or higher.

[0059] In some embodiments, the active agent or other treatment is administered when the subject exhibits signs or symptoms of CRS and / or exhibits grade 1 CRS, or is administered within 24 hours after the subject exhibits the first sign or symptom of grade 1 CRS following administration of the therapy. In some embodiments, the sign or symptom of grade 1 CRS is fever; and / or the active agent or other treatment is administered within 24 hours after the first sign of fever following administration of the therapy.

[0060] In some embodiments, there is further provided an active agent or other treatment for use as a pharmaceutical in treating, preventing, delaying, or reducing the onset of toxicity in a subject who has previously been administered a therapy, including immunotherapy and / or cell therapy, wherein the active agent or other treatment is administered within 24 hours of the first symptom of fever following administration of the therapy.

[0061] In some embodiments, the present invention further provides the use of an active substance or other treatment for the manufacture of a medicament for treating, preventing, delaying or reducing the occurrence of toxicity in a subject previously administered a therapy, including immunotherapy and / or cell therapy.In some embodiments, (a) the active substance or other treatment is administered to the subject: (i) less than or equal to 10, 7, 6, 5, 4 or 3 days after the start of administering a therapy to the subject; and / or (ii) the subject does not show signs or symptoms of severe cytokine release syndrome (CRS) and / or does not show CRS of grade 2 or higher; and / or (iii) the subject does not show signs or symptoms of severe neurotoxicity and / or does not show neurotoxicity of grade 2 or higher; and / or (b) between the start of administering a therapy to the subject and the administration of the active substance or other treatment, (i) the subject does not show severe CRS and / or does not show CRS of grade 2 or higher, and / or (ii) the subject does not show severe neurotoxicity and / or does not show neurotoxicity of grade 2 or higher. In some embodiments, the active agent or other treatment is administered when the subject exhibits signs or symptoms of CRS and / or exhibits grade 1 CRS, or is administered within 24 hours after the subject exhibits the first sign or symptom of grade 1 CRS following administration of the therapy. In some embodiments, the sign or symptom of grade 1 CRS is fever; and / or the active agent or other treatment is administered within 24 hours after the first sign of fever following administration of the therapy.

[0062] In some embodiments, there is further provided the use of an active agent or other treatment for the manufacture of a medicament for treating, preventing, delaying or reducing the onset of toxicity in a subject previously administered a therapy, including immunotherapy and / or cell therapy, wherein the active agent or other treatment is administered within 24 hours of the first symptom of fever following administration of the therapy.

[0063] In some embodiments of the active agents, other treatments, or uses thereof provided herein, the active agent or other treatment is administered within about 16 hours, within about 12 hours, within about 8 hours, within about 2 hours, or within about 1 hour after the first sign of fever following administration of the therapy.

[0064] In some embodiments, the fever is a persistent fever. In some embodiments, the fever is a fever that does not decrease or does not decrease by more than 1° C. following treatment with an antipyretic drug, and / or the fever has not decreased by more than 1° C. following treatment of the subject with an antipyretic drug. In some embodiments, the fever comprises a temperature of at least 38.0° C. or at least about 38.0° C. In some embodiments, the fever comprises a temperature of 38.0° C. to 42.0° C., 38.0° C. to 39.0° C., 39.0° C. to 40.0° C., or 40.0° C. to 42.0° C., or about 38.0° C. to 42.0° C., about 38.0° C. to 39.0° C., about 39.0° C. to 40.0° C., or about 40.0° C. to 42.0° C. (inclusive); or the fever comprises a temperature of 38.5° C., 39.0° C., 39.5° C., 40.0 ... This includes temperatures greater than 0.0°C, 41.0°C, 42.0°C or greater than about 38.5°C, about 39.0°C, about 39.5°C, about 40.0°C, about 41.0°C, about 42.0°C or greater than or equal to 38.5°C, 39.0°C, 39.5°C, 40.0°C, 41.0°C, 42.0°C or about 38.5°C, about 39.0°C, about 39.5°C, about 40.0°C, about 41.0°C, about 42.0°C.

[0065] In some embodiments, the active agent or other treatment is or comprises a steroid or an antagonist or inhibitor of a cytokine receptor or cytokine selected from among IL-10, IL-10R, IL-6, IL-6 receptor, IFNγ, IFNGR, IL-2, IL-2R / CD25, MCP-1, CCR2, CCR4, MIP1β, CCR5, TNFα, TNFR1, IL-1, and IL-1Rα / IL-1β. In some embodiments, the antagonist or inhibitor is or comprises an active agent selected from among an antibody or antigen-binding fragment, a small molecule, a protein or peptide, and a nucleic acid.

[0066] In some embodiments, the active agent or other treatment is or comprises an active agent selected from among tocilizumab, cituximab, sarilumab, olokizumab (CDP6038), ercilimomab, ALD518 / BMS-945429, sirukumab (CNTO 136), CPSI-2634, ARGX-109, FE301, and FM101. In some embodiments, the active agent or other treatment is or comprises tocilizumab. In some embodiments, tocilizumab is administered at a dosage of 1 mg / kg to 10 mg / kg, 2 mg / kg to 8 mg / kg, 2 mg / kg to 6 mg / kg, 2 mg / kg to 4 mg / kg, or 6 mg / kg to 8 mg / kg, or about 1 mg / kg to 10 mg / kg, about 2 mg / kg to 8 mg / kg, about 2 mg / kg to 6 mg / kg, about 2 mg / kg to 4 mg / kg, or about 6 mg / kg to 8 mg / kg, inclusive, or tocilizumab is administered at a dosage of at least 2 mg / kg, at least 4 mg / kg, at least 6 mg / kg, or at least 8 mg / kg, or at least about 2 mg / kg, at least about 4 mg / kg, at least about 6 mg / kg, or at least about 8 mg / kg, or about 2 mg / kg, about 4 mg / kg, about 6 mg / kg, or about 8 mg / kg.

[0067] In some embodiments, the active agent is or comprises a steroid, which is optionally a corticosteroid, which is optionally a glucocorticoid. In some embodiments, the corticosteroid is or comprises dexamethasone or prednisone. In some embodiments, the steroid is administered at an equivalent dosage of 1.0 mg to 20 mg dexamethasone / day, 1.0 mg to 10 mg dexamethasone / day, or 2.0 mg to 6.0 mg dexamethasone / day, or about 1.0 mg to 20 mg dexamethasone / day, about 1.0 mg to 10 mg dexamethasone / day, or about 2.0 mg to 6.0 mg dexamethasone / day, inclusive. In some embodiments, the steroid is formulated for intravenous or oral administration.

[0068] In some embodiments of the active substances, other treatments, or their uses provided herein, the therapy is or includes cell therapy. In some embodiments, the cell therapy is or includes adoptive cell therapy. In some embodiments, the therapy is or includes tumor infiltrating lymphocyte (TIL) therapy, transgenic TCR therapy, or recombinant receptor expressing cell therapy, and the therapy is optionally T cell therapy, and optionally chimeric antigen receptor (CAR) expressing cell therapy. In some embodiments, the therapy is cell therapy including a dose of cells expressing a recombinant receptor, and the recombinant receptor binds to, recognizes, or targets an antigen associated with a disease or condition; and / or the recombinant receptor is a T cell receptor or a functional non-T cell receptor; and / or the recombinant receptor is a chimeric antigen receptor (CAR).

[0069] In some embodiments, the CAR comprises an extracellular antigen recognition domain that specifically binds to an antigen, and an intracellular signaling domain that comprises an ITAM. In some embodiments, the antigen is CD19. In some embodiments, the intracellular signaling domain comprises the intracellular domain of the CD3 zeta (CD3ζ) chain. In some embodiments, the CAR further comprises a costimulatory signaling region. In some embodiments, the costimulatory signaling domain comprises the signaling domain of CD28 or 4-1BB.

[0070] In some embodiments, the therapy is cell therapy comprising a dose of cells comprising T cells. In some embodiments, the T cells are CD4+ or CD8+. In some embodiments, the T cells are autologous to the subject. In some embodiments, the disease or condition is tumor or cancer. In some embodiments, the disease or condition is leukemia or lymphoma. In some embodiments, the disease or condition is non-Hodgkin's lymphoma (NHL) or acute lymphoblastic leukemia (ALL).

[0071] In some embodiments, the subject is pre-treated with a chemotherapeutic agent prior to administration of the therapy. In some embodiments, the chemotherapeutic agent comprises an active agent selected from the group consisting of cyclophosphamide, fludarabine, and / or combinations thereof. [Brief description of the drawings]

[0072] [Figure 1A] Figure 1 shows the toxicity profile of an exemplary subject treated with CAR-expressing T cells. Figure 1A shows the toxicity profile of a subject who shows mild toxic side effects following treatment with CAR-expressing T cells, and no intervention is used for toxicity. The time frame of CNS toxicity is depicted. [Figure 1B]Figure 1B shows the toxicity profile of an exemplary subject treated with CAR-expressing T cells. Figure 1B shows the toxicity profile of a subject with severe side effects, and intervention methods are performed using tocilizumab (toci) when CRS symptoms are severe, hypertensive therapy when hypotension develops, and dexamethasone when following hypertensive therapy. The time frame in which CNS toxicity exists is depicted. [Figure 2A] Correlation of peak cytokine levels for IL-6 in subjects with (yes) and without (no) severe CRS at day 28 after CAR+ T cell infusion is shown. p-values ​​indicate statistically significant differences between subjects with and without severe CRS within the same cohort. [Figure 2B] Correlation of peak cytokine levels for IFN-γ in subjects with (yes) and without (no) severe CRS at day 28 after CAR+ T cell infusion is shown. p-values ​​indicate statistically significant differences between subjects with and without severe CRS within the same cohort. [Figure 2C] Correlation of peak cytokine levels for Granzyme B in subjects with (yes) and without (no) severe CRS at day 28 after CAR+ T cell infusion is shown. p-values ​​indicate statistically significant differences between subjects with and without severe CRS within the same cohort. [Figure 2D] Correlation of peak cytokine levels for IL-2 in subjects with (yes) and without (no) severe CRS at day 28 after CAR+ T cell infusion is shown. p-values ​​indicate statistically significant differences between subjects with and without severe CRS within the same cohort. [Diagram 3]Depicts the percentage of CAR+ T cells among total T cells in the blood of subjects at various days after infusion of CAR+ T cells after receiving intervention with dexamethasone (Dex), tocilizumab (toci) or prednisone + recombinant IL-1 receptor antagonist anakinra (pred+ anakinra) to treat severe toxicity. Depicts the onset of severe CRS (sCRS) and severe neurotoxicity (sNTox). Peak proliferation of CAR+ T cells was 454 cells / μL. Proliferation was not affected by administration of intervention therapy. [Figure 4] Figures 4A and 4B show the peak numbers of CAR T cells per microliter of peripheral blood in subjects with (yes) and without (no) severe CRS or severe neurotoxicity, respectively. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0073] Detailed Description Provided herein are methods involving early or preemptive treatment to prevent or ameliorate potential toxicity that may be associated with certain therapies when they are administered to a subject.

[0074] All publications, including patent documents, scientific literature, and databases, referred to in this application are incorporated by reference in their entirety for all purposes to the same extent as if each individual publication was individually incorporated by reference. To the extent that the definitions set forth herein differ or are otherwise inconsistent with those set forth in the patents, applications, published applications, and other publications incorporated herein by reference, the definitions set forth herein shall take precedence over the definitions incorporated herein by reference.

[0075] The section headings used herein are for organizational purposes only and should not be construed as limiting the subject matter described.

[0076] I. Preemptive intervention methods using toxic targeting agents Provided are methods involving administration of immunotherapy, such as cell therapy (e.g., CAR-T cell therapy), and administration of a toxic targeting agent for early intervention of or risk of developing toxicity to immunotherapy (e.g., toxicity that is or includes cytokine release syndrome (CRS) or neurotoxicity). In some embodiments, the methods involve administration of a toxic targeting agent when the signs or symptoms of cytokine release syndrome (CRS) resulting from immunotherapy, such as cell therapy, are relatively mild and / or not severe. In some embodiments, the methods allow treatment of a subject with a therapy for treating a disease or disorder, such as immunotherapy or cell therapy, which may otherwise cause moderate to severe CRS or neurotoxicity side effects in the subject. In the provided methods, early intervention or preemptive treatment with a toxic targeting agent prevents or improves the risk of moderate to severe CRS or neurotoxicity, while maintaining the efficacy of the therapy, such as the durability of the therapy, in the case of cell therapy.

[0077] In some embodiments, the subject has undergone or is undergoing therapy, such as immunotherapy or cell therapy, for example, to treat a disease or condition in the subject. For example, in some embodiments, the cell therapy is adoptive cell therapy, including therapy involving administration of cells expressing a chimeric receptor specific to the disease or disorder of interest, such as chimeric antigen receptor (CAR) and / or other recombinant antigen receptor, as well as other adoptive immune cell and adoptive T cell therapies. In some embodiments, the adoptive cell therapy involves administration of a dose of cells expressing a recombinant receptor, such as a CAR or other recombinant antigen receptor. In some embodiments, the chimeric receptor, such as a chimeric antigen receptor, contains one or more domains that combine a ligand binding domain (e.g., an antibody or antibody fragment) that provides specificity for a desired antigen (e.g., a tumor antigen) with an intracellular signaling domain. In some embodiments, the intracellular signaling domain is an activated intracellular domain portion, such as a T cell activation domain, that provides a primary activation signal. In some embodiments, the intracellular signaling domain contains or further contains a costimulatory signaling domain to promote effector function. In some embodiments, the chimeric receptor, when engineered into an immune cell, can modulate T cell activity, and in some cases, can modulate T cell differentiation or homeostasis, thereby resulting in engineered cells with improved longevity, survival and / or persistence in vivo, such as for use in adoptive cell therapy methods.

[0078] Adoptive cell therapy (including those involving the administration of cells expressing chimeric receptors specific for a disease or disorder of interest, such as chimeric antigen receptors (CARs) and / or other recombinant antigen receptors, as well as other adoptive immune cell and adoptive T cell therapies) can be effective in the treatment of cancer and other diseases and disorders. In some situations, the available approaches to adoptive cell therapy may not always be entirely satisfactory. In some circumstances, optimal efficacy may depend on the ability of the administered cells to recognize and bind to a target, e.g., a target antigen; migrate, localize and successfully enter the appropriate site in the subject, tumor and its environment; become activated, proliferate; exert various effector functions, including cytotoxic killing and secretion of various factors (e.g., cytokines); persist (including long-term); differentiate, transition or engage in reprogramming to certain phenotypic states (e.g., effector, long-lived memory, less differentiated, and effector states); provide an effective and robust recall response following clearance and re-exposure to the target ligand or antigen; and avoid or reduce exhaustion, anergy, terminal differentiation, and / or differentiation to suppressive states.

[0079] In some aspects, the embodiment provided is based on the observation that the efficacy of adoptive cell therapy may be limited by the occurrence of toxicity in the subject to which such cells are administered, and this toxicity may be severe in some cases.For example, in some cases, the administration of a dose of cells expressing recombinant receptors, such as CAR, may cause toxicity or the risk of such toxicity, such as CRS or neurotoxicity.In some cases, higher doses of such cells may increase the efficacy of treatment, for example, by increasing exposure to cells, for example, by promoting proliferation and / or persistence, while they may also cause even greater risk of developing toxicity or more severe toxicity.In some cases, subjects with higher disease burdens may also have a greater risk of developing toxicity or more severe toxicity.

[0080] Some available methods for treating or ameliorating toxicity may not always be completely satisfactory. Many such approaches focus on targeting downstream effects of toxicity, such as by cytokine blockade, and / or delivering active substances, such as high doses of steroids, which may also eliminate or impair the function of the administered cells. Furthermore, such approaches often involve administration of such interventions only upon detection of physical signs or symptoms of toxicity, which are generally accompanied by signs or symptoms of moderate or severe toxicity (e.g., moderate or severe CRS or moderate or severe neurotoxicity). For example, Figures 1A and 1B provide a comparison of toxicity profiles, where one subject (shown in Figure 1B) is in need of intervention and is administered such active substances when severe symptoms of CRS are present. Many of these other approaches also do not prevent other forms of toxicity, such as neurotoxicity, that may be associated with adoptive cell therapy.

[0081] In some cases, this is done when such symptoms are severe, which may therefore require even more severe or more extreme treatment (e.g., higher dosages or increased frequency of administration) to ameliorate or treat toxicity.

[0082] The use of certain alternative approaches does not provide a satisfactory solution to such problems. In some cases, such active substances and therapies (e.g., steroids) are themselves associated with toxic side effects. Such side effects may be even greater at higher doses or frequencies, making it necessary to administer or treat with active substances or therapies to treat or ameliorate the severity of toxicity that may result from cell therapy. Furthermore, in some cases, it is believed that active substances or therapies for treating toxicity may limit the efficacy of cell therapy, such as the efficacy of chimeric receptors (e.g., CARs) expressed on cells provided as part of cell therapy (Sentman (2013) Immunotherapy, 5:10).

[0083] The provided methods provide advantages over available approaches. In some embodiments, the provided methods involve early or preemptive treatment of subjects before the subject shows more than mild physical signs or symptoms of toxicity, for example, before the subject shows severe physical signs or symptoms of toxicity. In some embodiments, treatment occurs when mild physical signs or symptoms of CRS, such as grade 1 CRS, are present, but before moderate or severe CRS develops, or before grade 2 or grade 3 CRS develops. In some embodiments, treatment occurs when mild physical signs or symptoms of neurotoxicity, such as grade 1 neurotoxicity, are present, but before moderate or severe neurotoxicity develops, or before grade 2 or grade 3 neurotoxicity develops. In some embodiments, treatment with toxic targeting agents occurs when no physical signs or symptoms of neurotoxicity develop. Thus, in some cases, the provided methods provide the ability to intervene early before undesirable CNS-related outcomes can occur. In some cases, the ability to intervene early in treating a toxic outcome or the potential for a toxic outcome may mean being able to reduce the dosage of a toxicity targeting agent to treat or ameliorate the toxicity and / or being able to reduce the frequency of administration of such an active agent or therapy.

[0084] In some embodiments, the methods provided include administering a toxic targeting agent to a subject who has been administered a therapy, such as immunotherapy (immunotherapy) or cell therapy. In some embodiments, the toxic targeting agent is an active agent that can treat, prevent, delay, or reduce the occurrence of toxicity in a subject. Exemplary such toxic targeting agents are described below.

[0085] In some embodiments, the toxic targeting agent is administered (i) less than or equal to 10, 7, 6, 5, 4, or 3 days after the start of administration of therapy. In some embodiments, the toxic targeting agent is administered when the subject does not show signs or symptoms of severe cytokine release syndrome (CRS) and / or does not show CRS of grade 2 or higher. In some embodiments, between the start of administration of therapy (e.g., cell therapy) and the time of administration of the toxic targeting agent, the subject does not show CRS of severe and / or does not show CRS of grade 2 or higher. In some embodiments, the toxic targeting agent is administered when the subject does not show signs or symptoms of severe neurotoxicity and / or does not show neurotoxicity of grade 2 or higher. In some embodiments, between the start of administration of therapy (e.g., cell therapy) and the time of administration of the toxic targeting agent, the subject does not show CRS of severe neurotoxicity and / or does not show CRS of grade 2 or higher.

[0086] In some embodiments, the methods provided are designed to result in, or include features that result in, a lower degree of toxicity, toxic outcomes or symptoms, toxicity-promoting profiles, toxicity-promoting factors, or toxicity-promoting characteristics, e.g., symptoms or outcomes associated with or indicative of cytokine release syndrome (CRS) or neurotoxicity, e.g., compared to administration of a therapy in which an active agent or other treatment is administered to a subject after the onset of severe CRS or after the onset of grade 2 or higher CRS.

[0087] In some aspects, the toxic outcome of a therapy, such as a cell therapy, is, is associated with, or exhibits cytokine release syndrome (CRS) or severe CRS (sCRS). CRS, such as sCRS, can occur in some cases after adoptive T cell therapy and after other biological products are administered to a subject. Davila et al., Sci Transl. Med. 6, 224ra25 (2014); Brentjens et al., Sci. Transl. Med. 5, 177ra38 (2013); Grupp et al., N. Engl. J. Med. 368, 1509-1518 (2013); 2709-2720 (2012); see Xu et al., Cancer Letters 343 (2014) 172-78.

[0088] Typically, CRS is caused by an exacerbated systemic immune response mediated, for example, by T cells, B cells, NK cells, monocytes, and / or macrophages. Such cells can release a large amount of inflammatory mediators, for example, cytokines and chemokines. Cytokines can trigger acute inflammatory responses and / or induce endothelial organ damage that can cause microvascular leakage, heart failure, or death. Severe, life-threatening CRS can lead to pulmonary infiltration and damage, renal failure, or disseminated intravascular coagulation. Other severe, life-threatening toxicities can include cardiac toxicity, respiratory distress, neurotoxicity, and / or liver failure.

[0089] The outcomes, signs and symptoms of CRS are known and include those described herein. In some embodiments, when a particular dosing regimen or administration results in a particular CRS-related outcome, sign or symptom, or when a particular dosing regimen or administration does not result in a particular CRS-related outcome, sign or symptom, a particular outcome, sign and symptom, and / or its quantity or extent, may be specified.

[0090] In the context of administration of CAR-expressing cells, CRS, including severe CRS, typically occurs 6-20 days after infusion of the cells expressing the CAR. See Xu et al., Cancer Letters 343 (2014) 172-78. In some cases, CRS occurs less than 6 days or more than 20 days after infusion of the CAR T cells. The incidence and timing of CRS may be related to baseline cytokine levels or tumor burden at the time of infusion. Generally, CRS is accompanied by elevated serum levels of interferon (IFN)-γ, tumor necrosis factor (TNF)-α, and / or interleukin (IL)-2. Other cytokines that may be rapidly induced in CRS are IL-1β, IL-6, IL-8, and IL-10.

[0091] In order to predict which patients are likely at risk of developing sCRS, CRS criteria that appear to correlate with the onset of CRS have been developed (see Davilla et al. Science translational medicine. 2014;6(224):224ra25). Factors include fever, hypoxia, hypotension, neurological changes, and elevated serum levels of inflammatory cytokines, such as a set of seven cytokines (IFNγ, IL-5, IL-6, IL-10, Flt-3L, fractalkine, and GM-CSF) whose treatment-induced elevations can correlate well with both pre-treatment disease burden, such as tumor burden, and sCRS symptoms. Other guidelines for the diagnosis and management of CRS are known (see, e.g., Lee et al, Blood. 2014;124(2):188-95). In some embodiments, the criteria reflecting CRS grade are those detailed in Table 1 below.

[0092] Table 1. Example grading criteria for CRS JPEG2024156736000001.jpg101153

[0093] In some embodiments, the subject experiences, following administration, (1) a fever of at least 38° C. for at least three days; (2) (a) a maximum fold change of at least 75 for at least two of the following seven cytokines: interferon gamma (IFNγ), GM-CSF, IL-6, IL-10, Flt-3L, fractalkine, and IL-5, compared to levels immediately following administration, and / or (b) a maximum fold change of at least 250 for at least one of the following seven cytokines: interferon gamma (IFNγ), GM-CSF, IL-6, IL-10, Flt-3L, fractalkine, and IL-5, compared to levels immediately following administration; and (c) at least one clinical sign of toxicity, e.g., hypotension (relief from the administration of at least one intravenous vasoactive hypertensive agent). A subject is considered to have developed "severe CRS" ("sCRS") in response to or associated with the administration of a cell therapy or dose of cells if the subject exhibits elevated cytokines including any of the following: hypertension (requiring a PO2 pressor) or hypoxia (PO2<90%) or one or more neurological disorders (including mental status changes, obtundation, and / or seizures). In some embodiments, severe CRS includes grade 3 or higher CRS, e.g., CRS as set forth in Table 1.

[0094] In some embodiments, the outcome is associated with severe CRS or grade 3 CRS or higher, e.g., grade 4 or higher, as described in Table 1. In some embodiments, these include one or more of the following: persistent fever, e.g., persistent fever at a particular temperature, e.g., above or about 38° C., for 2 or more days, e.g., 3 or more days, e.g., 4 or more days, or for at least 3 consecutive days; fever above or about 38° C.; elevated cytokines, e.g., at least two cytokines (e.g., from the group consisting of interferon gamma (IFNγ), GM-CSF, IL-6, IL-10, Flt-3L, fractalkine, and IL-5, and / or tumor necrosis factor alpha (TNFα)). At least two of the maximum fold change of the cytokines, such as a maximum fold change of at least 75 or at least about 75, or at least one of the maximum fold change of such cytokines, such as a maximum fold change of at least 250 or at least about 250; and / or at least one clinical sign of toxicity, such as hypotension (e.g., as measured by at least one intravenous vasoactive hypertensive agent); hypoxia (e.g., plasma oxygen (PO2) level of less than 90% or less than about 90%); and / or one or more neurological disorders, including mental status changes, obtundation, and seizures. In some embodiments, severe CRS includes CRS that requires management or treatment in an intensive care unit (ICU).

[0095] In some embodiments, severe CRS comprises a combination of (1) persistent fever (fever of at least 38° C. for at least 3 days) and (2) a CRP serum level of at least 20 mg / dL or at least about 20 mg / dL. In some embodiments, severe CRS comprises hypotension requiring the use of two or more vasopressors, or respiratory failure requiring mechanical ventilation. In some embodiments, the dosage of the vasopressor is increased in a second or subsequent administration.

[0096] In some embodiments, severe CRS or grade 3 CRS includes increased alanine aminotransferase, increased aspartate aminotransferase, chills, febrile neutropenia, headache, left ventricular dysfunction, encephalopathy, hydrocephalus, and / or tremors.

[0097] In some embodiments, the provided method involves early intervention before the onset of severe CRS in a subject, or before the onset of grade 2 or grade 3 CRS.In some embodiments, it is understood that while physical signs or symptoms of CRS may be present, such signs or symptoms are generally mild and / or not severe.In some embodiments, the toxic targeting agent is administered when the subject shows grade 1 CRS, or within 24 hours after the subject shows the first signs or symptoms of grade 1 CRS.In some embodiments, the toxic targeting agent is administered to the subject when the first persistent fever develops, or within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18 or 24 hours of fever, such as persistent fever.

[0098] In some embodiments, the subject exhibits a fever, and in some aspects is treated when the subject exhibits such a fever and / or exhibits or has exhibited a fever for a particular period of time.

[0099] In some embodiments, the fever of a subject is characterized as the subject's body temperature being at or above a certain threshold temperature or level (or being measured as being at or above a certain threshold temperature or level).In some aspects, the threshold temperature is associated with at least mild fever, at least moderate fever, and / or at least hyperthermia.In some embodiments, the threshold temperature is a certain temperature or range. For example, the threshold temperature may be 38, 39, 40, 41, or 42°C, or about 38, about 39, about 40, about 41, or about 42°C, or at least 38, at least 39, at least 40, at least 41, or at least 42°C, or at least about 38, at least about 39, at least about 40, at least about 41, or at least about 42°C, and / or in the range of 38°C to 39°C or about 38°C to about 39°C, 39°C to 40°C or about 39°C to about 40°C, 40°C to 41°C or about 40°C to about 41°C, or 41°C to 42°C or about 41°C to about 42°C.

[0100] In some embodiments, the fever is persistent fever; in some aspects, the subject is treated when it is determined that the subject has persistent fever, e.g., within 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, or less of such a determination subsequent to an initial therapy that has the potential to induce toxicity, such as a disease-targeted therapy, or of the first such determination.

[0101] In some embodiments, a subject is determined or considered to have and / or have a persistent fever if the subject exhibits a fever at or above the relevant threshold temperature and the subject's fever or body temperature does not fluctuate by more than about 1°C or about 1°C, generally about 0.5°C, 0.4°C, 0.3°C or 0.2°C or about 0.5°C, 0.4°C, 0.3°C or 0.2°C. The absence of such fluctuations by or above a certain amount is generally measured over a period of time (e.g., over a 24-hour, 12-hour, 8-hour, 6-hour, 3-hour, or 1-hour period, which may be measured from the first symptom of a first temperature or fever above the indicated threshold). For example, in some embodiments, a subject is considered or determined to exhibit a persistent fever if the subject exhibits a fever of at least 38° C. or at least 39° C. or at least about 38° C. or at least about 39° C., which does not fluctuate in temperature by more than or about 0.5° C., 0.4° C., 0.3° C., or 0.2° C. over a 6 hour period, over an 8 hour period, over a 12 hour period, or over a 24 hour period.

[0102] In some embodiments, if a subject exhibits a fever that is at or above a relevant threshold temperature, and following a specified treatment, such as a treatment designed to reduce fever, such as treatment with an antipyretic drug, the subject's fever or body temperature does not decrease or does not decrease by or by more than a specified amount (e.g., by more than 1°C; generally does not fluctuate by or by more than about 0.5°C, 0.4°C, 0.3°C, or 0.2°C), the subject has and / or is determined or deemed to have a persistent fever. The antipyretic may comprise any active substance, such as a compound, composition, or ingredient, that reduces fever, such as one of any number of active substances known to have antipyretic effects, such as NSAIDs (e.g., ibuprofen, naproxen, ketoprofen, and nimesulide), salicylates, such as aspirin, choline salicylate, magnesium salicylate, and sodium salicylate, paracetamol, acetaminophen, metamizole, nabumetone, phenaxone, antipyrine, antipyretic.In some embodiments, the antipyretic is acetaminophen.In some embodiments, acetaminophen can be administered orally or intravenously at a dose of up to 12.5 mg / kg every 4 hours.In some embodiments, it is or comprises ibuprofen or aspirin. For example, a subject is considered to have a persistent fever if the subject exhibits or is determined to exhibit a fever of at least 38°C or at least 39°C or at least about 38°C or at least about 39°C that does not decrease or does not decrease by more than or about 0.5°C, 0.4°C, 0.3°C or 0.2°C, or by 1%, 2%, 3%, 4% or 5%, or about 1%, 2%, 3%, 4% or 5%, over a 6 hour period, over an 8 hour period, or over a 12 hour period, or over a 24 hour period, even after treatment with an antipyretic such as acetaminophen.In some embodiments, the dosage of the antipyretic is a dosage normally effective in such a subject to reduce fever or a particular type of fever, such as fever associated with a bacterial or viral infection, e.g., a localized or systemic infection.

[0103] In some embodiments, one or more toxic targeting therapies are administered at or shortly after a subject is determined or confirmed (e.g., for the first time) to have persistent fever, for example, as measured according to any of the above-mentioned embodiments. In some embodiments, one or more toxic targeting therapies are administered within a certain period of such confirmation or determination, for example, within 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, or 8 hours.

[0104] In some embodiments, the toxic targeting agent is administered prior to physical signs or symptoms of neurotoxicity. In some cases, neurotoxicity, including severe neurotoxicity, is a toxic outcome that can be associated with the administration of various therapies, such as cell therapy.

[0105] In some embodiments, symptoms associated with clinical risk of neurotoxicity include confusion, delirium, expressive aphasia, obtundation, myoclonus, lethargy, altered mental status, convulsions, seizure-like activity, seizures (optionally confirmed by electroencephalography [EEG]), high levels of beta amyloid (Aβ), high levels of glutamate, and high levels of oxygen radicals. In some embodiments, neurotoxicity is graded based on severity (e.g., using a grade 1-5 scale) (see, e.g., Guido Cavaletti & Paola Marmiroli Nature Reviews Neurology 6, 657-666 (December 2010); National Cancer Institute - Common Toxicity Criteria version 4.03 (NCI-CTCAE v4.03)).

[0106] In some cases, neurological symptoms may be the earliest symptom of sCRS. In some embodiments, neurological symptoms have been observed to begin 5-7 days after cell therapy infusion. In some embodiments, the duration of neurological changes may be 3-19 days. In some cases, recovery of neurological changes occurs after other symptoms of sCRS have resolved. In some embodiments, the time or extent of resolution of neurological changes is not hastened by treatment with anti-IL-6 and / or steroids.

[0107] In some embodiments, a subject is considered to have developed "severe neurotoxicity" in response to or following administration of a cell therapy or a dose of cells if, after administration, the subject exhibits symptoms that limit self-care (e.g., bathing, dressing and undressing, eating food, using the toilet, taking medications) from among: 1) symptoms of peripheral motor neuropathy, including inflammation or degeneration of peripheral motor nerves; 2) symptoms of peripheral sensory neuropathy, including inflammation or degeneration of peripheral sensory nerves, dysesthesias, e.g., distortions of sensory perception causing abnormal and unpleasant sensations, neuralgias, e.g., intense and painful sensations along a nerve or nerve group, and / or paresthesias, dysfunction of sensory neurons causing abnormal skin sensations of tingling, numbness, pressure, cold, and warmth in the absence of stimulation. In some embodiments, severe neurotoxicity includes grade 3 or higher neurotoxicity, e.g., neurotoxicity as set forth in Table 2.

[0108] Table 2. Exemplary grading criteria for neurotoxicity JPEG2024156736000002.jpg60153

[0109] In some embodiments, the method reduces symptoms, outcomes, or factors associated with CRS, including symptoms, outcomes, or factors associated with severe CRS or CRS of grade 3 or higher, compared to other methods. For example, a subject treated according to the method may have undetectable and / or reduced symptoms, outcomes, or factors of CRS, e.g., severe CRS or CRS of grade 3 or higher, such as any of those shown and described in Table 1.

[0110] In some embodiments, the method reduces the symptoms associated with CNS outcome or neurotoxicity compared to other methods.For example, the subject treated according to the method may not detect and / or reduce symptoms of neurotoxicity, such as limb weakness or numbness, loss of memory, vision, and / or intelligence, cognitive and behavioral problems including uncontrollable compulsive and / or compulsive behavior, delusions, headache, loss of motor control, cognitive decline, and autonomic nervous system dysfunction, and sexual dysfunction, compared to the subject treated according to other methods that administer toxic targeting agent after severe CRS or severe neurotoxicity or other toxic outcomes have developed.In some embodiments, the subject treated according to the method of the present invention may reduce symptoms associated with peripheral motor neuropathy, peripheral sensory neuropathy, dysethesia, neuralgia, or paresthesias.

[0111] In some embodiments, the method reduces the outcomes associated with neurotoxicity, including damage to the nervous system and / or brain, such as neuronal death.In some aspects, the method reduces the levels of factors associated with neurotoxicity, such as beta amyloid (Aβ), glutamic acid, and oxygen radicals.

[0112] In some embodiments, subjects administered therapy in combination with early intervention using a toxicity targeting agent have reduced symptoms, outcomes, or factors associated with CRS or associated with CNS-related outcomes or neurotoxicity (e.g., severe neurotoxicity or grade 3 or higher neurotoxicity) compared to methods involving alternative treatment regimens in which an active agent or other treatment is administered to a subject after the onset of severe CRS or after the onset of grade 2 or higher CRS or grade 2 or higher neurotoxicity. In some embodiments, CRS (e.g., severe CRS or grade 3 or higher CRS) or CNS-related or neurotoxicity (e.g., severe neurotoxicity or grade 3 or higher neurotoxicity) outcomes are reduced by more than 50%, 60%, 70%, 80%, 90% or more.

[0113] In some embodiments, administration of cell therapy causes another adverse event.In some embodiments, adverse events include, but are not limited to, increased alanine aminotransferase, increased aspartate aminotransferase, chills, febrile neutropenia, headache, hypotension, left ventricular dysfunction, encephalopathy, hydrocephalus, seizures, and / or tremor.In some embodiments, the intervention method provided herein improves or reduces such adverse events.

[0114] In some embodiments, the methods provided include administration of a toxicity targeting agent (e.g., an active agent for improving neurotoxicity or CRS, such as severe neurotoxicity or severe CRS) for improving toxicity outcomes at a reduced or lower dosage compared to the dosage of such active agent administered to the subject when physical signs or symptoms of severe CRS or neurotoxicity develop, and / or when the subject exhibits grade 2 or grade 3 CRS or neurotoxicity, and / or more than 6, 7, 8, 9, 10, 11, 12, 13, or 14 days after administration or initiation of cell therapy or after administration or initiation of a first dose of cell therapy. In some embodiments, the dose reduction is at least 1.2-fold, at least 1.3-fold, at least 1.4-fold, at least 1.5-fold, at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, or at least 10-fold.

[0115] In some embodiments, the methods provided include administering a toxicity targeting agent at a reduced frequency in a dosing cycle or regimen compared to the dosing frequency of the active agent in a dosing cycle or regimen of such active agent that is initiated when physical signs or symptoms of severe CRS or neurotoxicity develop, and / or when the subject exhibits grade 2 or grade 3 CRS or neurotoxicity, and / or more than 3 days (e.g., more than 3-14 days, e.g., more than 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 days) after administration or initiation of a cell therapy or after administration or initiation of a first dose of a cell therapy. In some embodiments, where a reference treatment regimen or cycle of an active agent (e.g., a steroid) involves administration over 3 days, the reduced dosing frequency can be a reduction to administration over 1 or 2 days.

[0116] In some embodiments, the methods provided relate to the administration of cell therapy, such as for the treatment of diseases or conditions, including various tumors, e.g., the administration of cells in adoptive cell therapy. The methods involve the administration of engineered cells expressing recombinant receptors designed to recognize and / or specifically bind to disease or condition-associated molecules, and to generate a response, e.g., an immune response, against such molecules when bound to such molecules. The receptors can include chimeric receptors, e.g., chimeric antigen receptors (CARs), and other transgenic antigen receptors, including transgenic T cell receptors (TCRs). In some embodiments, the methods provided are followed by early intervention therapy to treat toxicity in the subject after initiation of cell therapy as described, e.g., early intervention is initiated before signs or symptoms of grade 2 or higher CRS or severe CRS develop, or before signs or symptoms of grade 2 or higher neurotoxicity or severe neurotoxicity develop.

[0117] A. Cellular Therapy and Engineered Cells In some aspects, the therapeutic method provided involves administering to a subject, e.g., a patient, cells expressing recombinant receptors and compositions thereof. In some embodiments, the cells contain or are engineered to contain engineered receptors, e.g., engineered antigen receptors, e.g., chimeric antigen receptors (CARs), or T cell receptors (TCRs). The cells include populations of such cells, compositions that contain and / or are enriched for such cells, e.g., enriched or selected for certain types of cells, such as T cells or CD8+ or CD4+ cells. Among the compositions are pharmaceutical compositions and formulations for administration, such as for adoptive cell therapy.

[0118] In some embodiments, the cells contain one or more nucleic acids introduced via genetic engineering, thereby expressing recombinant or genetically engineered products of such nucleic acids. In some embodiments, gene transfer is accomplished by first stimulating the cells, e.g., combining the cells with a stimulus that induces a response, such as proliferation, survival, and / or activation, e.g., as measured by expression of cytokines or activation markers, and then transducing the activated cells and expanding them in culture to sufficient numbers for clinical use.

[0119] Various methods for introducing genetically engineered components, such as antigen receptors, such as CARs, are well known and can be used with the methods and compositions provided.Exemplary methods include those for transferring the nucleic acid encoding the receptor, including those via viruses, such as retroviruses or lentiviruses, transduction, transposons, and electroporation.

[0120] 1. Recombinant Receptor The cells generally express recombinant receptors, e.g., antigen receptors, e.g., functional non-TCR antigen receptors, e.g., chimeric antigen receptors (CARs), and other antigen-binding receptors, e.g., transgenic T cell receptors (TCRs). Among the receptors are other chimeric receptors.

[0121] A chimeric antigen receptor (CAR) Exemplary antigen receptors, including CARs, and methods for engineering such receptors and for introducing such receptors into cells are described, for example, in International Patent Application Publication Nos. WO200014257, WO2013126726, WO2012 / 129514, WO2014031687, WO2013 / 166321, WO2013 / 071154, WO2013 / 123061, U.S. Patent Application Publication Nos. US2002131960, US2013287748, US20130149, and the like. 337, U.S. Patent Nos. 6,451,995, 7,446,190, 8,252,592, 8,339,645, 8,398,282, 7,446,179, 6,410,319, 7,070,995, 7,265,209, 7,354,762, 7,446,191, 8,324,353, and 8,479,118, and European Patent Application No. EP 2 537 416, and / or Sadelain et al., Cancer Discov. 2013 April; 3(4): 388-398; Davila et al. (2013) PLoS ONE 8(4): e61338; Turtle et al., Curr. Opin. Immunol., 2012 October; 24(5): 633-39; Wu et al., Cancer, 2012 March 18(2): 160-75. In some aspects, the antigen receptor includes a CAR described in U.S. Patent No. 7,446,190 and those described in International Patent Application Publication No. WO / 2014055668 A1.Examples of CARs include those disclosed in any of the publications mentioned above, e.g., WO2014031687, US 8,339,645, US 7,446,179, US 2013 / 0149337, U.S. Pat. No. 7,446,190, U.S. Pat. No. 8,389,282, Kochenderfer et al., 2013, Nature Reviews Clinical Oncology, 10, 267-276 (2013); Wang et al. (2012) J. Immunother. 35(9): 689-701; and Brentjens et al., Sci Transl Med. 2013 5(177). See also WO2014031687, US 8,339,645, US 7,446,179, US 2013 / 0149337, US Patent No. 7,446,190, and US Patent No. 8,389,282. Chimeric receptors, e.g., CARs, generally comprise an extracellular antigen-binding domain, e.g., a portion of an antibody molecule, generally the variable heavy (VH) and / or variable light (VL) chain regions of an antibody, e.g., an scFv antibody fragment.

[0122] In some embodiments, the antigen targeted by the receptor is a polypeptide. In some embodiments, it is a carbohydrate or other molecule. In some embodiments, the antigen is selectively expressed or overexpressed on disease or condition cells, such as tumor or pathogenic cells, compared to normal or non-target cells or tissues. In other embodiments, the antigen is expressed on normal cells and / or expressed on engineered cells.

[0123] The antigen targeted by the receptor, in some embodiments, is orphan tyrosine kinase receptor ROR1, tEGFR, Her2, L1-CAM, CD19, CD20, CD22, mesothelin, CEA, and hepatitis B surface antigen, anti-folate receptor, CD23, CD24, CD30, CD33, CD38, CD44, EGFR, EGP-2, EGP-4, EPHa2, ErbB2, 3, or 4, FBP, fetal acetylcholine e e) Receptors, including GD2, GD3, HMW-MAA, IL-22R-α, IL-13R-α2, kdr, kappa light chain, Lewis Y, L1-cell adhesion molecule, MAGE-A1, mesothelin, MUC1, MUC16, PSCA, NKG2D ligand, NY-ESO-1, MART-1, gp100, carcinoembryonic antigen, ROR1, TAG72, VEGF-R2, carcinoembryonic antigen (CEA), prostate specific antigen, PSMA, Her2 / neu, estrogen receptor, progesterone receptor, ephrin B2, CD123, c-Met, GD-2, and MAGE A3, CE7, Wilms' tumor 1 (WT-1), cyclins, e.g., cyclin A1 (CCNA1), and / or biotinylated molecules, and / or molecules expressed by HIV, HCV, HBV, or other pathogens.

[0124] In some embodiments, the CAR binds to a pathogen-specific antigen. In some embodiments, the CAR is specific for a viral antigen (e.g., HIV, HCV, HBV, etc.), a bacterial antigen, and / or a parasitic antigen.

[0125] In some embodiments, the antibody portion of the recombinant receptor, e.g., CAR, further comprises at least a portion of an immunoglobulin constant region, e.g., a hinge region, e.g., an IgG4 hinge region, and / or a CH1 / CL and / or an Fc region. In some embodiments, the constant region or portion is a constant region or portion of a human IgG, e.g., an IgG4 or IgG1. In some aspects, the portion of the constant region serves as a spacer region between the antigen recognition component, e.g., an scFv, and a transmembrane domain. The spacer can be of a length that enhances the responsiveness of the cell after antigen binding compared to the absence of the spacer. Exemplary spacers, e.g., hinge regions, include those described in International Patent Application Publication No. WO2014031687. In some examples, the spacer is 12 amino acids or about 12 amino acids in length, or is 12 amino acids or less in length. Exemplary spacers include spacers having at least about 10-229 amino acids, at least about 10-200 amino acids, at least about 10-175 amino acids, at least about 10-150 amino acids, at least about 10-125 amino acids, at least about 10-100 amino acids, at least about 10-75 amino acids, at least about 10-50 amino acids, at least about 10-40 amino acids, at least about 10-30 amino acids, at least about 10-20 amino acids, or at least about 10-15 amino acids, including any integer between the endpoints of any of the ranges recited. In some embodiments, the spacer region has about 12 amino acids or less, about 119 amino acids or less, or about 229 amino acids or less. Exemplary spacers include an IgG4 hinge only, an IgG4 hinge linked to a CH2 and CH3 domain, or an IgG4 hinge linked to a CH3 domain. Exemplary spacers include, but are not limited to, those described in Hudecek et al. (2013) Clin. Cancer Res., 19:3153, International Patent Application Publication No. WO2014031687, U.S. Patent No. 8,822,647, or U.S. Patent Application Publication No. US2014 / 0271635.

[0126] In some embodiments, the constant region or portion is a constant region or portion of a human IgG, e.g., IgG4 or IgG1. In some embodiments, the spacer has the sequence ESKYGPPCPPCP (set forth in SEQ ID NO:1) and is encoded by the sequence set forth in SEQ ID NO:2. In some embodiments, the spacer has the sequence set forth in SEQ ID NO:3. In some embodiments, the spacer has the sequence set forth in SEQ ID NO:4. In some embodiments, the constant region or portion is a constant region or portion of IgD. In some embodiments, the spacer has the sequence set forth in SEQ ID NO:5. In some embodiments, the spacer has an amino acid sequence that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to any of SEQ ID NOs:1, 3, 4, or 5.

[0127] This antigen recognition domain is generally linked to one or more intracellular signaling components, such as, in the case of CAR, an antigen receptor complex, e.g., a signaling component that mimics activation through a TCR complex and / or another cell surface receptor. Thus, in some embodiments, the antigen binding component (e.g., an antibody) is linked to one or more transmembrane domains and an intracellular signaling domain. In some embodiments, the transmembrane domain is fused to an extracellular domain. In one embodiment, the transmembrane domain that is naturally associated with one of the domains in the receptor, e.g., CAR, is used. In some cases, the transmembrane domain is selected or modified by amino acid substitution to avoid binding of such domains to the transmembrane domain of the same or different surface membrane protein, in order to minimize interaction with other members of the receptor complex.

[0128] The transmembrane domain, in some embodiments, is derived from either a natural or synthetic source. If the source is natural, the domain, in some aspects, is derived from any membrane-bound or transmembrane protein. The transmembrane region comprises (i.e., at least comprises) a transmembrane region from the alpha, beta, or zeta chain of the T-cell receptor, CD28, CD3ε, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154. Alternatively, the transmembrane domain, in some embodiments, is synthetic. In some aspects, the synthetic transmembrane domain comprises primarily hydrophobic residues, e.g., leucine and valine. In some aspects, triplets of phenylalanine, tryptophan, and valine are found at each end of the synthetic transmembrane domain. In some embodiments, the linkage is by a linker, spacer, and / or transmembrane domain.

[0129] Among the intracellular signaling domains are those that mimic or resemble signals through natural antigen receptors, signals through a combination of such receptors and costimulatory receptors, and / or signals through costimulatory receptors alone. In some embodiments, a short oligopeptide or polypeptide linker, e.g., a linker 2-10 amino acids in length, e.g., a linker containing glycine and serine, e.g., a glycine-serine doublet, is present between the transmembrane domain and the cytoplasmic signaling domain of the CAR to form the linkage.

[0130] The receptor, e.g., CAR, generally comprises at least one intracellular signaling component. In some embodiments, the receptor comprises an intracellular component of the TCR complex, e.g., a TCR CD3 chain, e.g., CD3ζ chain, which mediates T cell activation and cytotoxicity. Thus, in some aspects, the antigen-binding portion is linked to one or more cell signaling modules. In some embodiments, the cell signaling module comprises a CD3 transmembrane domain, a CD3 intracellular signaling domain, and / or other CD transmembrane domains. In some embodiments, the receptor, e.g., CAR, further comprises one or more additional molecules, e.g., a portion of Fc receptor γ, CD8, CD4, CD25, or CD16. For example, in some aspects, the CAR or other chimeric receptor comprises a chimeric molecule of CD3-zeta (CD3-ζ) or Fc receptor γ with CD8, CD4, CD25, or CD16.

[0131] In some embodiments, when a CAR or other chimeric receptor is linked, the cytoplasmic domain or intracellular signaling domain of the receptor activates at least one of the normal effector functions or responses of an immune cell, such as a T cell engineered to express a CAR. For example, in some situations, the CAR induces a T cell function, such as cytolytic activity or T helper activity, such as secretion of cytokines or other factors. In some embodiments, a truncated portion of the intracellular signaling domain of an antigen receptor component or a costimulatory molecule is used instead of an intact immunostimulatory chain, for example, if it transmits an effector function signal. In some embodiments, the intracellular signaling domain comprises the cytoplasmic sequence of a T cell receptor (TCR), and in some aspects also comprises the cytoplasmic sequence of a co-receptor that, in the natural context, works in concert with such receptor to initiate signal transduction after antigen receptor binding.

[0132] In the context of natural TCR, full activation generally requires not only TCR-mediated signal transduction but also costimulatory signal.Thus, in some embodiments, CAR also includes a component for generating secondary or costimulatory signal to promote full activation.In other embodiments, CAR does not include a component for generating costimulatory signal.In some aspects, additional CAR is expressed in the same cell to provide a component for generating secondary or costimulatory signal.

[0133] T cell activation is described in some aspects as being mediated by two types of cytoplasmic signaling sequences: cytoplasmic signaling sequences that initiate antigen-dependent primary activation via the TCR (primary cytoplasmic signaling sequences), and cytoplasmic signaling sequences that act to provide secondary or costimulatory signals in an antigen-independent manner (secondary cytoplasmic signaling sequences). In some aspects, the CAR comprises one or both of these signaling components.

[0134] In some aspects, CAR comprises a primary cytoplasmic signaling sequence that regulates the primary activation of TCR complex.The primary cytoplasmic signaling sequence that acts to stimulate may contain a signaling motif known as immunoreceptor tyrosine-based activation motif or ITAM.Examples of primary cytoplasmic signaling sequences that contain ITAM include the primary cytoplasmic signaling sequences that are derived from TCRzeta, FcRgamma, FcRbeta, CD3gamma, CD3delta, CD3epsilon, CD8, CD22, CD79a, CD79b, and CD66d.In some embodiments, the cytoplasmic signaling molecule in CAR contains a cytoplasmic signaling domain, part thereof, or sequence that is derived from CD3zeta.

[0135] In some embodiments, the CAR comprises the signaling domain and / or transmembrane portion of a costimulatory receptor, such as CD28, 4-1BB, OX40, DAP10, and ICOS. In some aspects, the same CAR comprises both an activating component and a costimulatory component.

[0136] In some embodiments, one CAR comprises an activation domain, while another CAR that recognizes another antigen provides the costimulatory component. In some embodiments, the CAR comprises an activating CAR or a stimulatory CAR, a costimulatory CAR, both expressed on the same cell (see WO2014 / 055668). In some aspects, the cell comprises one or more stimulatory CARs or an activating CAR and / or a costimulatory CAR. In some embodiments, the cell further comprises an inhibitory CAR (iCAR, see Fedorov et al., Sci. Transl. Medicine, 5(215) (December, 2013)), e.g., a CAR that recognizes an antigen other than an antigen associated with and / or specific to a disease or condition, and the activation signal delivered through the disease-targeting CAR is attenuated or inhibited by the binding of the inhibitory CAR to its ligand, e.g., to reduce off-target effects.

[0137] In some embodiments, the intracellular signaling domain comprises a CD28 transmembrane and signaling domain linked to a CD3 (e.g., CD3-zeta) intracellular domain. In some embodiments, the intracellular signaling domain comprises a chimeric CD28 and / or CD137 (4-1BB, TNFRSF9) costimulatory domain linked to a CD3zeta intracellular domain.

[0138] In some embodiments, the CAR comprises one or more, e.g., two or more, costimulatory domains and an activation domain, e.g., a primary activation domain, in the cytoplasmic portion. Exemplary CARs include the intracellular components CD3-zeta, CD28, and 4-1BB.

[0139] In some embodiments, the CAR or other antigen receptor further comprises a marker, e.g., a cell surface marker, that can be used to confirm the transduction or engineering of cells to express a receptor, e.g., a truncated version of the cell surface receptor, e.g., truncated EGFR (tEGFR). In some aspects, the marker comprises all or a portion (e.g., truncated) of CD34, NGFR, or epidermal growth factor receptor (e.g., tEGFR). In some embodiments, the nucleic acid encoding the marker is operably linked to a polynucleotide encoding a linker sequence, e.g., a cleavable linker sequence, e.g., T2A. For example, the marker, optionally the linker sequence, can be any as disclosed in International Patent Application Publication No. WO2014031687. For example, the marker can be a truncated EGFR (tEGFR), optionally linked to a linker sequence, e.g., a T2A cleavable linker sequence. Exemplary polypeptides of truncated EGFR (e.g., tEGFR) include the amino acid sequence set forth in SEQ ID NO:7 or 16, or an amino acid sequence that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:7 or 16. Exemplary T2A linker sequences include the amino acid sequence set forth in SEQ ID NO:6, or an amino acid sequence that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:6.

[0140] In some embodiments, the marker is a molecule not naturally found on T cells or on the surface of T cells, e.g., a cell surface protein, or portion thereof. In some embodiments, the molecule is a non-self molecule, e.g., a non-self protein, i.e., a molecule that is not recognized as "self" by the immune system of the host into which the cells are adoptively transferred.

[0141] In some embodiments, the marker does not perform a therapeutic function and / or produce no effect other than its use as a marker for genetic engineering, e.g., to select successfully engineered cells. In other embodiments, the marker may be a therapeutic molecule or a molecule that exerts some other desired effect, e.g., a ligand that the cell encounters in vivo, e.g., a co-stimulatory or immune checkpoint molecule to enhance and / or attenuate the response of said cells upon adoptive transfer, as well as to encounter a ligand.

[0142] In some cases, the CAR is referred to as a first-generation CAR, a second-generation CAR, and / or a third-generation CAR. In some aspects, the first-generation CAR is a CAR that only produces a signal induced by the CD3 chain when the antigen is bound; in some aspects, the second-generation CAR is a CAR that produces such a signal and a costimulatory signal, for example, a CAR that contains an intracellular signaling domain derived from a costimulatory receptor such as CD28 or CD137; in some aspects, the third-generation CAR is a CAR that contains multiple costimulatory domains of different costimulatory receptors.

[0143] In some embodiments, the chimeric antigen receptor comprises an extracellular portion containing an antibody or antibody fragment. In some aspects, the chimeric antigen receptor comprises an extracellular portion containing an antibody or fragment and an intracellular signaling domain. In some embodiments, the antibody or fragment comprises an scFv and the intracellular domain contains an ITAM. In some aspects, the intracellular signaling domain comprises the signaling domain of the zeta chain of the CD3-zeta (CD3ζ) chain. In some embodiments, the chimeric antigen receptor comprises a transmembrane domain linking the extracellular domain and the intracellular signaling domain. In some aspects, the transmembrane domain contains the transmembrane portion of CD28. In some embodiments, the chimeric antigen receptor contains the intracellular domain of a T cell costimulatory molecule. The extracellular domain and the transmembrane domain can be linked directly or indirectly. In some embodiments, the extracellular domain and the transmembrane are linked by a spacer, e.g., any spacer described herein. In some embodiments, the receptor contains the extracellular portion of the molecule from which the transmembrane domain was derived, e.g., the CD28 extracellular portion. In some embodiments, the chimeric antigen receptor contains, for example, between the transmembrane domain and the intracellular signaling domain, an intracellular domain derived from a T cell costimulatory molecule or a functional variant thereof. In some aspects, the T cell costimulatory molecule is CD28 or 41BB.

[0144] For example, in some embodiments, the CAR contains an antibody, e.g., an antibody fragment, a transmembrane domain that is or contains a transmembrane portion of CD28 or a functional variant thereof, and an intracellular signaling domain that contains a signaling portion of CD28 or a functional variant thereof and a signaling portion of CD3ζ or a functional variant thereof. In some embodiments, the CAR contains an antibody, e.g., an antibody fragment, a transmembrane domain that is or contains a transmembrane portion of CD28 or a functional variant thereof, and an intracellular signaling domain that contains a signaling portion of 4-1BB or a functional variant thereof and a signaling portion of CD3ζ or a functional variant thereof. In some such embodiments, the receptor further comprises a spacer that contains a portion of an Ig molecule, e.g., a human Ig molecule, e.g., an Ig hinge, e.g., an IgG4 hinge, e.g., a hinge-only spacer.

[0145] In some embodiments, the transmembrane domain of the recombinant receptor, e.g., CAR, is or comprises the transmembrane domain of human CD28 (e.g., Accession No. P01747.1) or a variant thereof, e.g., the amino acid sequence set forth in SEQ ID NO:8, or an amino acid sequence exhibiting at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:8; in some embodiments, the transmembrane domain containing a portion of the recombinant receptor is or comprises the amino acid sequence set forth in SEQ ID NO:9, or an amino acid sequence exhibiting at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:9. The present invention relates to an amino acid sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to NO:9, or at least about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or more sequence identity to NO:9.

[0146] In some embodiments, the intracellular signaling component of the recombinant receptor, e.g., CAR, contains the intracellular costimulatory signaling domain of human CD28 or a functional variant or portion thereof, e.g., a domain with a LL→GG substitution at positions 186-187 of the native CD28 protein. For example, the intracellular signaling domain may comprise the amino acid sequence set forth in SEQ ID NO:10 or 11, or an amino acid sequence exhibiting at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:10 or 11. In some embodiments, the intracellular domain comprises the intracellular costimulatory signaling domain of 4-1BB (e.g., Accession No. Q07011.1) or a functional variant or portion thereof, e.g., the amino acid sequence set forth in SEQ ID NO:12, or an amino acid sequence exhibiting at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:12.

[0147] In some embodiments, the intracellular signaling domain of the recombinant receptor, e.g., CAR, comprises a human CD3 stimulatory signaling domain or a functional variant thereof, e.g., the 112 AA cytoplasmic domain of isoform 3 of human CD3 (Accession Number: P20963.2), or a CD3 zeta signaling domain described in U.S. Patent No. 7,446,190 or U.S. Patent No. 8,911,993. For example, in some embodiments, the intracellular signaling domain comprises an amino acid sequence set forth in SEQ ID NO: 13, 14 or 15, or an amino acid sequence exhibiting at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 13, 14 or 15.

[0148] In some aspects, the spacer contains only the hinge region of an IgG, e.g., only the hinge region of an IgG4 or IgG1, e.g., a hinge-only spacer as shown in SEQ ID NO:1. In other embodiments, the spacer is or contains an Ig hinge, e.g., an IgG4-derived hinge, optionally linked to a CH2 domain and / or a CH3 domain. In some embodiments, the spacer is an Ig hinge, e.g., an IgG4 hinge, linked to a CH2 domain and a CH3 domain, e.g., an IgG4 hinge, as shown in SEQ ID NO:4. In some embodiments, the spacer is an Ig hinge, e.g., an IgG4 hinge, linked to only the CH3 domain, e.g., an IgG4 hinge, as shown in SEQ ID NO:3. In some embodiments, the spacer is or includes a glycine-serine rich sequence or other flexible linker, e.g., a known flexible linker.

[0149] For example, in some embodiments, the CAR comprises an antibody, e.g., an antibody fragment, including an scFv, a spacer, e.g., a portion of an immunoglobulin molecule, e.g., a spacer containing a hinge region and / or one or more constant regions of a heavy chain molecule, e.g., an Ig-hinge-containing spacer, a transmembrane domain containing all or a portion of a CD28-derived transmembrane domain, a CD28-derived intracellular signaling domain, and a CD3 zeta signaling domain. In some embodiments, the CAR comprises an antibody or fragment, e.g., an scFv, a spacer, e.g., any Ig-hinge-containing spacer, a CD28-derived transmembrane domain, a 4-1BB-derived intracellular signaling domain, and a CD3 zeta signaling domain.

[0150] In some embodiments, the nucleic acid molecule encoding such a CAR construct further comprises a sequence encoding a T2A ribosomal skipping element and / or a tEGFR sequence, e.g., downstream of the sequence encoding the CAR. In some embodiments, the sequence encodes a T2A ribosomal skipping element as set forth in SEQ ID NO:6, or an amino acid sequence exhibiting at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:6. In some embodiments, T cells expressing an antigen receptor (e.g., CAR) can also be made to express truncated EGFR (EGFRt) as a non-immunogenic selection epitope (e.g., by introduction of a construct encoding CAR and EGFRt separated by a T2A ribosomal switch to express the two proteins from the same construct), which can then be used as a marker to detect such cells (see, e.g., U.S. Patent No. 8,802,374). In some embodiments, the sequence encodes a tEGFR sequence as set forth in SEQ ID NO:7 or 16, or an amino acid sequence exhibiting at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:7 or 16.

[0151] The recombinant receptor expressed by the cell administered to the subject, for example, CAR, generally recognizes or specifically binds to the molecule expressed in, associated with, and / or specific to the disease or condition being treated or the cell.When specifically bound to this molecule, for example, an antigen, the receptor generally delivers an immunostimulatory signal, for example, a signal transmitted by ITAM, to the cell, thereby promoting the immune response that targets the disease or condition.For example, in some embodiments, the cell expresses a CAR that specifically binds to the antigen expressed by the cell or tissue of the disease or condition or the antigen associated with the disease or condition.

[0152] b.TCR In some embodiments, engineered antigen receptors include recombinant T cell receptors (TCRs) and / or TCRs cloned from natural T cells. In some embodiments, high affinity T cell clones for target antigens (e.g., cancer antigens) are identified, isolated from patients, and introduced into cells. In some embodiments, TCR clones for target antigens are made in transgenic mice engineered with human immune system genes (e.g., human leukocyte antigen system, or HLA). See, e.g., tumor antigens (see, e.g., Parkhurst et al. (2009) Clin Cancer Res. 15:169-180 and Cohen et al. (2005) J Immunol. 175:5799-5808). In some embodiments, phage display is used to isolate TCRs against a target antigen (see, e.g., Varela-Rohena et al. (2008) Nat Med. 14:1390-1395 and Li (2005) Nat Biotechnol. 23:349-354).

[0153] In some embodiments, after a T cell clone is obtained, the TCR alpha and beta chains are isolated and cloned into a gene expression vector. In some embodiments, the TCR alpha and beta genes are linked via a picornavirus 2A ribosomal skipping peptide so that both chains are co-expressed. In some embodiments, gene transfer of the TCR is accomplished via a retroviral or lentiviral vector or via a transposon (see, e.g., Baum et al. (2006) Molecular Therapy: The Journal of the American Society of Gene Therapy. 13:1050-1063; Frecha et al. (2010) Molecular Therapy: The Journal of the American Society of Gene Therapy. 18:1748-1757; an Hackett et al. (2010) Molecular Therapy: The Journal of the American Society of Gene Therapy. 18:674-683).

[0154] c. Multi-targeting In some embodiments, the cells and methods include a multi-targeting strategy, such as expressing two or more engineered receptors on cells, each of which recognizes the same antigen and typically includes different intracellular signaling components.Such a multi-targeting strategy is described, for example, in International Patent Application Publication No. WO 2014055668 A1 (which describes, for example, the combination of an activating CAR and a costimulatory CAR that target two different antigens that are present individually on off-target cells, for example, on normal cells, but are present together only on the cells of the disease or condition that is to be treated), and Fedorov et al., Sci. Transl. Medicine, 5(215) (December, 2013) (which describes a cell that expresses an activating CAR and an inhibitory CAR, for example, the activating CAR binds to an antigen that is expressed on both normal or non-diseased cells and the cells of the disease or condition that is to be treated, and the inhibitory CAR binds to another antigen that is expressed only on normal cells or cells that are not desired to be treated).

[0155] For example, in some embodiments, the cells generally include a receptor that expresses a first engineered antigen receptor (e.g., CAR or TCR) that can induce an activation signal to the cell when specifically bound to an antigen recognized by the first receptor, e.g., the first antigen. In some embodiments, the cells generally further include a second engineered antigen receptor (e.g., CAR or TCR), e.g., a chimeric costimulatory receptor, that can induce a costimulatory signal to the immune cell when specifically bound to a second antigen recognized by the second receptor. In some embodiments, the first antigen and the second antigen are the same. In some embodiments, the first antigen and the second antigen are different.

[0156] In some embodiments, the first and / or second engineered antigen receptor (e.g., CAR or TCR) can induce activation signals to cells. In some embodiments, the receptor comprises an intracellular signaling component containing ITAM or ITAM-like motifs. In some embodiments, the activation induced by the first receptor involves signaling or protein expression changes in cells, such as ITAM phosphorylation and / or initiation of ITAM-mediated signaling cascades, formation of immune synapses and / or clustering of molecules (e.g., CD4 or CD8) near the bound receptor, activation of one or more transcription factors, such as NF-κB and / or AP-1, and / or induction of gene expression of factors such as cytokines, proliferation, and / or survival, which results in the initiation of immune response.

[0157] In some embodiments, the first and / or second receptor comprises the intracellular signaling domain of a costimulatory receptor such as CD28, CD137 (4-1BB), OX40, and / or ICOS. In some embodiments, the first and second receptor comprise the intracellular signaling domain of different costimulatory receptors. In one embodiment, the first receptor contains a CD28 costimulatory signaling region and the second receptor contains a 4-1BB costimulatory signaling region, or vice versa.

[0158] In some embodiments, the first and / or second receptor comprises both an intracellular signaling component containing an ITAM or ITAM-like motif and an intracellular signaling domain of a costimulatory receptor.

[0159] In some embodiments, the first receptor contains an intracellular signaling component that contains ITAM or ITAM-like motifs, and the second receptor contains an intracellular signaling domain of a costimulatory receptor.The costimulatory signal in combination with the activation signal induced in the same cell leads to an immune response, for example, an increase in T cell-mediated effector functions such as gene expression, secretion of cytokines and other factors, and cell death, which leads to a robust and long-lasting immune response.

[0160] In some embodiments, the ligation of only the first receptor or the ligation of only the second receptor does not induce a robust immune response.In some aspects, when only one receptor is ligated, the cell is tolerized or unresponsive to antigen, or inhibited, and / or is not induced to proliferate, secrete factors, or perform effector functions.However, in some such embodiments, when multiple receptors are ligated, such as when a cell expressing a first antigen and a second antigen is encountered, a desired response occurs, such as complete immune activation or stimulation, as shown by, for example, secretion of one or more cytokines, proliferation, persistence, and / or performing immune effector functions, such as cytotoxic killing of target cells.

[0161] In some embodiments, the two receptors induce activating and inhibiting signals to cells, so that when one of the receptors binds to an antigen, the cell is activated or induced to respond, but when the second inhibitory receptor binds to an antigen, a signal is induced to suppress or weaken the response.An example is the combination of an activating CAR and an inhibitory CAR or iCAR.Such a strategy can be used, for example, in this case, the activating CAR binds to an antigen that is expressed in disease or condition but is also expressed on normal cells, and the inhibitory receptor binds to another antigen that is expressed on normal cells but is not expressed on disease or condition cells.

[0162] In some embodiments, multi-targeting strategies are used when antigens associated with a particular disease or condition are expressed either transiently (e.g., when stimulated in conjunction with genetic engineering) or permanently on the surface of non-diseased cells and / or on the surface of the engineered cells themselves.In such cases, the need to link two separate and individually specific antigen receptors may improve specificity, selectivity, and / or efficacy.

[0163] In some embodiments, the multiple antigens, for example the first antigen and the second antigen, are expressed in the targeted cell, tissue, or disease or condition, for example on cancer cells.In some aspects, the cell, tissue, disease or condition is multiple myeloma or multiple myeloma cells.In some embodiments, one or more of the multiple antigens are also generally expressed on the cell that is not desired to be targeted by cell therapy, for example on the surface of normal or non-diseased cells or tissues, and / or on the surface of the engineered cell itself.In such an embodiment, specificity and / or efficacy are achieved by the need to couple multiple receptors to achieve a cellular response.

[0164] 2. Cells and Cell Preparation for Genetic Manipulation Among the cells that express the receptor and are administered by the methods provided are engineered cells. Genetic engineering generally involves the introduction of nucleic acids encoding recombinant or engineered components into a composition containing the cells, for example by retroviral transduction, transfection, or transformation.

[0165] In some embodiments, the nucleic acid is heterologous, i.e., not normally present in the cell or sample obtained from the cell, e.g., obtained from another organism or cell, e.g., a cell that has been engineered, and / or not normally found in the organism from which such cell was obtained. In some embodiments, the nucleic acid is non-naturally occurring, e.g., a nucleic acid not found in nature, including a nucleic acid that includes a chimeric combination of nucleic acids encoding various domains derived from multiple different cell types.

[0166] Said cell is generally a eukaryotic cell, for example a mammalian cell, typically a human cell.In some embodiments, said cell is derived from blood, bone marrow, lymph, or lymphoid organ, and is a cell of immune system, for example a myeloid or lymphoid cell, including a cell of innate or adaptive immunity, for example a lymphocyte, typically a T cell and / or a NK cell.Other exemplary cells include stem cells, for example multipotent stem cells and pluripotent stem cells, including induced pluripotent stem cells (iPSC).Said cell is typically a primary cell, for example a cell that is directly isolated from a subject and / or that is isolated from a subject and frozen. In some embodiments, the cells include one or more subsets of T cells or other cell types, e.g., total T cell population, CD4+ cells, CD8+ cells, and subpopulations thereof, e.g., one or more subsets of T cells or other cell types defined by function, activation state, maturity, differentiation potential, proliferation, recirculation, localization, and / or persistence ability, antigen specificity, type of antigen receptor, presence in a particular organ or compartment, marker or cytokine secretion profile, and / or degree of differentiation. The cells may be allogeneic and / or autologous with respect to the subject to be treated. Among the methods are off-the-shelf methods. In some aspects, e.g., in the case of off-the-shelf techniques, the cells are pluripotent and / or multipotent, e.g., stem cells, e.g., induced pluripotent stem cells (iPSCs). In some embodiments, the methods include steps of isolating cells from a subject, preparing, treating, culturing, and / or manipulating the cells, and reintroducing the cells into the same subject before or after cryopreservation.

[0167] Among the subtypes and subpopulations of T cells and / or CD4+ T cells and / or CD8+ T cells are naive T (T N ) cells, effector T cells (T EFF ), memory T cells and their subtypes, such as stem cell memory T (T SCM ), Central Memory T(T CM ), Effector Memory T (T EM), or highly differentiated effector memory T cells, tumor infiltrating lymphocytes (TILs), immature T cells, mature T cells, helper T cells, cytotoxic T cells, mucosa-associated invariant T (MAIT) cells, natural and adaptive regulatory T (Treg) cells, helper T cells, e.g., TH1 cells, TH2 cells, TH3 cells, TH17 cells, TH9 cells, TH22 cells, follicular helper T cells, α / β T cells, and δ / γ T cells.

[0168] In some embodiments, the cells are natural killer (NK) cells. In some embodiments, the cells are monocytes or granulocytes, such as myeloid cells, macrophages, neutrophils, dendritic cells, mast cells, eosinophils, and / or basophils.

[0169] In some embodiments, the cells contain one or more nucleic acids introduced via genetic engineering, thereby expressing recombinant or engineered products of such nucleic acids. In some embodiments, the nucleic acids are heterologous, i.e., not normally present in the cell or sample obtained from the cell, e.g., obtained from another organism or cell, e.g., not normally found in the cell being engineered and / or the organism from which such cell was obtained. In some embodiments, the nucleic acids are non-naturally occurring, e.g., nucleic acids not found in nature, including nucleic acids that contain chimeric combinations of nucleic acids encoding various domains from multiple different cell types.

[0170] In some embodiments, the preparation of engineered cells includes one or more culture steps and / or preparation steps. The cells for introducing the nucleic acid encoding the transgenic receptor, e.g., CAR, may be isolated from a sample, e.g., a biological sample, e.g., a biological sample obtained from or derived from a subject. In some embodiments, the subject from which the cells are isolated is a subject with a disease or condition, or a subject that requires cell therapy or is administered cell therapy. In some embodiments, the subject is a human being that requires a particular therapeutic intervention, e.g., adoptive cell therapy, in which cells are isolated, treated, and / or engineered.

[0171] Thus, the cells are in some embodiments primary cells, e.g., primary human cells.The samples include tissues, fluids, and other samples taken directly from subjects, as well as samples resulting from one or more processing steps, e.g., separation, centrifugation, genetic manipulation (e.g., transduction with viral vectors), washing, and / or incubation.Biological samples can be samples obtained directly from biological sources or processed samples.Biological samples include, but are not limited to, bodily fluids, e.g., blood, plasma, serum, cerebrospinal fluid, synovial fluid, urine, and sweat, tissue and organ samples, including processed samples obtained therefrom.

[0172] In some aspects, the sample from which the cells are obtained or isolated is blood or blood-derived sample, apheresis or leukapheresis product, or obtained from it.Exemplary samples include whole blood, peripheral blood mononuclear cells (PBMC), white blood cells, bone marrow, thymus, tissue biopsy, tumor, leukemia, lymphoma, lymph node, lymphoid tissue associated with the digestive tract, lymphoid tissue associated with mucosa, spleen, other lymphoid tissue, liver, lung, stomach, intestine, colon, kidney, pancreas, breast, bone, prostate, cervix, testis, ovary, tonsil, or other organ, and / or cells derived therefrom.Samples include samples from autologous and allogeneic sources in the context of cell therapy, e.g., adoptive cell therapy.

[0173] In some embodiments, the cells are derived from a cell line, e.g., a T cell line. The cells are, in some embodiments, obtained from xenogeneic sources, e.g., mouse, rat, non-human primate, and pig.

[0174] In some embodiments, said cell isolation comprises one or more preparation steps and / or cell separation steps that are not based on affinity.In some examples, cells are washed, centrifuged, and / or incubated in the presence of one or more reagents, for example, to remove undesirable components, to concentrate desired components, to lyse cells, or to remove cells that are sensitive to certain reagents.In some examples, cells are separated based on one or more characteristics, such as density, adhesion, size, sensitivity and / or resistance to certain components.

[0175] In some instances, cells from the subject's circulating blood are obtained, for example, by apheresis or leukapheresis. In some aspects, the sample contains lymphocytes, including T cells, monocytes, granulocytes, B cells, other nucleated white blood cells, red blood cells, and / or platelets, and in some aspects, cells other than red blood cells and platelets.

[0176] In some embodiments, blood cells collected from a subject are washed, e.g., to remove the plasma fraction and to place the cells in an appropriate buffer or medium for subsequent processing steps. In some embodiments, the cells are washed with phosphate buffered saline (PBS). In some embodiments, the washing solution is free of calcium and / or magnesium and / or many or all divalent cations. In some aspects, the washing step is accomplished by a semi-automated "flow-through" centrifuge (e.g., Cobe 2991 cell processor, Baxter) according to the manufacturer's instructions. In some aspects, the washing step is accomplished by tangential flow filtration (TFF) according to the manufacturer's instructions. In some embodiments, after washing, the cells are washed in various biocompatible buffers, e.g., Ca ++ / Mg ++ In certain embodiments, the components of the blood cell sample are removed and the cells are resuspended directly in culture medium.

[0177] In some embodiments, the methods include density-based cell separation methods, such as preparation of white blood cells from peripheral blood by red blood cell lysis and centrifugation through a Percoll or Ficoll gradient.

[0178] In some embodiments, the isolation method includes the separation of various cell types based on the expression or presence of one or more specific molecules, such as surface markers, such as surface proteins, intracellular markers, or nucleic acids, in cells.In some embodiments, any known method for separating based on such markers can be used.In some embodiments, the separation is based on affinity or immunoaffinity.For example, the isolation in some aspects includes the separation of cells and cell populations based on the cellular expression or expression level of one or more markers, typically cell surface markers, for example, by incubating with an antibody or binding partner that specifically binds to such marker, typically followed by a washing step, and separating the cells that are bound to the antibody or binding partner from the cells that are not bound to the antibody or binding partner.

[0179] Such separation steps may be based on positive selection, where cells bound to the reagent are retained for further use, and / or on negative selection, where cells that are not bound to the antibody or binding partner are retained. In some instances, both fractions are retained for further use. In some aspects, negative selection may be particularly useful when antibodies that specifically identify cell types within a heterogeneous population are not available, such that separation is best performed based on markers expressed by cells other than the desired population.

[0180] Separation does not necessarily enrich or remove 100% of a particular cell population or cell that expresses a particular marker.For example, positive selection or enrichment of a particular type of cell, such as the cell that expresses a marker, refers to an increase in the number or percentage of such cells, but does not necessarily completely eliminate the cells that do not express this marker.Similarly, negative selection, removal or depletion of a particular type of cell, such as the cell that expresses a marker, refers to a decrease in the number or percentage of such cells, but does not necessarily completely remove all such cells.

[0181] In some cases, multiple separation steps are performed, in which the positively selected or negatively selected fraction from one step is subjected to another separation step, such as a subsequent positive selection or negative selection.In some cases, in one separation step, the cells expressing multiple markers can be simultaneously depleted, for example, by incubating cells with multiple antibodies or binding partners, each specific to the marker targeted for negative selection.Similarly, multiple cell types can be simultaneously positively selected by incubating cells with multiple antibodies or binding partners that are expressed on the surface of various cell types.

[0182] For example, in some aspects, specific T cell subpopulations, e.g., cells that are positive for one or more surface markers or express high levels of one or more surface markers, e.g., CD28 + , CD62L + , CCR7 + , CD27 + , CD127 + , CD4 + , CD8 + , CD45RA + , and / or CD45RO + T cells are isolated by positive or negative selection methods.

[0183] For example, CD3 + , CD28 + T cells can be positively selected using anti-CD3 / anti-CD28 antibody-conjugated magnetic beads (e.g., DYNABEADS® M-450 CD3 / CD28 T Cell Expander).

[0184] In some embodiments, isolation is performed by enriching for a particular cell population by positive selection or by depleting a particular cell population by negative selection. In some embodiments, positive or negative selection is performed by selectively detecting one or more surface markers (markers) expressed on the surface of the positively or negatively selected cells, respectively.+ ) or one or more surface markers that are expressed at relatively high levels (markers high This is accomplished by incubating the cells with one or more antibodies or other binding agents that specifically bind to the IgG1A polypeptide.

[0185] In some embodiments, T cells are separated from the PBMC sample by negative selection of a marker expressed on the surface of non-T cells, e.g., B cells, monocytes, or other leukocytes, e.g., CD14. + Helper and CD8 + To isolate cytotoxic T cells, CD4 + Selection step or CD8 + A selection process is used. + Populations and CD8 + The population can be further sorted into subpopulations by positive or negative selection directed against markers expressed on the surface or in relatively high abundance on one or more naive, memory, and / or effector T cell subpopulations.

[0186] In some embodiments, further comprising CD8 + Cells are enriched or depleted for naive, central memory, effector memory, and / or central memory stem cells, e.g., by positive or negative selection based on surface antigens associated with each subpopulation. In some embodiments, central memory T (T CM ) cells are enriched and in some aspects the efficacy is particularly robust in such subpopulations. See Terakura et al. (2012) Blood.1:72-82; Wang et al. (2012) J Immunother. 35(9):689-701. In some embodiments, T CM Enriched CD8 + T cells and CD4 +Combining T cells further increases efficacy.

[0187] In embodiments, the memory T cells are CD8 + CD62L on peripheral blood lymphocytes + Subsets and CD62L - PBMCs are, for example, immunohistochemically stained with anti-CD8 and anti-CD62L antibodies to detect CD62L - CD8 + Fraction and / or CD62L + CD8 + Fractions can be concentrated or depleted.

[0188] In some embodiments, central memory T (T CM In some aspects, the enrichment of T cells is based on positive or abundant surface expression of CD45RO, CD62L, CCR7, CD28, CD3, and / or CD127; in some aspects, it is based on negative selection against cells that express or highly express CD45RA and / or granzyme B. In some aspects, the enrichment of T cells is based on positive or abundant surface expression of CD45RO, CD62L, CCR7, CD28, CD3, and / or CD127; in some aspects, it is based on negative selection against cells that express or highly express CD45RA and / or granzyme B. CM Cell-enriched CD8 + The population is isolated by depletion of cells expressing CD4, CD14, and CD45RA, followed by positive selection or enrichment for cells expressing CD62L. In one aspect, central memory T (T CM Enrichment of CD4 cells is performed starting with a negative fraction of cells selected on the basis of CD4 expression, which is subjected to negative selection on the basis of expression of CD14 and CD45RA, and positive selection on the basis of CD62L. Such selections are performed simultaneously in some aspects and sequentially in other aspects, in either order. In some aspects, both the positive and negative fractions from the CD4-based separation are retained and enriched for CD8, CD14, or CD45RA expression for use in later steps of the method, optionally after one or more additional positive or negative selection steps. + The same CD4 expression-based selection process used in the preparation of the cell population or subpopulation may be used to select CD4 + They may also be used to generate cell populations or subpopulations.

[0189] In certain instances, the PBMC sample or other white blood cell sample is CD4 + The cells are subjected to selection, where both the negative and positive fractions are retained, and the negative fraction is then subjected to negative selection based on expression of CD14 and CD45RA or CD19, and positive selection based on markers characteristic of central memory T cells, e.g., CD62L or CCR7, where positive and negative selection can be performed in either order.

[0190] CD4 + T helper cells are sorted into naive, central memory, and effector cells by identifying cell populations that bear cell surface antigens. CD4 + Lymphocytes can be obtained by standard methods. In some embodiments, naive CD4 + T lymphocytes are CD45RO - , CD45RA + , CD62L + , CD4 + In some embodiments, the T cells are central memory CD4 + The cells are CD62L + and CD45RO + In some embodiments, the effector CD4 + The cells are CD62L - and CD45RO - It is.

[0191] In one example, negative selection resulted in CD4 +To enrich cells, monoclonal antibody cocktails typically include antibodies against CD14, CD20, CD11b, CD16, HLA-DR, and CD8. In some embodiments, the antibody or binding partner is bound to a solid support or matrix, such as magnetic or paramagnetic beads, to allow cell separation for positive and / or negative selection. For example, in some embodiments, the cells and cell populations are separated or isolated using immunomagnetic (or affinitymagnetic) separation methods (reviewed in Methods in Molecular Medicine, vol. 58: Metastasis Research Protocols, Vol. 2: Cell Behavior In Vitro and In Vivo, p 17-25 Edited by: SA Brooks and U. Schumacher (Copyright) Humana Press Inc., Totowa, NJ).

[0192] In some aspects, the sample or composition of cells to be separated is incubated with small, magnetizable or magnetically responsive materials, such as magnetically responsive particles or microparticles, such as paramagnetic beads (e.g., Dynalbeads or MACS beads).The magnetically responsive materials, such as particles, are generally attached directly or indirectly to a binding partner, such as an antibody, that specifically binds to a molecule, such as a surface marker, present on the surface of the cell or cell population that is desired to be separated, such as the cell or cell population that is desired to be negatively selected or positively selected.

[0193] In some embodiments, magnetic particles or beads comprise a magnetically responsive material that is bound to a specific binding member, such as an antibody or other binding partner.There are many known magnetically responsive materials that can be used in magnetic separation methods.Suitable magnetic particles include those described in Molday, U.S. Pat. No. 4,452,773, and European Patent Specification EP452342B, which are incorporated herein by reference.Colloidal-sized particles are other examples, such as those described in Owen, U.S. Pat. No. 4,795,698, and Liberti et al., U.S. Pat. No. 5,200,084.

[0194] Incubation is generally carried out under conditions where the antibody or binding partner, or a molecule that specifically binds to such an antibody or binding partner, e.g., a secondary antibody or other reagent, that is attached to the magnetic particle or bead, specifically binds to the cell surface molecule if the cell surface molecule is present on the surface of cells in the sample.

[0195] In some aspects, the sample is placed in a magnetic field, and cells with magnetically responsive or magnetizable particles attached are attracted to the magnet or separated from unlabeled cells. In the case of positive selection, cells that are attracted to the magnet are retained; in the case of negative selection, cells that are not attracted (unlabeled cells) are retained. In some aspects, a combination of positive and negative selection is performed during the same selection step, and the positive and negative fractions are retained and further processed or subjected to additional separation steps.

[0196] In certain embodiments, magnetically responsive particles are coated with a primary antibody or other binding partner, a secondary antibody, a lectin, an enzyme, or streptavidin. In certain embodiments, magnetic particles are attached to cells via coating with a primary antibody specific for one or more markers. In certain embodiments, the cells are labeled with a primary antibody or binding partner rather than beads, and then magnetic particles coated with a cell type-specific secondary antibody or other binding partner (e.g., streptavidin) are added. In certain embodiments, streptavidin-coated magnetic particles are used together with biotinylated primary or secondary antibodies.

[0197] In some embodiments, the magnetically responsive particles are left attached to the cells for subsequent incubation, culture, and / or manipulation; in some aspects, the particles are left attached to the cells for administration to a patient. In some embodiments, the magnetizable particles or magnetically responsive particles are removed from the cells. Methods for removing magnetizable particles from cells are known, including, for example, the use of competitive non-labeled competitive antibodies, magnetizable particles, or antibodies conjugated with cleavable linkers. In some embodiments, the magnetizable particles are biodegradable.

[0198] In some embodiments, affinity-based selection is selection via magnetic activated cell sorting (MACS) (Miltenyi Biotec, Auburn, CA). Magnetic activated cell sorting (MACS) systems can select cells with high purity that have magnetized particles attached. In certain embodiments, MACS operates in a mode where non-target and target species are eluted sequentially after an external magnetic field is applied. That is, cells attached to magnetized particles are held in place while unattached species are eluted. Then, after this first elution step is completed, species that were trapped in the magnetic field and prevented from elution are liberated in some manner so that such species can be eluted and collected. In certain embodiments, non-target cells are labeled and depleted from the heterogeneous population of cells.

[0199] In certain embodiments, the isolation or separation is performed using a system, device, or instrument that performs one or more of the isolation, cell preparation, separation, processing, incubation, culture, and / or formulation steps of the method.In some aspects, the system is used to perform each of these steps in a closed or sterile environment, for example, to minimize errors, user manipulation, and / or contamination.In one example, the system is the system described in International Patent Application Publication No. WO2009 / 072003, or US Patent Application Publication No. US 20110003380 A1.

[0200] In some embodiments, the system or device performs one or more, e.g., all, of the isolation, processing, manipulation, and formulation steps in an integrated or standalone system and / or in an automatic or programmable manner. In some aspects, the system or device includes a computer and / or computer program in communication with the system or device that allows a user to program, control, evaluate the outcome of, and / or adjust various aspects of the processing, isolation, manipulation, and formulation steps.

[0201] In some aspects, the separation and / or other steps are performed using a CliniMACS system (Miltenyi Biotec), for example, to automate the separation of cells at clinical scale levels in a closed, sterile system. Components may include an on-board microcomputer, a magnetic separation unit, a peristaltic pump, and various pinch valves. The on-board computer in some aspects controls all the components of the instrument and commands the system to perform repetitive procedures in a unified sequence. The magnetic separation unit in some aspects includes a movable permanent magnet and a holder for the selected column. The peristaltic pump controls the flow rate through the tubing set and, together with the pinch valves, ensures that the buffer flows through the system in a controlled manner and that the cells are constantly suspended.

[0202] The CliniMACS system, in some aspects, uses magnetizable particles bound to antibodies, which are delivered in a sterile, non-pyrogenic solution. In some embodiments, after the cells are labeled with magnetic particles, they are washed to remove excess particles. A cell preparation bag is then connected to a tubing set, which in turn is connected to a buffer-containing bag and a cell collection bag. The tubing set consists of pre-assembled sterile tubes, including a pre-column and a separation column, and is for single use only. After the separation program starts, the system automatically applies the cell sample to the separation column. The labeled cells are retained in the column, whereas the unlabeled cells are removed by a series of washing steps. In some embodiments, the cell population for use with the methods described herein is not labeled and is not retained in the column. In some embodiments, the cell population for use with the methods described herein is labeled and retained in the column. In some embodiments, after the magnetic field is removed, the cell population for use with the methods described herein is eluted from the column and collected in a cell collection bag.

[0203] In certain embodiments, the separation and / or other steps are performed using a CliniMACS Prodigy system (Miltenyi Biotec). The CliniMACS Prodigy system, in some aspects, is equipped with a cell processing unit that automatically washes the cells and fractionates them by centrifugation. The CliniMACS Prodigy system may also be equipped with a built-in camera and image recognition software that determines the optimal cell fractionation endpoint by identifying the macroscopic layers of the source cell product. For example, peripheral blood is automatically separated into layers of red blood cells, white blood cells, and plasma. The CliniMACS Prodigy system may also be equipped with a built-in cell growth chamber that performs cell culture protocols, such as cell differentiation and proliferation, antigen addition, and long-term cell culture. An input port allows for aseptic removal and replenishment of media. Cells can be monitored using a built-in microscope. See, e.g., Klebanoff et al. (2012) J Immunother. 35(9): 651-660, Terakura et al. (2012) Blood.1:72-82, and Wang et al. (2012) J Immunother. 35(9):689-701.

[0204] In some embodiments, the cell populations described herein are collected and enriched (or depleted) via flow cytometry. In flow cytometry, cells stained for multiple cell surface markers are carried in a fluid stream. In some embodiments, the cell populations described herein are collected and enriched (or depleted) via preparative scale (FACS) sorting. In certain embodiments, the cell populations described herein are collected and enriched (or depleted) by using a microelectromechanical system (MEMS) chip in combination with a FACS-based detection system (see, for example, International Patent Application Publication No. WO 2010 / 033140, Cho et al. (2010) Lab Chip 10, 1567-1573; and Godin et al. (2008) J Biophoton. 1(5):355-376). In either case, cells can be labeled with multiple markers, allowing for the isolation of well-defined T cell subsets with high purity.

[0205] In some embodiments, the antibody or binding partner is labeled with one or more detectable markers to facilitate separation for positive and / or negative selection.For example, separation can be based on binding with fluorescently labeled antibody.In some examples, cell separation based on binding of antibody or other binding partner specific to one or more cell surface markers is performed in fluid flow, for example, by fluorescent activated cell sorting (FACS) with sorting scale (FACS) and / or microelectromechanical system (MEMS) chip, for example, in combination with flow cytometry detection system.Using such method, positive selection and negative selection can be performed simultaneously based on multiple markers.

[0206] In some embodiments, the preparation method includes a step for freezing, e.g., cryopreserving, the cells before or after isolation, incubation, and / or manipulation. In some embodiments, the freezing step and subsequent thawing step removes granulocytes and, to some extent, monocytes in the cell population. In some embodiments, the cells are suspended in a freezing solution, e.g., after a washing step to remove plasma and platelets. Any of a variety of known freezing solutions and parameters can be used in some aspects. One example involves using PBS containing 20% ​​DMSO and 8% human serum albumin (HSA), or other suitable cell freezing medium. This is then diluted 1:1 with medium so that the final concentrations of DMSO and HSA are 10% and 4%, respectively. The cells are then typically frozen to -80°C at a rate of 1° per minute and stored in the vapor phase of a liquid nitrogen storage tank.

[0207] In some embodiments, the cells are incubated and / or cultured prior to or in conjunction with genetic manipulation. The incubation step may include culturing, developing, stimulating, activating, and / or expanding. The incubation and / or manipulation may be performed in a culture vessel, such as a unit, chamber, well, column, tube, tube set, valve, vial, culture dish, bag, or other vessel for culturing or growing cells. In some embodiments, the composition or cells are incubated under stimulatory conditions or in the presence of a stimulatory active substance. Such conditions include conditions designed to induce proliferation, expansion, activation, and / or survival of cells in a population, mimic antigen exposure, and / or prime cells for genetic manipulation, e.g., to introduce a recombinant antigen receptor.

[0208] The conditions may include one or more of a particular medium, temperature, oxygen content, carbon dioxide content, time, active substances such as nutrients, amino acids, antibiotics, ions, and / or stimuli such as cytokines, chemokines, antigens, binding partners, fusion proteins, recombinant soluble receptors, and any other active substances designed to activate cells.

[0209] In some embodiments, the stimulatory conditions or stimulatory actives include one or more actives, e.g., ligands, that can activate the intracellular signaling domain of the TCR complex. In some aspects, the actives turn on or initiate the TCR / CD3 intracellular signaling cascade in T cells. Such actives can include antibodies, e.g., antibodies specific for the TCR, e.g., anti-CD3. In some embodiments, the stimulatory conditions include one or more actives, e.g., ligands, e.g., anti-CD28, that can stimulate the costimulatory receptor. In some embodiments, such actives and / or ligands can be bound to a solid support, such as beads, and / or one or more cytokines. Optionally, the expansion method can further include adding anti-CD3 and / or anti-CD28 antibodies (e.g., at a concentration of at least about 0.5 ng / ml) to the culture medium. In some embodiments, the stimulatory actives include IL-2 and / or IL-15, e.g., IL-2 at a concentration of at least about 10 units / mL. In some aspects, the IL-2 concentration is at least about 10 units / mL. In some embodiments, the stimulatory active agent comprises PMA and ionomycin.

[0210] In some aspects, the incubation is carried out according to techniques such as those described in U.S. Pat. No. 6,040,177 to Riddell et al., Klebanoff et al. (2012) J Immunother. 35(9): 651-660, Terakura et al. (2012) Blood.1:72-82, and / or Wang et al. (2012) J Immunother. 35(9):689-701.

[0211] In some embodiments, T cells are expanded by adding feeder cells, e.g., non-dividing peripheral blood mononuclear cells (PBMCs), to the culture start composition (e.g., such that the resulting cell population contains at least about 5, 10, 20, or 40 or more PBMC feeder cells per T lymphocyte in the initial population to be expanded); and incubating the culture (e.g., for a time sufficient to expand the number of T cells). In some aspects, the non-dividing feeder cells may comprise gamma-irradiated PBMC feeder cells. In some embodiments, the PBMCs are gamma-irradiated in the range of about 3000-3600 rads to block cell division. In some aspects, the feeder cells are added to the culture medium before the population of T cells is added.

[0212] In some embodiments, the stimulatory conditions include a temperature suitable for the proliferation of human T lymphocytes, for example, at least about 25°C, typically at least about 30°C, and typically at or about 37°C. Optionally, the incubation may further include adding non-dividing EBV-transformed lymphoblastoid cells (LCL) as feeder cells. The LCL can be irradiated with gamma radiation in the range of about 6000-10,000 rads. The LCL feeder cells are provided in any suitable amount, such as, in some aspects, a ratio of LCL feeder cells to primary T lymphocytes of at least about 10:1.

[0213] In an embodiment, antigen-specific T cells, for example, antigen-specific CD4+ and / or CD8+ T cells, are obtained by stimulating naive or antigen-specific T lymphocytes with antigen.For example, antigen-specific T cell lines or clones against cytomegalovirus antigens can be generated by isolating T cells from infected subjects and stimulating the cells with the same antigen in vitro.

[0214] 3. Vectors and methods for genetic manipulation A variety of methods for introducing genetically engineered components, such as recombinant receptors, such as CAR or TCR, are well known and can be used with the methods and compositions provided.Exemplary methods include the method for transferring the nucleic acid encoding the receptor, including the method via virus, such as retrovirus or lentivirus, transduction, transposon, and electroporation.

[0215] In some embodiments, the recombinant nucleic acid is transferred to the cell using a recombinant infectious viral particle, such as a vector derived from Simian Virus 40 (SV40), adenovirus, or adeno-associated virus (AAV). In some embodiments, the recombinant nucleic acid is transferred to the T cell using a recombinant lentivirus or retrovirus vector, such as a gamma-retrovirus vector (see, for example, Koste et al. (2014) Gene Therapy 2014 Apr 3. doi: 10.1038 / gt.2014.25; Carlens et al. (2000) Exp Hematol 28(10): 1137-46; Alonso-Camino et al. (2013) Mol Ther Nucl Acids 2, e93; Park et al., Trends Biotechnol. 2011 November 29(11): 550-557).

[0216] In some embodiments, retroviral vectors, such as those derived from Moloney murine leukemia virus (MoMLV), myeloproliferative sarcoma virus (MPSV), mouse embryonic stem cell virus (MESV), murine stem cell virus (MSCV), spleen focus forming virus (SFFV), or adeno-associated virus (AAV), have long terminal repeats (LTRs). Most retroviral vectors are derived from murine retroviruses. In some embodiments, retroviruses include those derived from any avian or mammalian cell source. Retroviruses are typically amphotropic. Amphotropic means that retroviruses can infect host cells of several species, including humans. In one embodiment, the gene to be expressed replaces the retroviral gag, pol, and / or env sequences. A number of exemplary retroviral systems have been described (e.g., U.S. Pat. Nos. 5,219,740; 6,207,453; 5,219,740; Miller and Rosman (1989) BioTechniques 7:980-990; Miller, AD (1990) Human Gene Therapy 1:5-14; Scarpa et al. (1991) Virology 180:849-852; Burns et al. (1993) Proc. Natl. Acad. Sci. USA 90:8033-8037; and Boris-Lawrie and Temin (1993) Cur. Opin. Genet. Develop. 3:102-109).

[0217] Lentiviral transduction methods are known. Exemplary methods are described, for example, in Wang et al. (2012) J. Immunother. 35(9): 689-701; Cooper et al. (2003) Blood. 101:1637-1644; Verhoeyen et al. (2009) Methods Mol Biol. 506: 97-114; and Cavalieri et al. (2003) Blood. 102(2): 497-505.

[0218] In some embodiments, the recombinant nucleic acid is transferred to the T cell via electroporation (see, e.g., Chicaybam et al, (2013) PLoS ONE 8(3): e60298 and Van Tedeloo et al. (2000) Gene Therapy 7(16): 1431-1437). In some embodiments, the recombinant nucleic acid is transferred to the T cell via transposition (see, e.g., Manuri et al. (2010) Hum Gene Ther 21(4): 427-437; Sharma et al. (2013) Molec Ther Nucl Acids 2, e74; and Huang et al. (2009) Methods Mol Biol 506: 115-126). Other methods for introducing and expressing genetic material in immune cells include calcium phosphate transfection (e.g., as described in Current Protocols in Molecular Biology, John Wiley & Sons, New York. NY), protoplast fusion, cationic liposome-mediated transfection; microparticle bombardment facilitated by tungsten particles (Johnston, Nature, 346: 776-777 (1990)); and strontium phosphate DNA co-precipitation (Brash et al., Mol. Cell Biol., 7: 2031-2034 (1987)).

[0219] Other approaches and vectors for transferring nucleic acids encoding recombinant products are described, for example, in International Patent Application Publication No. WO2014055668 and U.S. Patent No. 7,446,190.

[0220] In some embodiments, cells, e.g., T cells, can be transfected with, e.g., T cell receptors (TCRs) or chimeric antigen receptors (CARs) either during or after proliferation. This transfection for the introduction of the gene of the desired receptor can be carried out, for example, using any suitable retroviral vector. The genetically modified cell population can then be released from the first stimulation (e.g., CD3 / CD28 stimulation) and then stimulated with a second type of stimulation, e.g., via the newly introduced receptor. This second type of stimulation can include antigen stimulation in the form of peptide / MHC molecules, cognate (bridge) ligands of the genetically introduced receptor (e.g., natural ligands of CAR), or any ligand (e.g., antibodies) that directly binds to the framework of the new receptor (e.g., by recognizing the constant region in the receptor). See, e.g., Cheadle et al, "Chimeric antigen receptors for T-cell based therapy" Methods Mol Biol. 2012; 907:645-66 or Barrett et al., Chimeric Antigen Receptor Therapy for Cancer Annual Review of Medicine Vol. 65: 333-347 (2014).

[0221] In some cases, vectors can be used that do not require cells, such as T cells, to be activated. In some such cases, cells can be selected and / or transduced before activation. Thus, cells can be manipulated before or after culturing the cells, in some cases simultaneously with or during at least a portion of the culturing.

[0222] In some aspects, cells are further engineered to promote the expression of cytokines or other factors.Additional nucleic acids, such as genes for introduction, include genes for improving efficacy of therapy, for example, by promoting survival and / or function of transferred cells, as described in Lupton SD et al., Mol. and Cell Biol., 11:6 (1991); and Riddell et al., Human Gene Therapy 3:319-338 (1992); genes for selecting and / or evaluating cells, for example, genes for providing genetic markers for evaluating in vivo survival or localization; genes for improving safety, for example, genes for improving safety by making cells sensitive to negative selection in vivo.See also PCT / US91 / 08442 and PCT / US94 / 05601 publications by Lupton et al., which describe the use of bifunctional selectable fusion genes obtained by fusing dominant positive selection markers with negative selection markers. See, for example, Riddell et al., U.S. Patent No. 6,040,177, columns 14-17.

[0223] In some situations, overexpression of stimulatory factors (e.g., lymphokines or cytokines) may be toxic to a subject. Thus, in some situations, engineered cells contain gene segments that render the cells susceptible to negative selection in vivo when administered, for example, in adoptive immunotherapy. For example, in some aspects, the cells are engineered to be eliminated as a result of altered in vivo conditions in the subject to which the cells are administered. A negatively selectable phenotype may result from the insertion of a gene that confers sensitivity to an administered active agent, e.g., a compound. Negatively selectable genes include the herpes simplex virus type I thymidine kinase (HSV-I TK) gene, which confers sensitivity to ganciclovir (Wigler et al., Cell 2:223, 1977); the cellular hypoxanthine phosphribosyltransferase (HPRT) gene, the cellular adenine phosphoribosyltransferase (APRT) gene, bacterial cytosine deaminase, (Mullen et al., Proc. Natl. Acad. Sci. USA. 89:33 (1992)).

[0224] B. Compositions and Formulations In some embodiments, the immunotherapy and / or cell therapy is provided as a composition or formulation, such as a pharmaceutical composition or pharmaceutical formulation. Such compositions can be used according to the methods provided, for example, in the prevention or treatment of diseases, conditions and disorders, or in detection, diagnostic and prognostic methods.

[0225] The term "pharmaceutical formulation" refers to a preparation in a form such that the biological activity of the active ingredient contained therein is effective, and which does not contain additional ingredients that are unacceptably toxic to the subject to which the formulation is administered.

[0226] "Pharmaceutically acceptable carrier" refers to an ingredient in a pharmaceutical formulation, other than an active ingredient, that is non-toxic to a subject. Pharmaceutically acceptable carriers include, but are not limited to, buffers, excipients, stabilizers, or preservatives.

[0227] In some embodiments, the T cell therapy, e.g., engineered T cells (e.g., CAR T cells), is formulated with a pharma- ceutically acceptable carrier. In some aspects, the choice of carrier is determined, in part, by the particular cells and / or the method of administration. Thus, there are a variety of suitable formulations. For example, the pharmaceutical composition may contain a preservative. Suitable preservatives may include, for example, methylparaben, propylparaben, sodium benzoate, and benzalkonium chloride. In some aspects, a mixture of two or more preservatives is used. The preservative or mixtures thereof are typically present in an amount of about 0.0001% to about 2% by weight of the total composition. Carriers are described, for example, in Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980). Pharmaceutically acceptable carriers are generally nontoxic to recipients at the dosages and concentrations employed and include, but are not limited to, buffers, such as phosphate, citric acid, and other organic acids; antioxidants, including ascorbic acid and methionine; preservatives (e.g., octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl alcohol or benzyl alcohol; alkyl parabens, such as methylparaben or propylparaben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins. , such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers, such as polyvinylpyrrolidone; amino acids, such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents, such as EDTA; sugars, such as sucrose, mannitol, trehalose, or sorbitol; counterions that form salts, such as sodium; metal complexes (e.g., Zn-protein complexes); and / or non-ionic surfactants, such as polyethylene glycol (PEG).

[0228] In some aspects, a buffering agent is included in the composition. Suitable buffering agents include, for example, citric acid, sodium citrate, phosphoric acid, potassium phosphate, and various other acids and salts. In some aspects, a mixture of two or more buffering agents is used. The buffering agent or mixture is typically present in an amount of about 0.001 to about 4% by weight based on the weight of the total composition. Methods for preparing administrable pharmaceutical compositions are known. Exemplary methods are described in further detail, for example, in Remington: The Science and Practice of Pharmacy, Lippincott Williams & Wilkins; 21st ed. (May 1, 2005).

[0229] The formulation may comprise an aqueous solution. The formulation or composition may also contain multiple active ingredients useful for the particular indication, disease or condition that is being prevented or treated with the cells, for example, one or more active ingredients whose activities complement the cells and / or do not adversely affect each other. Such active ingredients are suitably present in combination in an amount effective for the intended purpose. Thus, in some embodiments, the pharmaceutical composition further comprises other pharmacologic active substances or drugs, for example, chemotherapeutic agents such as asparaginase, busulfan, carboplatin, cisplatin, daunorubicin, doxorubicin, fluorouracil, gemcitabine, hydroxyurea, methotrexate, paclitaxel, rituximab, vinblastine, vincristine, etc.

[0230] In some embodiments, the pharmaceutical composition contains an effective amount, for example a therapeutically or prophylactically effective amount, of cells to treat or prevent a disease or condition. In some embodiments, the therapeutic or prophylactic efficacy is monitored by periodically evaluating the subject being treated. For repeated administration over several days or more, depending on the condition, the treatment is repeated until the desired suppression of disease symptoms occurs. However, other dosing regimens may be useful and can be determined. The desired dosage may be delivered by a single bolus administration of the composition, by multiple boluses of the composition, or by continuous infusion administration of the composition.

[0231] The cells can be administered using standard administration techniques, formulations, and / or devices. Formulations and devices, such as syringes and vials, are provided for storing and administering the compositions. The administration of the cells can be autologous or heterologous. For example, immunoresponsive cells or progenitor cells can be obtained from a subject and administered to the same subject or a different compatible subject. Immunoresponsive cells or their progeny derived from peripheral blood (e.g., obtained in vivo, ex vivo, or in vitro) can be administered via local injection, including catheter administration, systemic injection, local injection, intravenous injection, or parenteral administration. When a therapeutic composition (e.g., a pharmaceutical composition containing genetically modified immunoresponsive cells) is administered, it is generally formulated in the form of a unit dosage form for injection (solution, suspension, emulsion).

[0232] Formulations include those for oral, intravenous, intraperitoneal, subcutaneous, pulmonary, transdermal, intramuscular, intranasal, buccal, sublingual, or suppository administration. In some embodiments, the active agent or cell population is administered parenterally. As used herein, the term "parenteral" includes intravenous, intramuscular, subcutaneous, rectal, vaginal, and intraperitoneal administration. In some embodiments, the active agent or cell population is administered to a subject using peripheral systemic delivery by intravenous, intraperitoneal, or subcutaneous injection.

[0233] The composition is provided in some embodiments as a sterile liquid preparation, such as an isotonic aqueous solution, suspension, emulsion, dispersion, or as a viscous composition, which may be buffered to a selected pH in some aspects. Liquid preparations are usually easier to prepare than gels, other viscous compositions, and solid compositions. In addition, liquid compositions are somewhat more convenient to administer, particularly by injection. On the other hand, viscous compositions can be formulated within a suitable viscosity range to provide a long contact period with a particular tissue. The liquid or viscous composition may include a carrier, which may be a solvent or dispersion medium, including, for example, water, saline, phosphate buffered saline, polyol (e.g., glycerol, propylene glycol, liquid polyethylene glycol), and suitable mixtures thereof.

[0234] Sterile injections can be prepared by incorporating the cells in a solvent and mixing with, for example, a suitable carrier, diluent, or excipient, such as sterile water, saline, glucose, dextrose, etc. The composition can also be lyophilized. The composition can contain auxiliary substances, such as wetting agents, dispersing agents, or emulsifying agents (e.g., methylcellulose), pH buffering agents, gelling or viscosity enhancing additives, preservatives, flavoring agents, coloring agents, depending on the desired route of administration and preparation. In some aspects, standard textbooks can be consulted to prepare the appropriate preparation.

[0235] Various additives can be added to improve the stability and sterility of the composition, including antimicrobial preservatives, antioxidants, chelating agents, and buffers. The action of microorganisms can be prevented by various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, sorbic acid, etc. Prolonged absorption of injectable pharmaceutical forms can be achieved by using active substances that delay absorption, such as aluminum monostearate and gelatin.

[0236] The formulations to be used for in vivo administration are generally sterile. Sterility may be readily accomplished, for example, by filtration through sterile filtration membranes.

[0237] For prevention or treatment of disease, the appropriate dosage may depend on the type of disease being treated, the type of active agent, the type of cells or recombinant receptor, the severity and course of the disease, whether the active agent or cells are administered for prophylactic or therapeutic purposes, previous therapy, the subject's medical history and response to the active agent or cells, and the judgment of the attending physician. The compositions, in some embodiments, are suitably administered to the subject at one time or over a series of treatments.

[0238] C. Treatments and Methods In some embodiments, a dose of immunotherapy and / or cell therapy, e.g., cells expressing a recombinant receptor, is administered to a subject to treat or prevent a disease, condition, and disorder, including cancer. In some embodiments, immunotherapy and / or cell therapy, e.g., cells, populations, and compositions, are administered to a subject or patient having a particular disease or condition to be treated, e.g., via adoptive cell therapy, such as adoptive T cell therapy. In some embodiments, cells and compositions, e.g., engineered compositions and end-of-production compositions after incubation and / or other processing steps, are administered to a subject, e.g., a subject having a disease or condition or at risk for a disease or condition. In some aspects, the method thereby treats a disease or condition, e.g., by reducing tumor burden in a cancer expressing an antigen recognized by the engineered T cells, e.g., ameliorating one or more symptoms of the disease or condition. In some embodiments, the methods provided include early or preemptive intervention, including by administration of an active agent or therapy or other treatment administered in addition to the immunotherapy and / or cell therapy.

[0239] Methods for administering cells for adoptive cell therapy are known and may be used in conjunction with the provided methods and compositions.For example, adoptive T cell therapy methods are described, for example, in U.S. Patent Application Publication No. 2003 / 0170238 to Gruenberg et al.; U.S. Patent No. 4,690,915 to Rosenberg; Rosenberg (2011) Nat Rev Clin Oncol. 8(10):577-85).See, for example, Themeli et al. (2013) Nat Biotechnol. 31(10): 928-933; Tsukahara et al. (2013) Biochem Biophys Res Commun 438(1): 84-9; Davila et al. (2013) PLoS ONE 8(4): e61338.

[0240] The disease or condition to be treated may be any disease or condition in which the expression of an antigen is related to and / or involved in the pathogenesis of the disease state or disorder, e.g., causes, exacerbates, or otherwise contributes to such disease, condition, or disorder. Exemplary diseases and conditions may include diseases or conditions associated with cellular malignancy or transformation (e.g., cancer), autoimmune or inflammatory diseases, or infectious diseases, e.g., caused by bacteria, viruses, or other pathogens. Exemplary antigens, including antigens associated with various diseases and conditions that may be treated, are described above. In certain embodiments, the chimeric antigen receptor or transgenic TCR specifically binds to an antigen associated with the disease or condition.

[0241] Among the diseases, conditions and disorders are tumors, including solid tumors, hematological malignancies and melanomas, including local and metastatic tumors, infectious diseases, such as infections by viruses or other pathogens, such as HIV, HCV, HBV, CMV, and parasitic diseases, as well as autoimmune and inflammatory diseases. In some embodiments, the disease or condition is a tumor, cancer, malignancy, neoplasm, or other proliferative disease or disorder. Such diseases include, but are not limited to, leukemia, lymphoma, such as chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), non-Hodgkin's lymphoma, acute myeloid leukemia, multiple myeloma, refractory follicular lymphoma, mantle cell lymphoma, indolent B-cell lymphoma, B-cell malignant tumor, colon cancer, lung cancer, liver cancer, breast cancer, prostate cancer, ovarian cancer, skin cancer, melanoma, bone cancer, and brain cancer, ovarian cancer, epithelial cancer, renal cell carcinoma, pancreatic adenocarcinoma, Hodgkin's lymphoma, cervical cancer, colorectal cancer, glioblastoma, neuroblastoma, Ewing's sarcoma, medulloblastoma, osteosarcoma, synovial sarcoma, and / or mesothelioma.In some embodiments, the subject has acute lymphoblastic leukemia (ALL).In some embodiments, the subject has non-Hodgkin's lymphoma.

[0242] In some embodiments, the disease or condition is an infectious disease or condition, including, but not limited to, viral, retroviral, bacterial, and protozoan infections, immunodeficiencies, cytomegalovirus (CMV), Epstein-Barr virus (EBV), adenovirus, BK polyomavirus, etc. In some embodiments, the disease or condition is an autoimmune or inflammatory disease or condition, such as arthritis, e.g., rheumatoid arthritis (RA), type I diabetes, systemic lupus erythematosus (SLE), inflammatory bowel disease, psoriasis, scleroderma, autoimmune thyroid disease, Graves' disease, Crohn's disease, multiple sclerosis, asthma, and / or a transplant-related disease or condition.

[0243] In some embodiments, the antigen associated with the disease or disorder is orphan tyrosine kinase receptor ROR1, tEGFR, Her2, L1-CAM, CD19, CD20, CD22, mesothelin, CEA, and hepatitis B surface antigen, antifolate receptor, CD23, CD24, CD30, CD33, CD38, CD44, EGFR, EGP-2, EGP-4, EPHa2, ErbB2, 3, or 4, FBP, fetal acetylcholine receptor, GD2, GD3, HMW-MAA, IL-22R. -alpha, IL-13R-alpha2, kdr, kappa light chain, Lewis Y, L1-cell adhesion molecule, MAGE-A1, mesothelin, MUC1, MUC16, PSCA, NKG2D ligand, NY-ESO-1, MART-1, gp100, carcinoembryonic antigen, ROR1, TAG72, VEGF-R2, carcinoembryonic antigen (CEA), prostate specific antigen, PSMA, Her2 / neu, estrogen receptor, progesterone receptor, ephrin B2, CD123, CS-1, c-Met, GD-2, and MAGE A3, CE7, Wilms' tumor 1 (WT-1), cyclins, e.g., cyclin A1 (CCNA1), and / or biotinylated molecules, and / or molecules expressed by HIV, HCV, HBV, or other pathogens.

[0244] In some embodiments, cell therapy, such as adoptive T cell therapy, is carried out by autologous transfer, in which cells are isolated and / or otherwise prepared from the subject who is to receive cell therapy or from a sample derived from such a subject.Thus, in some aspects, the cells are derived from a subject, such as a patient who needs treatment, and the cells are isolated and processed before being administered to the same subject.

[0245] In some embodiments, cell therapy, such as adoptive T cell therapy, is carried out by allogeneic transfer, in which cells are isolated and / or otherwise prepared from a subject other than the subject who will receive cell therapy or the subject who will ultimately receive cell therapy, such as the first subject.In such embodiments, the cells are then administered to a different subject of the same species, such as the second subject.In some embodiments, the first subject and the second subject are genetically identical.In some embodiments, the first subject and the second subject are genetically similar.In some embodiments, the second subject expresses the same HLA class or supertype as the first subject.

[0246] The cells can be administered by any suitable means, for example, by bolus injection, injection, for example, intravenous or subcutaneous injection, intraocular injection, periocular injection, subretinal injection, intravitreal injection, transseptal injection, subscleral injection, intrachoroidal injection, intracameral injection, subconjectval injection, subconjuntival injection, subtenon injection, retrobulbar injection, peribulbar injection, or posterior juxtascleral delivery. In some embodiments, the cells are administered by parenteral, intrapulmonary, and intranasal administration, and, if desired, for localized treatment, by intralesional administration. Parenteral injection includes intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration. In some embodiments, a certain dose is administered by a single bolus of the cells. In some embodiments, a particular dose is administered by multiple bolus administration of the cells, for example over a period of no more than 3 days, or by continuous infusion administration of the cells.

[0247] For prevention or treatment of disease, the appropriate dosage may depend on the type of disease being treated, the type of cells or recombinant receptor, the severity and course of the disease, whether the cells are administered for prophylactic or therapeutic purposes, previous therapy, the subject's medical history and response to the cells, and the judgment of the attending physician. The compositions and cells are in some embodiments suitably administered to the subject at one time or over a series of treatments.

[0248] In some embodiments, the cells are administered as part of a combination treatment, e.g., simultaneously with another therapeutic intervention, e.g., an antibody or engineered cell or receptor or active agent, e.g., a cytotoxic agent or therapeutic agent, or sequentially in any order. The cells are co-administered in some embodiments with one or more additional therapeutic agents or with another therapeutic intervention, simultaneously or sequentially in any order. In some situations, the cells are co-administered with another therapy for a period of time short enough that the cell population enhances the effect of one or more additional therapeutic agents, or vice versa. In some embodiments, the cells are administered before one or more additional therapeutic agents. In some embodiments, the cells are administered after one or more additional therapeutic agents. In some embodiments, the one or more additional active agents include a cytokine, e.g., IL-2, for example, to enhance persistence. In some embodiments, the method includes administration of a chemotherapeutic agent.

[0249] In some embodiments, the methods include administering a chemotherapeutic agent, eg, a conditioning chemotherapeutic agent, eg, to reduce tumor burden prior to administration.

[0250] Preconditioning a subject with immunodepleting (eg, lymphodepleting) therapy can improve the efficacy of adoptive cellular therapy (ACT) in some aspects.

[0251] Thus, in some embodiments, the method comprises administering a preconditioning active agent to the subject before the start of cell therapy, such as a lymphodepleting agent or a chemotherapeutic agent, such as cyclophosphamide, fludarabine, or a combination thereof.For example, the preconditioning active agent can be administered to the subject at least 2 days before the start of cell therapy, such as at least 3 days, at least 4 days, at least 5 days, at least 6 days, or at least 7 days.In some embodiments, the preconditioning active agent is administered to the subject not more than 7 days before the start of cell therapy, such as not more than 6 days, not more than 5 days, not more than 4 days, not more than 3 days, or not more than 2 days.

[0252] In some embodiments, the subject is preconditioned with cyclophosphamide at a dose of 20 mg / kg to 100 mg / kg or about 20 mg / kg to about 100 mg / kg, for example, 40 mg / kg to 80 mg / kg or about 40 mg / kg to about 80 mg / kg. In some aspects, the subject is preconditioned with cyclophosphamide at 60 mg / kg or about 60 mg / kg. In some embodiments, cyclophosphamide may be administered in a single dose or in multiple doses, for example, given daily, every other day, or every third day. In some embodiments, cyclophosphamide is administered once a day for one or two days.

[0253] In some embodiments, where the lymphodepletion agent comprises fludarabine, the subject is administered 1 mg / m 2 ~100 mg / m 2 or about 1 mg / m 2 ~about 100 mg / m 2 , e.g., 10 mg / m 2 ~75 mg / m 2 or about 10 mg / m 2 ~about 75 mg / m 2 , 15 mg / m 2 ~50 mg / m 2 or about 15 mg / m2 ~about 50 mg / m 2 , 20 mg / m 2 ~30 mg / m 2 or about 20 mg / m 2 ~about 30 mg / m 2 , or 24 mg / m 2 ~26 mg / m 2 or about 24 mg / m 2 ~about 26 mg / m 2 In some cases, the subject is administered a dose of fludarabine of 25 mg / m 2 of fludarabine is administered. In some embodiments, fludarabine may be administered in a single dose or in multiple doses, for example, given daily, every other day, or every third day. In some embodiments, fludarabine is administered daily for 1-5 days, for example, 3-5 days.

[0254] In some embodiments, the lymphodepleting agent comprises a combination of active agents, e.g., a combination of cyclophosphamide and fludarabine. Thus, the combination of active agents may comprise cyclophosphamide at any dose or dosing schedule, e.g., the dose or dosing schedule described above, and fludarabine at any dose or dosing schedule, e.g., the dose or dosing schedule described above. For example, in some aspects, 60 mg / kg (about 2 g / m) of cyclophosphamide is administered prior to the first or subsequent dose. 2 ) of cyclophosphamide and 3 to 5 doses of 25 mg / m 2 Fludarabine is administered to the subject.

[0255] Once the cells are administered, the biological activity of the engineered cell population is measured in some embodiments, for example, by any of a number of known methods. Parameters evaluated include specific binding of engineered or natural T cells or other immune cells to an antigen in vivo, for example, by imaging, or ex vivo, for example, by ELISA or flow cytometry. In certain embodiments, the ability of the engineered cells to destroy target cells can be measured using any suitable method known in the art, for example, a cytotoxicity assay, for example, the cytotoxicity assay described in Kochenderfer et al., J. Immunotherapy, 32(7): 689-702 (2009), and Herman et al. J. Immunological Methods, 285(1): 25-40 (2004). In certain embodiments, the biological activity of the cells is also measured by assaying the expression and / or secretion of one or more cytokines, for example, CD107a, IFNγ, IL-2, and TNF. In some aspects, biological activity is measured by assessing a clinical outcome, for example, reduction in tumor burden or tumor mass.

[0256] In certain embodiments, engineered cells are further modified in any number of ways to improve therapeutic or preventive efficacy.For example, the engineered CAR or TCR expressed by the population can be directly or indirectly conjugated with targeting moiety via linker.Methods for conjugating compounds, such as CAR or TCR, with targeting moiety are known in the art.See, for example, Wadwa et al., J. Drug Targeting 3: 1 1 1 (1995) and U.S. Patent No. 5,087,616.

[0257] 1. Medication The pharmaceutical composition, in some embodiments of the methods provided herein, contains an amount of cells effective to treat or prevent a disease or condition, such as a therapeutically effective amount or a prophylactically effective amount. In some embodiments, the composition includes an amount of cells effective to reduce the burden of a disease or condition.

[0258] In the context of adoptive cell therapy, administering a given "dose" includes administering a given amount or number of cells as a single composition administration and / or an uninterrupted single administration, for example, as a single injection or continuous infusion, and also includes administering a given amount or number of cells as a divided dose provided in the form of multiple individual compositions or infusions over a specific period of time of up to 3 days.Thus, in some situations, a dose is a single administration or continuous administration of a specific number of cells given or starting at one time point.However, in some situations, a dose is administered in the form of multiple injections or infusions over a period of up to 3 days, for example, once a day for 3 or 2 days, or by multiple infusions over a day.

[0259] Thus, in some aspects, the dose of cells is administered in a single pharmaceutical composition, hi some embodiments, the dose of cells is administered in multiple compositions that together contain the first dose of cells.

[0260] The term "split dose" refers to a dose that is divided so as to be administered over several days. This type of administration is encompassed by the methods of the invention and is considered a single dose.

[0261] Thus, the dose may be administered as a split dose in some aspects. For example, in some embodiments, the dose may be administered to the subject over two or three days. An exemplary method for split dosing includes administering 25% of the dose on the first day and administering the remaining 75% of the dose on the second day. In other embodiments, 33% of the first dose may be administered on the first day, and the remaining 67% may be administered on the second day. In some aspects, 10% of the dose is administered on the first day, 30% of the dose is administered on the second day, and 60% of the dose is administered on the third day. In some embodiments, the split dose is not spread over more than three days.

[0262] In some embodiments, one or more successive or subsequent doses of cells can be administered to the subject. In some embodiments, the successive or subsequent doses of cells are administered more than 7, 14, 21, 28 or 35 days or more than about 7, 14, 21, 28 or 35 days after the start of administration of the first dose of cells. The successive or subsequent doses of cells can be more than, about the same as, or less than the first dose. In some embodiments, administration of T cell therapy, for example, administration of the first and / or second dose of cells, can be repeated.

[0263] In some embodiments, a dose of cells is administered to a subject according to the provided method. In some embodiments, the size or timing of the dose is determined as a function of the specific disease or condition in the subject. It is within the level of the person skilled in the art to empirically determine the size or timing of the dose for a specific disease. Dosage may vary depending on the disease or disorder and / or the specific characteristics of the patient and / or other treatments.

[0264] In certain embodiments, the individual populations of cells, or subtypes of cells, are in the range and / or amount of cells of about 100,000 to about 100 billion cells per kilogram of body weight of the subject, e.g., about 100,000 to about 50 billion cells (e.g., about 5 million cells, about 25 million cells, about 500 million cells, about 1 billion cells, about 5 billion cells, about 20 billion cells, about 30 billion cells, about 40 billion cells, or a range defined by any two of the aforementioned values), about 1 million to about 50 billion cells (e.g., about 5 million cells, about 25 million cells, about 500 million cells, about 1 billion cells, about 5 billion cells, about 20 billion cells, about 30 billion cells, about 40 billion cells, or a range defined by any two of the aforementioned values), e.g., about 10 million to about 100 billion cells. cells (e.g., about 20 million cells, about 30 million cells, about 40 million cells, about 60 million cells, about 70 million cells, about 80 million cells, about 90 million cells, about 10 billion cells, about 25 billion cells, about 50 billion cells, about 75 billion cells, about 90 billion cells, or a range defined by any two of the foregoing values), in some cases about 100 million cells to about 50 billion cells (e.g., about 120 million cells, about 250 million cells, about 350 million cells, about 450 million cells, about 650 million cells, about 800 million cells, about 900 million cells, about 3 billion cells, about 30 billion cells, about 45 billion cells), or any value within these ranges and / or per kilogram of the subject's body weight. Dosages may vary depending on the disease or disorder and / or specific characteristics of the patient and / or other treatments. In some embodiments, such values ​​refer to the number of recombinant receptor-expressing cells; in other embodiments, they refer to the number of T cells or PBMCs or total cells administered.

[0265] In some embodiments, the cell therapy comprises at least 0.1 x 10 6 Cells / kg (subject body weight), at least 0.2 x 10 6 At least 0.3 x 10 cells / kg 6 At least 0.4 x 10 cells / kg 6 At least 0.5 x 10 cells / kg6 Cells / kg, at least 1 x 10 6 Cells / kg, at least 2.0 x 10 6 Cells / kg, at least 3 x 10 6 cells / kg or at least 5 x 10 6 cells / kg, or at least about 0.1 x 10 6 Cells / kg (subject body weight), at least about 0.2 x 10 6 At least about 0.3 x 10 cells / kg 6 At least about 0.4 x 10 cells / kg 6 At least about 0.5 x 10 cells / kg 6 Cells / kg, at least approximately 1 x 10 6 At least about 2.0 x 10 cells / kg 6 Cells / kg, at least approximately 3 x 10 6 cells / kg, or at least about 5 x 10 6 cells / kg, or 0.1 x 10 6 Cells / kg (subject weight), 0.2 x 10 6 cells / kg, 0.3 x 10 6 cells / kg, 0.4 x 10 6 cells / kg, 0.5 x 10 6 cells / kg, 1 x 10 6 cells / kg, 2.0 x 10 6 cells / kg, 3 x 10 6 cells / kg or 5 x 10 6 cells / kg, or approximately 0.1 x 10 6 Cells / kg (subject weight), approximately 0.2 x 10 6 cells / kg, approximately 0.3 x 10 6 cells / kg, approximately 0.4 x 10 6 cells / kg, approximately 0.5 x 10 6 cells / kg, approximately 1 x 10 6 cells / kg, approximately 2.0 x 10 6 cells / kg, approximately 3 x 10 6 cells / kg or approximately 5 x 10 6 It involves administration of a dose with a cell number that is cells / kg.

[0266] In some embodiments, the cell therapy comprises 0.1 x 10 6 Cells / kg (subject weight) ~ 1.0 x 10 7 cells / kg or approximately 0.1 x 10 6 Cells / kg (subject weight) ~ 1.0 x 10 7 cells / kg, 0.5 x 10 6 cells / kg~5 x 10 6 cells / kg or approximately 0.5 x 10 6 cells / kg~5 x 10 6 cells / kg, 0.5 x 10 6 cells / kg~3 x 10 6 cells / kg or approximately 0.5 x 10 6 cells / kg~3 x 10 6 cells / kg, 0.5 x 10 6 cells / kg~2 x 10 6 cells / kg or approximately 0.5 x 10 6 cells / kg~2 x 10 6 cells / kg, 0.5 x 10 6 cells / kg~1 x 10 6 cells / kg or approximately 0.5 x 10 6 cells / kg~1 x 10 6 cells / kg, 1.0 x 10 6 Cells / kg (subject weight) ~5 x 10 6 cells / kg or approximately 1.0 x 10 6 Cells / kg (subject weight) ~5 x 10 6 cells / kg, 1.0 x 10 6 cells / kg~3 x 10 6 cells / kg or approximately 1.0 x 10 6 cells / kg~3 x 10 6 cells / kg, 1.0 x 10 6 cells / kg~2 x 10 6 cells / kg or approximately 1.0 x 10 6 cells / kg~2 x 10 6 cells / kg, 2.0 x 10 6 Cells / kg (subject weight) ~5 x 10 6 cells / kg or approximately 2.0 x 106 Cells / kg (subject weight) ~5 x 10 6 cells / kg, 2.0 x 10 6 cells / kg~3 x 10 6 cells / kg or approximately 2.0 x 10 6 cells / kg~3 x 10 6 cells / kg, or 3.0 x 10 6 Cells / kg (subject weight) ~5 x 10 6 cells / kg or approximately 3.0 x 10 6 Cells / kg (subject weight) ~5 x 10 6 It includes administration of a dose containing a cell number in cells / kg (inclusive).

[0267] In some embodiments, the dose of cells is 2 x 10 5 cells / kg or approximately 2 x 10 5 cells / kg ~ 2 x 10 6 cells / kg or approximately 2 x 10 6 cells / kg, e.g., 4 x 10 5 cells / kg or approximately 4 x 10 5 cells / kg ~ 1 x 10 6 cells / kg or approximately 1 x 10 6 cells / kg, or 6 x 10 5 cells / kg or approximately 6 x 10 5 cells / kg~8 x 10 5 cells / kg or approximately 8 x 10 5 In some embodiments, the dose of cells comprises 2 x 10 cells / kg per kilogram of subject body weight (cells / kg). 5 Cells (e.g., antigen-expressing cells, e.g., CAR-expressing cells), such as 3 x 10 5 Less than or equal to 3 x 10 cells / kg 5 Cells / kg or less, 4 x 10 5 Less than or equal to 4 x 10 cells / kg 5 Cells / kg or less, 5 x 10 5 Less than or equal to 5 x 10 cells / kg 5 Cells / kg or less, 6 x 10 5Less than or equal to 6 x 10 cells / kg 5 Cells / kg or less, 7 x 10 5 Less than or equal to 7 x 10 cells / kg 5 Cells / kg or less, 8 x 10 5 Less than or equal to 8 x 10 cells / kg 5 Cells / kg or less, 9 x 10 5 Less than or equal to 9 x 10 cells / kg 5 Cells / kg or less, 1 x 10 6 Less than or equal to 1 x 10 cells / kg 6 Cells / kg or less, or 2 x 10 6 Less than or equal to 2 x 10 cells / kg 6 In some embodiments, the dose of cells is at least 2 x 10 cells / kg per kilogram of subject body weight (cells / kg). 5 or at least about 2 x 10 5 of cells, or 2 x 10 5 cells or approximately 2 x 10 5 cells (e.g., antigen-expressing cells, e.g., CAR-expressing cells), e.g., at least 3 x 10 5 cells / kg or at least about 3 x 10 5 Cells / kg or 3 x 10 5 cells / kg or approximately 3 x 10 5 Cells / kg, at least 4 x 10 5 cells / kg or at least about 4 x 10 5 Cells / kg or 4 x 10 5 cells / kg or approximately 4 x 10 5 Cells / kg, at least 5 x 10 5 cells / kg or at least about 5 x 10 5 Cells / kg or 5 x 10 5 cells / kg or approximately 5 x 10 5 Cells / kg, at least 6 x 10 5 cells / kg or at least about 6 x 10 5 cells / kg or 6 x 10 5 cells / kg or approximately 6 x 10 5Cells / kg, at least 7 x 10 5 cells / kg or at least about 7 x 10 5 Cells / kg or 7 x 10 5 cells / kg or approximately 7 x 10 5 Cells / kg, at least 8 x 10 5 cells / kg or at least about 8 x 10 5 cells / kg or 8 x 10 5 cells / kg or approximately 8 x 10 5 Cells / kg, at least 9 x 10 5 cells / kg or at least about 9 x 10 5 cells / kg or 9 x 10 5 cells / kg or approximately 9 x 10 5 Cells / kg, at least 1 x 10 6 cells / kg or at least about 1 x 10 6 Cells / kg or 1 x 10 6 cells / kg or approximately 1 x 10 6 cells / kg, or at least 2 x 10 6 cells / kg or at least about 2 x 10 6 Cells / kg or 2 x 10 6 cells / kg or approximately 2 x 10 6 Contains cells / kg.

[0268] In some embodiments, cells are administered at a desired dosage, which in some aspects includes a desired dose or number of cells or cell types and / or a desired ratio of cell types.Thus, in some embodiments, the dosage of cells is based on the total number of cells (or number per kg body weight) and the desired ratio of individual populations or subtypes, such as the ratio of CD4+ to CD8+.In some embodiments, the dosage of cells is based on the desired total number of cells (or number per kg body weight) in each population or each cell type.In some embodiments, the dosage is based on a combination of such characteristics, such as a combination of the desired number of total cells, the desired ratio, and the desired total number of cells in each population.

[0269] In some embodiments, a population or subtype of cells, such as CD8 + and CD4 + T cells are administered at or within a tolerance of a desired dose of total cells, such as a desired dose of T cells. In some aspects, the desired dose is a desired number of cells, or a desired number of cells per unit of body weight of the subject to whom the cells are administered, e.g., cells / kg. In some aspects, the desired dose is at or exceeds a minimum number of cells, or at or exceeds a minimum number of cells per unit of body weight. In some aspects, within the total cells administered at a desired dose, individual populations or subtypes are selected to achieve a desired output ratio (e.g., CD4 + vs. CD8 + ratio), e.g., within a certain tolerance or error of such ratio.

[0270] In some embodiments, cells are administered at or within the tolerance of the desired dose of one or more of the individual populations or subtypes of cells, such as the desired dose of CD4+ cells and / or the desired dose of CD8+ cells.In some aspects, the desired dose is the desired cell number of a subtype or population, or the desired number of such cells per unit of body weight of the subject to whom the cells are administered, such as cells / kg.In some aspects, the desired dose is or exceeds the minimum number of cells of a population or subtype, or is or exceeds the minimum number of cells of a population or subtype per unit of body weight.

[0271] Thus, in some embodiments, dosage is based on a desired fixed dose and desired ratio of total cells and / or based on a desired fixed dose of one or more, e.g., each, of individual subtypes or subpopulations. Thus, in some embodiments, dosage is based on a desired fixed or minimum dose of T cells and CD4 + Cells vs. CD8 + Based on the desired ratio of cells and / or CD4 +Cells and / or CD8 + Based on desired fixation or minimum dose of cells.

[0272] In some embodiments, cells are administered at or within a tolerance range of a desired output ratio of multiple cell populations or subtypes, such as CD4+ and CD8+ cells or subtypes. In some aspects, the desired ratio can be a specific ratio or can be a range of ratios. For example, in some embodiments, the desired ratio (e.g., CD4 + Cells vs. CD8 + The ratio of cells is 1:5 or about 1:5 to 5:1 or about 5:1 (or more than about 1:5 and less than about 5:1), or 1:3 or about 1:3 to 3:1 or about 3:1 (or more than about 1:3 and less than about 3:1), for example, 2:1 or about 2:1 to 1:5 or about 1:5 (or more than about 1:5 and less than about 2:1), for example , 5:1, 4.5:1, 4:1, 3.5:1, 3:1, 2.5:1, 2:1, 1.9:1, 1.8:1, 1.7:1, 1.6:1, 1.5:1, 1.4:1, 1.3:1, 1.2:1, 1.1:1, 1:1, 1:1.1, 1:1.2, 1:1.3, 1:1.4, 1:1.5, 1:1.6, 1:1.7, 1:1.8, 1:1.9: 1:2, 1:2.5, 1:3, 1:3.5, 1:4, 1:4.5, or 1:5, or about 5:1, about 4.5:1, about 4:1, about 3.5:1, about 3:1, about 2.5:1, about 2:1, about 1.9:1, about 1.8:1, about 1.7:1, about 1.6:1, about 1.5:1, about 1.4:1, about 1.3:1, about 1.2:1, about 1.1:1, about 1:1, about 1:1.1, about 1:1.2, about 1:1.3, about 1:1.4, about 1:1.5, about 1:1.6, about 1:1.7, about 1:1.8, about 1:1.9: about 1:2, about 1:2.5, about 1:3, about 1:3.5, about 1:4, about 1:4.5, or about 1:5. In some aspects, the tolerance is within about 1%, about 2%, about 3%, about 4%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50% of the desired ratio, including any value within these ranges.

[0273] In certain embodiments, the number and / or concentration of cells refers to the number of recombinant receptor (e.g., CAR)-expressing cells. In other embodiments, the number and / or concentration of cells refers to the number or concentration of total cells, T cells, or peripheral blood mononuclear cells (PBMCs) administered.

[0274] In some aspects, the size of the dose is determined based on one or more criteria, e.g., the subject's response to prior treatment, e.g., chemotherapy; the disease burden in the subject, e.g., tumor mass, volume, size, or extent, the degree or type, stage of metastasis, and / or the likelihood or incidence of the subject developing a toxic outcome, e.g., CRS, macrophage activation syndrome, tumor lysis syndrome, neurotoxicity, and / or the host immune response to the administered cells and / or recombinant receptor.

[0275] II. Toxicity Targeting Agents that Treat or Ameliorate Symptoms of Toxicity In some embodiments, the method comprises early or preemptive intervention, including by administering an active agent or therapy or other treatment that treats the toxicity of immunotherapy and / or cell therapy, such as CRS or neurotoxicity, such as severe CRS or severe neurotoxicity, and / or prevents, delays, or reduces the risk of occurrence or onset of CRS or neurotoxicity, such as severe CRS or severe neurotoxicity.For example, in some embodiments, the active agent is a toxicity targeting agent or treatment or intervention.

[0276] In some embodiments, the active agent, e.g., a toxic targeting agent, is a steroid, an antagonist or inhibitor of a cytokine receptor, such as the IL-6 receptor, the CD122 receptor (IL-2R beta receptor), or CCR2, or an inhibitor of a cytokine, such as IL-6, MCP-1, IL-10, IFN-γ, IL-8, or IL-18. In some embodiments, the active agent is an agonist of a cytokine receptor and / or a cytokine (e.g., TGF-β). In some embodiments, the active agent, e.g., an agonist, antagonist, or inhibitor, is an antibody or antigen-binding fragment, a small molecule, a protein or peptide, or a nucleic acid.

[0277] In some embodiments, a fluid bolus may be used as an intervention, for example to treat the hypotension associated with CRS. In some embodiments, the target hematocrit level is >24%. In some embodiments, the intervention involves the use of absorbent resin techniques with blood or plasma filtration. In some cases, the intervention involves dialysis, plasmapheresis, or similar techniques. In some embodiments, vasopressors or acetaminophen may be used.

[0278] In some embodiments, the active agent may be administered continuously, intermittently, or simultaneously with or in the same composition as a therapy, such as cells for adoptive cell therapy. For example, the active agent may be administered prior to, during, simultaneously with, or after administration of immunotherapy and / or cell therapy.

[0279] In some embodiments, the active agent is administered at the time as described herein and according to the method provided.In some embodiments, the toxic targeting agent is administered within, for example, less than or equal to 3, 4, 5, 6, 7, 8, 9 or 10 days after the start of immunotherapy and / or cell therapy.In some embodiments, the toxic targeting agent is administered within 1, 2 or 3 days or within about 1, 2 or 3 days after the start of administration of immunotherapy and / or cell therapy.

[0280] In some embodiments, the active agent, for example, the toxic targeting agent, is administered to the subject after the start of administration of immunotherapy and / or cell therapy, when the subject does not show grade 2 or higher CRS or grade 2 or higher neurotoxicity. In some aspects, the toxic targeting agent is administered to the subject after the start of administration of immunotherapy and / or cell therapy, when the subject does not show severe CRS or severe neurotoxicity. Thus, in the provided method, between the start of administration of immunotherapy and / or cell therapy and the toxic targeting agent, the subject is a subject who does not show grade 2 or higher CRS, for example severe CRS, and / or does not show grade 2 or higher neurotoxicity, for example severe neurotoxicity.

[0281] Non-limiting examples of interventions to treat or ameliorate toxicity, such as severe CRS (sCRS), are described in Table 3. In some embodiments, the intervention includes tocilizumab or other toxicity targeting agents as described, which may be when the subject has persistent or persistent fever of greater than or about 38° C. or greater than or about 39° C. In some embodiments, the fever continues in the subject for more than 10 hours, more than 12 hours, more than 16 hours, or more than 24 hours prior to the intervention.

[0282] (Table 3) JPEG2024156736000003.jpg114153

[0283] In some cases, the active agent or therapy or intervention, such as a toxic targeting agent, is administered alone or as part of a composition or formulation, such as a pharmaceutical composition or formulation, as described herein.Accordingly, the active agent alone or as part of a pharmaceutical composition can be administered intravenously or orally, or by any other acceptable known administration route or as described herein.

[0284] In some embodiments, the dosage of the active agent or the frequency of administration of the active agent in the dosing regimen is reduced compared to the dosage of the active agent or the frequency of administration in a method in which the subject is treated with the active agent after CRS or neurotoxicity of grade 2 or higher is developed or diagnosed, e.g., after severe CRS, e.g., grade 3 or higher, is developed or diagnosed, or after severe neurotoxicity, e.g., grade 3 or higher, is developed or diagnosed (e.g., after physical signs or symptoms of CRS or neurotoxicity of grade 3 or higher appear). In some embodiments, the dosage of the active agent or the frequency of administration of the active agent in the dosing regimen is reduced compared to the dosage of the active agent or the frequency of administration in a method in which the subject is treated for CRS or neurotoxicity for more than 3 days, 4 days, 5 days, 6 days, 1 week, 2 weeks, 3 weeks, or more after administration of immunotherapy and / or cell therapy. In some embodiments, the dosage is reduced by more than 1.2-fold, 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold or more, or by more than about 1.2-fold, about 1.5-fold, about 2-fold, about 3-fold, about 4-fold, about 5-fold, about 6-fold, about 7-fold, about 8-fold, about 9-fold, about 10-fold or more. In some embodiments, the dosage is reduced by more than 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more, or by more than about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90% or more. In some embodiments, the dosing frequency is reduced, e.g., the number of daily doses is reduced, or the number of days of dosing is reduced.

[0285] A. Toxic Targeting Agents 1. Steroids In some embodiments, the active agent, e.g., a toxicity targeting agent, that treats and / or prevents, delays, or reduces the risk of developing or developing toxicity, e.g., grade 2 or higher or severe CRS or neurotoxicity, to immunotherapy and / or cell therapy is a steroid, e.g., a corticosteroid. Corticosteroids typically include glucocorticoids and mineralocorticoids.

[0286] Any corticosteroid, e.g., glucocorticoids, can be used in the methods provided herein. In some embodiments, glucocorticoids include synthetic and non-synthetic glucocorticoids. Exemplary glucocorticoids include, but are not limited to, alclometasone, algestone, beclomethasone (e.g., beclomethasone dipropionate), betamethasone (e.g., betamethasone 17-valerate, betamethasone sodium acetate, betamethasone sodium phosphate, betamethasone valerate), budesonide, clobetasol (e.g., clobetasol propionate), clobetasone, clocortolone (e.g., pi clocortolone, cloprednol, corticosterone, cortisone and hydrocortisone (e.g., hydrocortisone acetate), cortivazol, deflazacort, desonide, desoximetasone, dexamethasone (e.g., dexamethasone 21-phosphate, dexamethasone acetate, dexamethasone sodium phosphate), diflorasone (e.g., diflorasone diacetate), diflucortolone, difluprednate, enoxolone, fluazacor flucloronide, fludrocortisone (e.g., fludrocortisone acetate), flumethasone (e.g., flumethasone pivalate), flunisolide, fluocinolone (e.g., fluocinolone acetonide), fluocinonide, fluocortin, fluocortolone, fluorometholone (e.g., fluorometholone acetate), fluperolone (e.g., fluperol acetate), fluprednidene, fluprednisolone, flurandrenolide, fluticasone (e.g., hydrocortisone (e.g., hydrocortisone 21-butyrate, hydrocortisone aceponate, hydrocortisone acetate, hydrocortisone buteprate, hydrocortisone butyrate, hydrocortisone cypionate, hydrocortisone hemisuccinate, hydrocortisone probutateprobutate), hydrocortisone sodium phosphate, hydrocortisone sodium succinate, hydrocortisone valerate), loteprednol etabonate, mazipredone, medrysone, meprednisone, methylprednisolone (methylprednisolone aceponate, methylprednisolone acetate, methylprednisolone hemisuccinate, methylprednisolone sodium succinate), mometasone (e.g., mometasone furoate), paramethasone (e.g., paramethasone acetate), prednicarb, prednisolone (e.g., prednisolone 25-diethylaminoacetate, prednisolone sodium phosphate, Prednisolone 21-hemisuccinate, prednisolone acetate; prednisolone farnesylate, prednisolone hemisuccinate, prednisolone-21 (β-D-glucuronide), prednisolone metasulfobenzoate, prednisolone stearate, prednisolone tebutate, prednisolone tetrahydrophthalate), prednisone, prednibar, prednylidene, rimexolone, tixocortol, triamcinolone (e.g., triamcinolone acetonide, triamcinolone benetonide, triamcinolone hexacetonide, triamcinolone acetonide 21-palmitate, triamcinolone diacetate). These glucocorticoids and their salts are discussed in detail, for example, in Remington's Pharmaceutical Sciences, A. Osol, ed., Mack Pub. Co., Easton, Pa. (16th ed. 1980).

[0287] In some instances, the glucocorticoid is selected from among cortisone, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, and prednisone. In certain instances, the glucocorticoid is dexamethasone.

[0288] In some embodiments, the active agent is a corticosteroid and is administered in an amount that is therapeutically effective to treat, ameliorate or reduce one or more symptoms of toxicity to immunotherapy and / or cell therapy, such as CRS or neurotoxicity. In some embodiments, indicators of improvement or successful treatment include the determination of no relevant score on a toxicity grading scale (e.g., CRS or neurotoxicity grading scale), e.g., a score of less than 3, or a change in grading or severity on a grading scale as discussed herein, e.g., a change from a score of 4 to a score of 3, or a change from a score of 4 to a score of 2, 1, or 0.

[0289] In some aspects, the corticosteroid is provided at a therapeutically effective dose. The therapeutically effective concentration can be empirically determined by testing in known in vitro or in vivo (e.g., animal model) systems. The amount of the selected corticosteroid administered to ameliorate symptoms or adverse effects of toxicity to immunotherapy and / or cell therapy, such as CRS or neurotoxicity, can be determined by standard clinical techniques. In addition, animal models can be used to help identify optimal dosage ranges. The exact dosage, which can be empirically determined, can depend on the specific therapeutic preparation, regimen and dosing schedule, route of administration, and severity of disease.

[0290] The corticosteroid can be administered in any amount that is effective to ameliorate one or more symptoms associated with the toxicity, eg, associated with CRS or neurotoxicity. The corticosteroid, e.g., glucocorticoid, may be, for example, in an amount of 0.1-100 mg, 0.1-80 mg, 0.1-60 mg, 0.1-40 mg, 0.1-30 mg, 0.1-20 mg, 0.1-15 mg, 0.1-10 mg, 0.1-5 mg, 0.2-40 mg, 0.2-30 mg, 0.2-20 mg, 0.2-15 mg, 0.2-10 mg, 0.2-5 mg, 0.4-40 mg, 0.4-30 mg, 0.4-20 mg, 0.4-15 mg, 0.4-10 mg, 0.4-5 mg, 0.4-4 mg, 1-20 mg, 1-15 mg, or 1-10 mg, or about 0.1-100 mg, about 0.1-80 mg, about 0.1-60 mg, The compound may be administered to a 70 kg adult human subject in an amount of about 0.1 to 40 mg, about 0.1 to 30 mg, about 0.1 to 20 mg, about 0.1 to 15 mg, about 0.1 to 10 mg, about 0.1 to 5 mg, about 0.2 to 40 mg, about 0.2 to 30 mg, about 0.2 to 20 mg, about 0.2 to 15 mg, about 0.2 to 10 mg, about 0.2 to 5 mg, about 0.4 to 40 mg, about 0.4 to 30 mg, about 0.4 to 20 mg, about 0.4 to 15 mg, about 0.4 to 10 mg, about 0.4 to 5 mg, about 0.4 to 4 mg, about 1 to 20 mg, about 1 to 15 mg, or about 1 to 10 mg.Typically, the corticosteroid, e.g., glucocorticoid, is administered in an amount of 0.4 to 20 mg or about 0.4 to 20 mg, e.g., 0.4 mg, 0.5 mg, 0.6 mg, 0.7 mg, 0.75 mg, 0.8 mg, 0.9 mg, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 mg, 16 mg, 17 mg, 18 mg, 19 mg or 20 mg per dose. In some embodiments, the dosage is about 1 mg, about 13 mg, about 14 mg, about 15 mg, about 16 mg, about 17 mg, about 18 mg, about 19 mg or about 20 mg administered to an average adult human subject.

[0291] In some embodiments, the corticosteroid is administered at 0.001 mg / kg (of the subject), 0.002 mg / kg, 0.003 mg / kg, 0.004 mg / kg, 0.005 mg / kg, 0.006 mg / kg, 0.007 mg / kg, 0.008 mg / kg, 0.009 mg / kg, 0.01 mg / kg, 0.015 mg / kg, 0.02 mg / kg, 0.025 mg / kg, 0.03 mg / kg, 0.035 mg / kg, 0.04 mg / kg, 0.045 mg / kg, 0.05 mg / kg, 0.055 mg / kg, 0.06 mg / kg, 0.065 mg / kg, 0.07 mg / kg, 0.075 mg / kg, 0.08 mg / kg, 0.085 mg / kg, 0.09 mg / kg, 0.095 mg / kg, 0.095 mg / kg, 0.095 mg / kg, 0.095 mg / kg, 0.001 mg / kg, 0.002 mg / kg, 0.003 mg / kg, 0.004 mg / kg, 0.005 ... mg / kg, 0.1 mg / kg, 0.15 mg / kg, 0.2 mg / kg, 0.25 mg / kg, 0.30 mg / kg, 0.35 mg / kg, 0.40 mg / kg, 0.45 mg / kg, 0.50 mg / kg, 0.55 mg / kg, 0.60 mg / kg, 0.65 mg / kg, 0.70 mg / kg, 0.75 mg / kg, 0.80 mg / kg, 0.85 mg / kg, 0.90 mg / kg, 0.95 mg / kg, 1 mg / kg, 1.05 mg / kg, 1.1 mg / kg, 1.15 mg / kg, 1.20 mg / kg, 1.25 mg / kg, 1.3 mg / kg, 1.35 mg / kg or 1.4 mg / kg, or about 0.001 mg / kg, about 0.002 mg / kg, about 0.003 mg / kg mg / kg, about 0.004 mg / kg, about 0.005 mg / kg, about 0.006 mg / kg, about 0.007 mg / kg, about 0.008 mg / kg, about 0.009 mg / kg, about 0.01 mg / kg, about 0.015 mg / kg, about 0.02 mg / kg, about 0.025 mg / kg, about 0.03 mg / kg, about 0.035 mg / kg, about 0.04 mg / kg, about 0.045 mg / kg, about 0.05 mg / kg, about 0.055 mg / kg, about 0.06 mg / kg, about 0.065 mg / kg, about 0.07 mg / kg, about 0.075 mg / kg, about 0.08 mg / kg, about 0.085 mg / kg, about 0.09 mg / kg, about 0.095 mg / kg, approx. 0.1 mg / kg, approx. 0.and typically at a dosage of about 70-75 mg / kg, about 15 mg / kg, about 0.2 mg / kg, about 0.25 mg / kg, about 0.30 mg / kg, about 0.35 mg / kg, about 0.40 mg / kg, about 0.45 mg / kg, about 0.50 mg / kg, about 0.55 mg / kg, about 0.60 mg / kg, about 0.65 mg / kg, about 0.70 mg / kg, about 0.75 mg / kg, about 0.80 mg / kg, about 0.85 mg / kg, about 0.90 mg / kg, about 0.95 mg / kg, about 1 mg / kg, about 1.05 mg / kg, about 1.1 mg / kg, about 1.15 mg / kg, about 1.20 mg / kg, about 1.25 mg / kg, about 1.3 mg / kg, about 1.35 mg / kg or about 1.4 mg / kg. can be administered to an average adult human subject weighing 100 kg.

[0292] The corticosteroid, or glucocorticoid, e.g., dexamethasone, can be administered orally (tablets, liquid, or liquid concentrate), PO, intravenously (IV), intramuscularly, or by any other route known or described herein (e.g., with respect to pharmaceutical formulations). In some aspects, the corticosteroid is administered as a bolus, while in other aspects it may be administered over a period of time.

[0293] In some aspects, glucocorticoids can be administered for more than one day, for example, for two days, for three days, or for four days.In some embodiments, corticosteroids can be administered once a day, twice a day, or more than three times a day.For example, corticosteroids, such as dexamethasone, can be administered at 10 mg (or equivalent) IV twice a day for three days in some instances.

[0294] In some embodiments, the dosage of corticosteroid, e.g., glucocorticoid, is administered at successively lower dosages per treatment.Thus, in some such treatment regimes, the dosage of corticosteroid is tapered.For example, corticosteroid can be administered at an initial dosage of 4 mg (or an equivalent dosage, such as with reference to dexamethasone), and at each successive administration, the dosage can be lowered such that the dosage is 3 mg for the next administration, 2 mg for the next administration, and 1 mg for the next administration.

[0295] In general, the dose of corticosteroid administered will depend on the particular corticosteroid, as differences in potency exist between different corticosteroids. Typically, drugs vary in potency, and therefore it is understood that doses may vary to achieve equivalent effect. Table 4 shows equivalence by potency for various glucocorticoids and routes of administration. Equivalent potency in clinical dosing is well known. Information regarding equivalent steroid dosing (non-chronotherapeutic modalities) can be found in the British National Formulary (BNF) 37, March 1999.

[0296] Table 4. Glucocorticoid administration JPEG2024156736000004.jpg33153

[0297] Thus, in some embodiments, the steroid is administered at an equivalent dosage of 1.0 mg to 20 mg dexamethasone / day, or about 1.0 mg to 20 mg dexamethasone / day, such as 1.0 mg to 15 mg dexamethasone / day, 1.0 mg to 10 mg dexamethasone / day, 2.0 mg to 8 mg dexamethasone / day, or 2.0 mg to 6.0 mg dexamethasone / day, inclusive. In some cases, the steroid is administered at an equivalent dose of 4 mg or about 4 mg or 8 mg or about 8 mg dexamethasone / day.

[0298] In some embodiments, steroids are administered if fever persists after treatment with tocilizumab. For example, in some embodiments, dexamethasone is administered orally or intravenously at a dosage of 5-10 mg up to every 6-12 hours with persistent fever. In some embodiments, tocilizumab is administered simultaneously with or after supplemental oxygen.

[0299] 2. Other active substances In some embodiments, the active agent, e.g., a toxicity targeting agent, that treats or ameliorates symptoms of immunotherapy and / or cell therapy toxicity, such as CRS or neurotoxicity, targets a cytokine, e.g., an antagonist or inhibitor of a cytokine such as transforming growth factor beta (TGF-β), interleukin 6 (IL-6), interleukin 10 (IL-10), IL-2, MIP1β (CCL4), TNFα, IL-1, interferon gamma (IFN-γ), or monocyte chemoattractant protein-1 (MCP-1). In some embodiments, the active agent that treats or ameliorates symptoms of immunotherapy and / or cell therapy toxicity, such as CRS or neurotoxicity, targets (e.g., inhibits or is an antagonist of) a cytokine receptor, such as the IL-6 receptor (IL-6R), IL-2 receptor (IL-2R / CD25), MCP-1 (CCL2) receptor (CCR2 or CCR4), TGF-β receptor (TGF-βI, II, or III), IFN-γ receptor (IFNGR), MIP1β receptor (e.g., CCR5), TNFα receptor (e.g., TNFR1), IL-1 receptor (IL1-Rα / IL-1Rβ), or IL-10 receptor (IL-10R).

[0300] The amount of the selected active agent that treats or ameliorates the symptoms of toxicity of immunotherapy and / or cell therapy, such as CRS or neurotoxicity, administered to improve the symptoms or adverse effects of toxicity to immunotherapy and / or cell therapy, such as CRS or neurotoxicity, can be determined by standard clinical techniques.Exemplary adverse events include, but are not limited to, increased alanine aminotransferase, increased aspartate aminotransferase, chills, febrile neutropenia, headache, hypotension, left ventricular dysfunction, encephalopathy, hydrocephalus, seizures, and / or tremors.

[0301] In some embodiments, the active agent is administered in a dosage of 30 mg to 5000 mg or about 30 mg to 5000 mg, e.g., 50 mg to 1000 mg, 50 mg to 500 mg, 50 mg to 200 mg, 50 mg to 100 mg, 100 mg to 1000 mg, 100 mg to 500 mg, 100 mg to 200 mg, 200 mg to 1000 mg, 200 mg to 500 mg, or 500 mg to 1000 mg.

[0302] In some embodiments, the active agent is administered at a dose of 0.5 mg / kg to 100 mg / kg or about 0.5 mg / kg to 100 mg / kg, e.g., 1 mg / kg to 50 mg / kg, 1 mg / kg to 25 mg / kg, 1 mg / kg to 10 mg / kg, 1 mg / kg to 5 mg / kg, 5 mg / kg to 100 mg / kg, 5 mg / kg to 50 mg / kg, 5 mg / kg to 25 mg / kg, 5 mg / kg to 10 mg / kg, 10 mg / kg to 100 mg / kg, 10 mg / kg to 50 mg / kg, 10 mg / kg to 25 mg / kg, 25 mg / kg to 100 mg / kg, 25 mg / kg to 50 mg / kg or 50 mg / kg to 100 mg / kg, or at a dose of about 1 mg / kg to 50 mg / kg, about 1 mg / kg to 25 mg / kg, about 1 mg / kg to 10 mg / kg, about 1 mg / kg to 5 The compound is administered in the range of about 5 mg / kg to 100 mg / kg, about 5 mg / kg to 50 mg / kg, about 5 mg / kg to 25 mg / kg, about 5 mg / kg to 10 mg / kg, about 10 mg / kg to 100 mg / kg, about 10 mg / kg to 50 mg / kg, about 10 mg / kg to 25 mg / kg, about 25 mg / kg to 100 mg / kg, about 25 mg / kg to 50 mg / kg, or about 50 mg / kg to 100 mg / kg. In some embodiments, the active agent is administered at a dosage of 1 mg / kg to 10 mg / kg, 2 mg / kg to 8 mg / kg, 2 mg / kg to 6 mg / kg, 2 mg / kg to 4 mg / kg, or 6 mg / kg to 8 mg / kg, or about 1 mg / kg to 10 mg / kg, about 2 mg / kg to 8 mg / kg, about 2 mg / kg to 6 mg / kg, about 2 mg / kg to 4 mg / kg, or about 6 mg / kg to 8 mg / kg, inclusive.In some aspects, the active agent is administered at a dosage of at least 1 mg / kg, at least 2 mg / kg, at least 4 mg / kg, at least 6 mg / kg, at least 8 mg / kg, at least 10 mg / kg or more, or at least about 1 mg / kg, at least about 2 mg / kg, at least about 4 mg / kg, at least about 6 mg / kg, at least about 8 mg / kg, at least about 10 mg / kg or more, or about 1 mg / kg, about 2 mg / kg, about 4 mg / kg, about 6 mg / kg, about 8 mg / kg, about 10 mg / kg or more. In some embodiments, the active agent is administered at a dose of 4 mg / kg or 8 mg / kg.

[0303] In some embodiments, the active agent is administered by injection, for example, intravenous or subcutaneous injection, intraocular injection, periocular injection, subretinal injection, intravitreal injection, transseptal injection, subscleral injection, intrachoroidal injection, intracameral injection, subconjunctival injection, subconjunctival injection, subtenon injection, retrobulbar injection, peribulbar injection, or posterior juxtascleral delivery. In some embodiments, the active agent is administered by parenteral administration, intrapulmonary administration, and intranasal administration, and, if desired, for local treatment, intralesional administration. Parenteral injection includes intramuscular administration, intravenous administration, intraarterial administration, intraperitoneal administration, or subcutaneous administration.

[0304] In some embodiments, the amount of active agent is administered about or approximately twice daily, daily, every other day, three times a week, weekly, every other week, or once a month.

[0305] In some embodiments, the active agent is administered as part of a composition or formulation, such as a pharmaceutical composition or pharmaceutical formulation as described below. Thus, in some cases, a composition containing an active agent is administered as described below. In other aspects, the active agent is administered alone and can be administered by any known acceptable route of administration, or by the routes of administration described herein, for example, for compositions and pharmaceutical formulations.

[0306] In some embodiments, the active agent that treats or improves the symptoms of immunotherapy and / or cell therapy toxicity, such as CRS or neurotoxicity, is an antibody or antigen-binding fragment.In some embodiments, the active agent is tocilizumab, siltuximab, sarilumab, olokizumab (CDP6038), elcilimomab, ALD518 / BMS-945429, sirukumab (CNTO 136), CPSI-2634, ARGX-109, FE301, or FM101.

[0307] In some embodiments, the active agent is an antagonist or inhibitor of IL-6 or IL-6 receptor (IL-6R). In some aspects, the active agent is an antibody that neutralizes IL-6 activity, such as an antibody or antigen-binding fragment that binds to IL-6 or IL-6R. For example, in some embodiments, the active agent is or includes tocilizumab (atlizumab) or sarilumab, an anti-IL-6R antibody. In some embodiments, the active agent is an anti-IL-6R antibody described in U.S. Patent No. 8,562,991. In some cases, the active agent that targets IL-6 is an anti-IL-6 antibody, such as siltuximab, elcilimomab, ALD518 / BMS-945429, sirukumab (CNTO 136), CPSI-2634, ARGX-109, FE301, FM101, or olokizumab (CDP6038). In some aspects, the active agent may neutralize IL-6 activity by inhibiting ligand-receptor interaction. The feasibility of this general type of approach was demonstrated using natural receptor antagonists for interleukin-1. See Harmurn, CH et al., Nature (1990) 343:336-340. In some aspects, the IL-6 / IL-6R antagonist or inhibitor is an IL-6 mutein, such as those described in U.S. Pat. No. 5,591,827. In some embodiments, the active agent that is an antagonist or inhibitor of IL-6 / IL-6R is a small molecule, a protein or peptide, or a nucleic acid.

[0308] In some embodiments, the active agent is tocilizumab. In some embodiments, tocilizumab is administered as an early intervention according to the provided methods at a dosage of 1 mg / kg to 12 mg / kg or about 1 mg / kg to 12 mg / kg, for example, 4 mg / kg, 8 mg / kg, or 10 mg / kg, or about 4 mg / kg, 8 mg / kg, or about 10 mg / kg. In some embodiments, tocilizumab is administered by intravenous infusion. In some embodiments, tocilizumab is administered for persistent fever above 39°C lasting 10 hours unresponsive to acetaminophen. In some embodiments, if symptoms recur within 48 hours of the first dose, a second administration of tocilizumab is provided.

[0309] In some embodiments, the active agent is an agonist or stimulator of TGF-β or a TGF-β receptor (e.g., TGF-β receptor I, II, or III). In some aspects, the active agent is an antibody that increases TGF-β activity, such as an antibody or antigen-binding fragment that binds to TGF-β or one of its receptors. In some embodiments, the active agent that is an agonist or stimulator of TGF-β and / or its receptor is a small molecule, a protein or peptide, or a nucleic acid.

[0310] In some embodiments, the active agent is an antagonist or inhibitor of MCP-1 (CCL2) or MCP-1 receptor (e.g., MCP-1 receptor CCR2 or CCR4). In some aspects, the active agent is an antibody that neutralizes MCP-1 activity, such as an antibody or antigen-binding fragment that binds to MCP-1 or one of its receptors (CCR2 or CCR4). In some embodiments, the MCP-1 antagonist or inhibitor is any of those described in Gong et al. J Exp Med. 1997 Jul 7; 186(1): 131-137 or Shahrara et al. J Immunol 2008; 180:3447-3456. In some embodiments, the active agent that is an antagonist or inhibitor of MCP-1 and / or its receptor (CCR2 or CCR4) is a small molecule, a protein or peptide, or a nucleic acid.

[0311] In some embodiments, the active agent is an antagonist or inhibitor of IFN-γ or IFN-γ receptor (IFNGR). In some aspects, the active agent is an antibody that neutralizes IFN-γ activity, such as an antibody or antigen-binding fragment that binds to IFN-γ or its receptor (IFNGR). In some aspects, the IFN-γ neutralizing antibody is any of those described in Dobber et al. Cell Immunol. 1995 Feb;160(2):185-92 or Ozmen et al. J Immunol. 1993 Apr 1;150(7):2698-705. In some embodiments, the active agent that is an antagonist or inhibitor of IFN-γ / IFNGR is a small molecule, a protein or peptide, or a nucleic acid.

[0312] In some embodiments, the active agent is an antagonist or inhibitor of IL-10 or IL-10 receptor (IL-10R). In some aspects, the active agent is an antibody that neutralizes IL-10 activity, such as an antibody or antigen-binding fragment that binds to IL-10 or IL-10R. In some aspects, the IL-10 neutralizing antibody is any of those described in Dobber et al. Cell Immunol. 1995 Feb;160(2):185-92 or Hunter et al. J Immunol. 2005 Jun 1;174(11):7368-75. In some embodiments, the active agent that is an antagonist or inhibitor of IL-10 / IL-10R is a small molecule, a protein or peptide, or a nucleic acid.

[0313] B. Compositions and Formulations In some embodiments, active agent, for example, toxicity targeting agent, is provided as a composition or formulation, such as pharmaceutical composition or pharmaceutical formulation.Such composition can be used according to the provided method, such as in early intervention for prevention, treatment or improvement of toxicity, such as delaying, alleviating, reducing CRS or neurotoxicity in subject.

[0314] In some embodiments, the toxic targeting agent is formulated with a pharmaceutical carrier. Such a carrier may include, for example, a carrier such as a diluent, adjuvant, excipient, or vehicle with which the active agent is administered. Examples of suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by EW Martin. Such compositions contain a therapeutically effective amount of the active agent, generally in purified form, together with a suitable amount of carrier, so as to provide a form for proper administration to a patient. Such pharmaceutical carriers may be sterile liquids, such as water and oils, such as oils of petroleum, animal, vegetable, or synthetic origin, such as peanut oil, soybean oil, mineral oil, and sesame oil. Saline solutions and aqueous dextrose and glycerol solutions may also be used as liquid carriers, particularly for injection solutions. Pharmaceutical compositions can contain any one or more of diluents, adjuvants, anti-adherents, binders, coatings, fillers, flavorings, colorings, lubricants, flow agents, preservatives, surfactants, adsorbents, emulsifiers, pharmaceutical excipients, pH buffers, or sweeteners, and combinations thereof.In some embodiments, pharmaceutical compositions can be in liquid, solid, lyophilized powder, gel form, and / or combinations thereof.In some aspects, the choice of carrier is determined in part by specific active substance and / or by method of administration.

[0315] In some embodiments, the pharmaceutical composition may contain a preservative. Suitable preservatives may include, for example, methylparaben, propylparaben, sodium benzoate, and benzalkonium chloride. In some aspects, a mixture of two or more preservatives is used. The preservative or mixture thereof is typically present in an amount of about 0.0001% to about 2% by weight of the total composition. Carriers are described, for example, by Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980). Pharmaceutically acceptable carriers are generally nontoxic to recipients at the dosages and concentrations employed and include, but are not limited to, buffers, such as phosphate, citric acid, and other organic acids; antioxidants, including ascorbic acid and methionine; preservatives (e.g., octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl alcohol or benzyl alcohol; alkyl parabens, such as methylparaben or propylparaben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins. , such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers, such as polyvinylpyrrolidone; amino acids, such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents, such as EDTA; sugars, such as sucrose, mannitol, trehalose, or sorbitol; counterions that form salts, such as sodium; metal complexes (e.g., Zn-protein complexes); and / or non-ionic surfactants, such as polyethylene glycol (PEG).

[0316] In some aspects, a buffering agent is included in the composition. Suitable buffering agents include, for example, citric acid, sodium citrate, phosphoric acid, potassium phosphate, and various other acids and salts. In some aspects, a mixture of two or more buffering agents is used. The buffering agent or mixture is typically present in an amount of about 0.001 to about 4% by weight based on the weight of the total composition. Methods for preparing administrable pharmaceutical compositions are known. Exemplary methods are described in further detail, for example, in Remington: The Science and Practice of Pharmacy, Lippincott Williams & Wilkins; 21st ed. (May 1, 2005).

[0317] In some embodiments, active substance is administered in the form of salt, for example, pharmaceutically acceptable salt.Suitable pharmaceutically acceptable acid addition salt includes those derived from mineral acid, for example, hydrochloric acid, hydrobromic acid, phosphoric acid, metaphosphoric acid, nitric acid and sulfuric acid, and organic acid, for example, tartaric acid, acetic acid, citric acid, malic acid, lactic acid, fumaric acid, benzoic acid, glycolic acid, gluconic acid, succinic acid, and arylsulfonic acid, for example, p-toluenesulfonic acid.

[0318] The active ingredient can be encapsulated in microcapsules, colloidal drug delivery systems (e.g., liposomes, albumin microspheres, microemulsions, nanoparticles and nanocapsules), or macroemulsions. In some embodiments, pharmaceutical compositions are formulated as inclusion complexes, such as cyclodextrin inclusion complexes, or as liposomes. Liposomes can be useful for targeting active substances to specific tissues. Many methods are available for preparing liposomes, such as those described in, for example, Szoka et al., Ann. Rev. Biophys. Bioeng., 9: 467 (1980), and U.S. Patent Nos. 4,235,871, 4,501,728, 4,837,028, and 5,019,369.

[0319] In some aspects, pharmaceutical compositions can use sustained release delivery system, delayed release delivery system, and sustained release delivery system, so that the delivery of the composition occurs in sufficient time to cause the sensitization of the site to be treated before the sensitization of the site to be treated.Many types of release delivery systems can be utilized and are known.Such systems can avoid repeated administration of the composition, thereby increasing the convenience of the subject and the physician.

[0320] In some embodiments, the pharmaceutical composition contains an active substance in an amount effective to ameliorate toxicity and / or prevent, delay, or reduce the risk of toxicity occurrence or onset, e.g., in a therapeutically or prophylactically effective amount. The therapeutic or prophylactic efficacy is monitored in some embodiments by periodically evaluating the treated subject. For repeated administration over several days or more, depending on the condition, the treatment is repeated until the desired suppression of toxicity or symptoms associated with toxicity occurs and / or until there is no risk of toxicity occurring. However, other dosing regimens may be useful and can be determined. The desired dosage may be delivered by a single bolus administration of the composition, by multiple bolus administrations of the composition, or by continuous infusion administration of the composition.

[0321] The active agent can be administered by any suitable means, for example, by bolus injection, injection, for example, intravenous or subcutaneous injection, intraocular injection, periocular injection, subretinal injection, intravitreal injection, transseptal injection, subscleral injection, intrachoroidal injection, intracameral injection, subconjunctival injection, subconjunctival injection, subtenon injection, retrobulbar injection, peribulbar injection, or posterior juxtascleral delivery. In some embodiments, the active agent is administered by parenteral, intrapulmonary, and intranasal administration, and, if desired, by intralesional administration for localized treatment. Parenteral infusion includes intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration. In some embodiments, a certain dose is administered by a single bolus injection of the active agent. In some embodiments, a certain dose is administered by multiple bolus injections of the active agent.

[0322] For ameliorating toxicity and / or delaying, reducing, or preventing the risk of toxicity, the appropriate dosage may depend on the type of toxicity being treated, the type of active agent, the type of cells or recombinant receptor previously administered to the subject, the severity and course of the disease, whether the active agent or cells are administered for prophylactic or therapeutic purposes, previous therapy, the subject's medical history and response to the active agent or cells, and the judgment of the attending physician. The compositions are, in some embodiments, suitably administered to the subject at one time or over a series of treatments.

[0323] Said cells or active substance can be administered using standard administration techniques, formulations, and / or devices.Formulations and devices, such as syringes and vials, are provided for storing and administering compositions.When a therapeutic composition (e.g., a pharmaceutical composition that contains an active substance that treats or improves symptoms of toxicity, such as CRS or neurotoxicity) is administered, it is generally formulated in the form of a unit dosage form for injection (solution, suspension, emulsion).

[0324] Formulations include those for oral, intravenous, intraperitoneal, subcutaneous, pulmonary, transdermal, intramuscular, intranasal, buccal, sublingual, or suppository administration. In some embodiments, the active agent is administered parenterally. In some embodiments, the active agent is administered to a subject using peripheral systemic delivery by intravenous, intraperitoneal, or subcutaneous injection.

[0325] The composition is provided in some embodiments as a sterile liquid preparation, such as an isotonic aqueous solution, suspension, emulsion, dispersion, or as a viscous composition, which may be buffered to a selected pH in some aspects. Liquid preparations are usually easier to prepare than gels, other viscous compositions, and solid compositions. In addition, liquid compositions are somewhat more convenient to administer, particularly by injection. On the other hand, viscous compositions can be formulated within a suitable viscosity range to provide a long contact period with a particular tissue. The liquid or viscous composition may include a carrier, which may be a solvent or dispersion medium, including, for example, water, saline, phosphate buffered saline, polyoi (e.g., glycerol, propylene glycol, liquid polyethylene glycol), and suitable mixtures thereof.

[0326] Sterile injections can be prepared by incorporating the active substance in a solvent and mixing with suitable carriers, diluents, or excipients, such as sterile water, saline, glucose, dextrose, etc. The compositions can also be lyophilized. The compositions can contain auxiliary substances, such as wetting agents, dispersing agents, or emulsifying agents (e.g., methylcellulose), pH buffering agents, gelling or viscosity enhancing additives, preservatives, flavoring agents, coloring agents, depending on the desired route of administration and preparation. In some aspects, standard textbooks can be consulted to prepare suitable preparations.

[0327] Various additives can be added to improve the stability and sterility of the composition, including antimicrobial preservatives, antioxidants, chelating agents, and buffers. The action of microorganisms can be prevented by various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, sorbic acid, etc. Prolonged absorption of injectable pharmaceutical forms can be achieved by using active substances that delay absorption, such as aluminum monostearate and gelatin.

[0328] Sustained-release preparations may be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody in the form of shaped articles, e.g. films, or microcapsules.

[0329] The formulations to be used for in vivo administration are generally sterile. Sterility may be readily accomplished, for example, by filtration through sterile filtration membranes.

[0330] In some embodiments, the toxic targeting agent is typically formulated and administered in a unit dosage form or multiple dosage form. Each unit dosage contains a predetermined amount of the therapeutically active compound sufficient to produce a desired therapeutic effect in association with the required pharmaceutical carrier, vehicle or diluent. In some embodiments, the unit dosage form includes, but is not limited to, tablets, capsules, pills, powders, granules, sterile parenteral solutions or suspensions, and oral solutions or suspensions, and oil-water emulsions, containing a suitable amount of the compound or its pharma-ceutically acceptable derivatives. The unit dosage form can be contained in ampoules and syringes, or can be individually packaged in tablets or capsules. The unit dosage form can be administered in fractions or multiples thereof. In some embodiments, the multiple dosage form is a plurality of identical unit dosage forms packaged in a single container, which are administered in separate unit dosage forms. Examples of multiple dosage forms include vials, bottles of tablets or capsules, or bottles of pints or gallons.

[0331] III. EXEMPLARY EMBODIMENTS Among the aspects provided are: 1. 1. A method of treatment comprising administering to a subject an active agent or other treatment capable of treating, preventing, delaying, or reducing the onset of toxicity, At the time of administration, the subject has previously been administered a therapy, including an immunotherapy and / or a cellular therapy; (a) administration of the active substance or other treatment: (i) less than 10, 7, 6, 5, 4, or 3 days after initiation of administration of the therapy; or 10, 7, 6, 5, 4, or 3 days or less; and / or (ii) the subject does not exhibit signs or symptoms of severe cytokine release syndrome (CRS) and / or does not exhibit CRS of grade 2 or higher; and / or (iii) The subject does not exhibit signs or symptoms of severe neurotoxicity and / or does not exhibit grade 2 or higher neurotoxicity. and / or (b) between the start of administration of the therapy and the administration of the active agent or other treatment; (i) the subject does not exhibit severe CRS and / or does not exhibit grade 2 or higher CRS, and / or (ii) the subject does not experience severe neurotoxicity and / or does not experience grade 2 or higher neurotoxicity; method. 2. (a) administering to a subject having a disease or condition a therapy, including an immunotherapy or cell therapy; and (b) administering to the subject an active agent or other treatment capable of treating, preventing, delaying, or reducing the onset of toxicity: (i) when administration of the active agent or other treatment occurs less than 10, 7, 6, 5, 4, or 3 days after initiation of administration of therapy; and / or (ii) administration of the active agent or other treatment is at a time when the subject does not exhibit signs or symptoms of severe cytokine release syndrome (CRS) and / or does not exhibit CRS of grade 2 or higher; and / or (iii) between the start of administration of the therapy and the time of administration of the active agent or other treatment, the subject does not exhibit severe CRS and / or does not exhibit CRS of grade 2 or higher; and / or (iv) administration of the active agent or other treatment is at a time when the subject does not exhibit signs or symptoms of severe neurotoxicity and / or does not exhibit grade 2 or higher neurotoxicity; and / or (v) the subject does not experience severe neurotoxicity and / or does not experience grade 2 or higher neurotoxicity between the start of administration of the therapy and the start of administration of the active agent or other treatment; process A method of treatment comprising: 3. The method of embodiment 1 or embodiment 2, wherein said active agent or other treatment is administered at the time the subject shows signs or symptoms of CRS and / or exhibits grade 1 CRS, or within 24 hours after the subject exhibits the first sign or symptom of grade 1 CRS following initiation of administration of said therapy. 4. Grade 1 signs or symptoms of CRS include fever; and / or The active agent or other treatment is administered within 24 hours after the first sign of fever following the initiation of administration of the therapy. The method according to any one of aspects 1 to 3. 5. 1. A method of treatment comprising administering to a subject previously administered a therapy, including immunotherapy and / or cell therapy, an active agent or other treatment capable of treating, preventing, delaying, or reducing the onset of toxicity, The active agent or other treatment is administered within 24 hours of the first symptom of fever following the start of administration of the therapy; Treatment method. 6. The method of embodiment 1 or embodiment 5, further comprising the step of administering to the subject a therapy for treating the disease or condition prior to the step of administering said active agent or other treatment. 7. (a) administering to a subject having a disease or condition a therapy, including an immunotherapy and / or a cell therapy; and (b) administering to the subject an active agent or other treatment capable of treating, preventing, delaying, or reducing the onset of toxicity within 24 hours after the first sign of fever following initiation of administration of said therapy. A method of treatment comprising: 8. The method of any of embodiments 1-7, wherein the active agent or other treatment is administered within about 16 hours, within about 12 hours, within about 8 hours, within about 2 hours, or within about 1 hour after the first sign of fever following initiation of administration of the therapy. 9. The method of any of aspects 4-8, wherein the heat is a persistent heat. 10. Fever that does not decrease after treatment with antipyretics or does not decrease by more than 1°C; and / or Fever has not decreased by more than 1°C following treatment of the subject with an antipyretic medication; The method according to any one of aspects 4 to 9. 11. The method of any of embodiments 4-10, wherein the heat comprises a temperature of at least 38.0°C or at least about 38.0°C. 12. Fever includes a temperature between 38.0°C and 42.0°C, between 38.0°C and 39.0°C, between 39.0°C and 40.0°C, or between 40.0°C and 42.0°C, or between about 38.0°C and 42.0°C, between about 38.0°C and 39.0°C, between about 39.0°C and 40.0°C, or between about 40.0°C and 42.0°C, inclusive; or Fever includes temperatures greater than or equal to about 38.5°C, 39.0°C, 39.5°C, 40.0°C, 41.0°C, 42.0°C, or greater than or equal to about 38.5°C, 39.0°C, 39.5°C, 40.0°C, 41.0°C, 42.0°C, The method according to any one of aspects 4 to 11. 13. The method of any of embodiments 1-12, wherein the active agent or other treatment is administered less than 5 days after initiation of administration of the therapy, less than 4 days after initiation of administration of the therapy, or less than 3 days after initiation of administration of the therapy. 14. 14. The method of any of embodiments 1-13, wherein said therapy is or comprises a cell therapy. 15. The method of embodiment 14, wherein said cell therapy is or comprises adoptive cell therapy. 16. The method of any of aspects 1-15, wherein said therapy is or comprises tumor infiltrating lymphocyte (TIL) therapy, transgenic TCR therapy, or recombinant receptor-expressing cell therapy, which is optionally T cell therapy, optionally chimeric antigen receptor (CAR)-expressing cell therapy. 17. 17. The method of any of embodiments 1-16, wherein said active agent or other treatment is or comprises a steroid, or an antagonist or inhibitor of a cytokine receptor or cytokine selected from among IL-10, IL-10R, IL-6, IL-6 receptor, IFNγ, IFNGR, IL-2, IL-2R / CD25, MCP-1, CCR2, CCR4, MIP1β, CCR5, TNFα, TNFR1, IL-1, and IL-1Rα / IL-1β. 18. The method of embodiment 17, wherein said antagonist or inhibitor is or comprises an active agent selected from among an antibody or antigen-binding fragment, a small molecule, a protein or peptide, and a nucleic acid. 19. The method of embodiment 17 or embodiment 18, wherein said active agent or other treatment is or comprises an active agent selected from among tocilizumab, situximab, sarilumab, olokizumab (CDP6038), ercilimomab, ALD518 / BMS-945429, sirukumab (CNTO 136), CPSI-2634, ARGX-109, FE301, and FM101. 20. The method of any of embodiments 1-19, wherein the active agent or other treatment is or comprises tocilizumab. twenty one. Tocilizumab is administered at a dosage of 1 mg / kg to 10 mg / kg, 2 mg / kg to 8 mg / kg, 2 mg / kg to 6 mg / kg, 2 mg / kg to 4 mg / kg, or 6 mg / kg to 8 mg / kg, or about 1 mg / kg to 10 mg / kg, about 2 mg / kg to 8 mg / kg, about 2 mg / kg to 6 mg / kg, about 2 mg / kg to 4 mg / kg, or about 6 mg / kg to 8 mg / kg, inclusive; or Tocilizumab is administered at a dosage of at least 2 mg / kg, at least 4 mg / kg, at least 6 mg / kg, or at least 8 mg / kg, or at least about 2 mg / kg, at least about 4 mg / kg, at least about 6 mg / kg, or at least about 8 mg / kg, or about 2 mg / kg, about 4 mg / kg, about 6 mg / kg, or about 8 mg / kg; The method of embodiment 20. twenty two. further comprising administering to the subject a second active agent, which optionally is a steroid; The steroid: (i) within 7, 8, or 9 days after initiation of administration of said therapy; (ii) within 24 hours after the first sign of hypotension following initiation of administration of said therapy; (iii) following initiation of administration of said therapy, when the subject exhibits grade 2 cytokine release syndrome (CRS) or within 24 hours after the subject exhibits the first signs of grade 2 CRS; and / or (iv) following initiation of administration of said therapy, when the subject exhibits grade 2 neurotoxicity, or within 24 hours after the subject exhibits the first sign or symptom of grade 2 neurotoxicity. Administer, The method of any one of aspects 1 to 21. twenty three. 1. A method of treatment comprising administering a steroid to a subject receiving a therapy, including immunotherapy and / or cell therapy, The administration of the steroid: (i) within 7, 8, or 9 days after initiation of administration of the therapy; (ii) within 24 hours after the first sign of hypotension following initiation of administration of the therapy; (iii) following initiation of administration of the therapy, when the subject exhibits grade 2 cytokine release syndrome (CRS) or within 24 hours after the subject exhibits the first signs of grade 2 CRS; and / or (iv) following initiation of administration of the therapy, when the subject exhibits grade 2 neurotoxicity, or within 24 hours after the subject exhibits the first sign or symptom of grade 2 neurotoxicity. Get started, Treatment method. twenty four. The method of embodiment 23, comprising the step of administering to the subject a therapy for treating the disease or condition prior to the step of administering the steroid. twenty five. (a) administering to a subject having a disease or condition a therapy, including an immunotherapy and / or a cell therapy; and (b) administering to the subject a steroid, The administration of the steroid: (i) within 7, 8, or 9 days after initiation of administration of the therapy; (ii) within 24 hours after the first sign of hypotension following initiation of administration of the therapy; (iii) following initiation of administration of the therapy, when the subject exhibits grade 2 cytokine release syndrome (CRS) or within 24 hours after the subject exhibits the first signs of grade 2 CRS; and / or (iv) following initiation of administration of the therapy, when the subject exhibits grade 2 neurotoxicity, or within 24 hours after the subject exhibits the first sign or symptom of grade 2 neurotoxicity. Start, process A method of treatment comprising: 26. 26. The method of any of embodiments 22-25, wherein upon administration of the steroid, the subject does not exhibit severe CRS, does not exhibit Grade 3 or higher CRS, or does not exhibit severe neurotoxicity or does not exhibit Grade 3 or higher neurotoxicity. 27. The method of any of embodiments 22-26, wherein the steroid is administered within 24 hours after or contemporaneously with the first sign of hypotension following initiation of administration of said therapy. 28. The method of any of embodiments 22-27, wherein the steroid is administered simultaneously with the initiation of vasopressor therapy. 29. Low blood pressure: Systolic blood pressure of less than 90 mm Hg, 80 mm Hg, or 70 mm Hg, or less than about 90 mm Hg, about 80 mm Hg, or about 70 mm Hg; or Diastolic blood pressure less than 60 mm Hg, 50 mm Hg, or 40 mm Hg Including, The method of any one of aspects 22 to 28. 30. The method of any of embodiments 1-17 and 22-29, wherein the active agent is or comprises a steroid, which optionally is or comprises a corticosteroid, which optionally is a glucocorticoid. 31. The method of embodiment 30, wherein the corticosteroid is or comprises dexamethasone or prednisone. 32. 32. The method of any of embodiments 17 or 22-31, wherein the steroid is administered at an equivalent dosage of 1.0 mg to 20 mg dexamethasone / day, 1.0 mg to 10 mg dexamethasone / day, or 2.0 mg to 6.0 mg dexamethasone / day, or about 1.0 mg to 20 mg dexamethasone / day, about 1.0 mg to 10 mg dexamethasone / day, or about 2.0 mg to 6.0 mg dexamethasone / day, inclusive. 33. The method of any of embodiments 17 or 22-32, wherein the steroid is administered intravenously or orally. 34. administering an active agent or other treatment that can treat, prevent, delay, or reduce the onset of associated toxicity prior to administering the steroid; (i) the active agent or other treatment is administered less than or not more than 10, 7, 6, 5, 4, or 3 days after the start of administration of the therapy; and / or (ii) the active agent or other treatment is administered at a time when the subject does not exhibit signs or symptoms of severe cytokine release syndrome (CRS) and / or does not exhibit Grade 2 or higher CRS; and / or (iii) the subject does not exhibit severe CRS and / or does not exhibit grade 2 or higher CRS between the start of administration of the therapy and the time of administration of the active agent or other treatment; and / or (iv) the active agent or other treatment is administered at a time when the subject is not exhibiting signs or symptoms of severe neurotoxicity and / or is not exhibiting grade 2 or higher neurotoxicity; and / or (v) the subject does not experience severe neurotoxicity and / or CRS of grade 2 or higher between the start of administration of the therapy and the administration of the active agent or other treatment; The method of any one of aspects 23 to 33. 35. The method of embodiment 34, wherein the active agent or other treatment is administered at the time the subject exhibits grade 1 CRS or within 24 hours after the subject exhibits the first sign or symptom of grade 1 CRS. 36. Grade 1 The first sign or symptom of CRS is fever; or The active agent or other treatment is administered within 24 hours after the first sign of fever following the initiation of administration of the therapy; The method of embodiment 34 or embodiment 35. 37. further comprising the step of administering an active agent or other treatment capable of treating, preventing, delaying, or reducing the onset of toxicity prior to the step of administering the steroid; The active agent or other treatment is administered within 24 hours after the first sign of fever following the initiation of administration of the therapy; The method of any one of aspects 23 to 36. 38. The method of embodiment 36 or embodiment 37, wherein said active agent or other treatment is administered within about 16 hours, within about 12 hours, within about 8 hours, within about 2 hours, or within about 1 hour after the first sign of fever following initiation of administration of said therapy. 39. The method of any one of embodiments 36-38, wherein the heat is persistent heat. 40. Fever that does not decrease after treatment with antipyretics or does not decrease by more than 1°C; and / or Fever has not decreased by more than 1°C following treatment of the subject with an antipyretic medication; The method of any one of aspects 36 to 39. 41. The method of any of embodiments 36-40, wherein the heat comprises a temperature of at least 38.0°C or at least about 38.0°C. 42. Fever includes a temperature between 38.0°C and 42.0°C, between 38.0°C and 39.0°C, between 39.0°C and 40.0°C, or between 40.0°C and 42.0°C, or between about 38.0°C and 42.0°C, between about 38.0°C and 39.0°C, between about 39.0°C and 40.0°C, or between about 40.0°C and 42.0°C, inclusive; or Fever includes temperatures greater than or equal to about 38.5°C, 39.0°C, 39.5°C, 40.0°C, 41.0°C, 42.0°C, or greater than or equal to about 38.5°C, 39.0°C, 39.5°C, 40.0°C, 41.0°C, 42.0°C, The method of any one of embodiments 36 to 41. 43. The method of any of embodiments 34-42, wherein the active agent or other treatment is administered less than 5 days after initiation of administration of the therapy, less than 4 days after initiation of administration of the therapy, or less than 3 days after initiation of administration of the therapy. 44. The method of any of aspects 23 to 43, wherein the therapy is a cell therapy. 45. The method of embodiment 44, wherein said cell therapy is adoptive cell therapy. 46. The method of any of aspects 23 to 45, wherein the therapy is tumor infiltrating lymphocyte (TIL) therapy, transgenic TCR therapy, or recombinant receptor-expressing cell therapy, which is optionally T cell therapy, and optionally chimeric antigen receptor (CAR)-expressing cell therapy. 47. The method of any of embodiments 34-46, wherein said active agent or other treatment is an antagonist or inhibitor of a cytokine receptor or cytokine selected from among IL-10, IL-10R, IL-6, IL-6 receptor, IFNγ, IFNGR, IL-2, IL-2R / CD25, MCP-1, CCR2, CCR4, MIP1β, CCR5, TNFα, TNFR1, IL-1, and IL-1Rα / IL-1β. 48. The method of embodiment 47, wherein said antagonist or inhibitor is or comprises an active agent selected from among an antibody or antigen-binding fragment, a small molecule, a protein, a peptide, and a nucleic acid. 49. The method of embodiment 47 or embodiment 48, wherein said active agent or other treatment is or comprises an active agent selected from among tocilizumab, cituximab, sarilumab, olokizumab (CDP6038), ersilimomab, ALD518 / BMS-945429, sirukumab (CNTO 136), CPSI-2634, ARGX-109, FE301, and FM101. 50. The method of any of embodiments 34-49, wherein the active agent or other treatment is or comprises tocilizumab. 51. Tocilizumab is administered at a dosage of 1 mg / kg to 10 mg / kg, 2 mg / kg to 8 mg / kg, 2 mg / kg to 6 mg / kg, 2 mg / kg to 4 mg / kg, or 6 mg / kg to 8 mg / kg, or about 1 mg / kg to 10 mg / kg, about 2 mg / kg to 8 mg / kg, about 2 mg / kg to 6 mg / kg, about 2 mg / kg to 4 mg / kg, or about 6 mg / kg to 8 mg / kg, inclusive; or Tocilizumab is administered at a dosage of at least 2 mg / kg, at least 4 mg / kg, at least 6 mg / kg, or at least 8 mg / kg, or at least about 2 mg / kg, at least about 4 mg / kg, at least about 6 mg / kg, or at least about 8 mg / kg, or about 2 mg / kg, about 4 mg / kg, about 6 mg / kg, or about 8 mg / kg; The method of embodiment 50. 52. The therapy is or includes a cell therapy, and the number of cells administered is about 0.25 x 10 6 Cells / kg (subject weight) ~5 x 10 6 cells / kg, 0.5 x 10 6 Cells / kg (subject weight) ~3 x 10 6 cells / kg, approximately 0.75 x 10 6 cells / kg~2.5 x 10 6 cells / kg or approximately 1 x 10 6 cells / kg~2 x 10 6 52. The method of any one of embodiments 1 to 51, wherein the amount of cells / kg (inclusive) is 100%. 53. The method of any of embodiments 1-52, wherein said therapy is or comprises a cell therapy, and the cells are administered in a single pharmaceutical composition comprising the cells. 54. the therapy is or comprises a cell therapy, the dose of cells is a split dose, and the dose of cells is administered in multiple compositions comprising, in total, the dose of cells over a period of 3 days or less; The method of any one of embodiments 1 to 52. 55. The method of any of embodiments 1-54, wherein the disease or condition is a tumor or cancer. 56. The method of any of embodiments 1-55, wherein the disease or condition is leukemia or lymphoma. 57. The method of any of embodiments 1-56, wherein the disease or condition is non-Hodgkin's lymphoma (NHL) or acute lymphoblastic leukemia (ALL). 58. the therapy is a cell therapy comprising a dose of cells expressing a recombinant receptor; the recombinant receptor binds to, recognizes or targets an antigen associated with a disease or condition; and / or the recombinant receptor is a T cell receptor or a functional non-T cell receptor; and / or The recombinant receptor is a chimeric antigen receptor (CAR). The method of any one of embodiments 1 to 57. 59. The method of embodiment 58, wherein the CAR comprises an extracellular antigen recognition domain that specifically binds to an antigen, and an intracellular signaling domain that comprises an ITAM. 60. The method of embodiment 59, wherein the antigen is CD19. 61. The method of embodiment 60, wherein the intracellular signaling domain comprises the intracellular domain of the CD3 zeta (CD3ζ) chain. 62. The method of embodiment 60 or embodiment 61, wherein the CAR further comprises a costimulatory signaling region. 63. The method of embodiment 62, wherein the costimulatory signaling domain comprises the signaling domain of CD28 or 4-1BB. 64. The method of any of aspects 1-63, wherein the therapy is a cell therapy comprising a dose of cells, including T cells. 65. The method of embodiment 64, wherein the T cells are CD4+ or CD8+. 66.

[0046] Embodiment 66. The method of embodiment 64 or embodiment 65, wherein the T cells are autologous to the subject. 67. and / or the method further comprises administering a chemotherapeutic agent prior to administering said therapy; the subject has been pre-treated with a chemotherapeutic agent prior to the start of administration of said therapy; The method of any one of embodiments 1 to 66. 68. The method of embodiment 67, wherein the chemotherapeutic agent comprises an active agent selected from the group consisting of cyclophosphamide, fludarabine, and / or combinations thereof. 69. The method of embodiment 67 or embodiment 68, wherein the chemotherapeutic agent is administered 2 to 5 days prior to the start of administration of said therapy. 70. The chemotherapy agent is 1 mg / m 2 ~100 mg / m 2 or about 1 mg / m 2 ~100 mg / m 2 , 10 mg / m 2 ~75 mg / m 2 or about 10 mg / m 2 ~75 mg / m 2 , 15 mg / m 2 ~50 mg / m 2 or about 15 mg / m 2 ~50 mg / m 2 , 20 mg / m 2 ~30 mg / m 2 or about 20 mg / m 2 ~30 mg / m 2 , or 24 mg / m 2 ~26 mg / m 2 or about 24 mg / m 2 ~26 mg / m 2 and / or the chemotherapeutic agent is cyclophosphamide administered at or about 20 mg / kg to 100 mg / kg, 40 mg / kg to 80 mg / kg, or 30 mg / kg to 60 mg / kg, The method of any one of aspects 67 to 69. 71. a toxicity outcome in a subject at or up to about the 7th, 8th, 9th, 10th, 11th, 12th, 13th, 14th, 15th, 16th, 17th, 18th, 19th, 20th, 21st, 22nd, 23rd, 24th, 25th, 26th, 27th, 28th, 29th, or 30th day following administration of said therapy is not detectable or is reduced when compared to a method comprising an alternative treatment regimen; In the alternative treatment regimen, the subject is administered the active agent or other treatment after the onset of severe CRS or after the onset of grade 2 or higher CRS. The method of any one of embodiments 1 to 70. 72. The method of embodiment 71, wherein the toxicity outcome is reduced by more than 50%, 60%, 70%, 80%, 90% or more. 73. The method of embodiment 71 or embodiment 72, wherein the toxicity outcome is symptoms associated with neurotoxicity of grade 3 or higher, or symptoms associated with CRS of grade 2 or higher. 74. The method of any of embodiments 71-73, wherein the toxicity outcome is grade 3 or greater neurotoxicity including one or more symptoms selected from confusion, delirium, expressive aphasia, obtundation, myoclonus, lethargy, altered mental status, convulsions, seizure-like activity, and seizures. 75. The method of any of embodiments 71-73, wherein the toxicity outcome is Grade 3 or greater CRS including one or more symptoms selected from the following: persistent fever above or above 38°C for at least 3 consecutive days; hypotension requiring high doses of vasopressors or multiple vasopressors; hypoxia, optionally including plasma oxygen (PO2) levels below or below 90%; and respiratory failure requiring mechanical ventilation. 76. the therapy is a cell therapy comprising administration of cells; the cells exhibit increased or prolonged proliferation and / or persistence in the subject compared to administration of the cell therapy in a subject in an alternative cohort or in a treatment group using an alternative treatment regimen or in a corresponding subject; The alternative treatment regimen includes administering the cell therapy and subsequently administering the active agent or other treatment after the onset of severe CRS or after the onset of grade 2 or higher CRS; Optionally, the subject in the alternative treatment regimen is not administered the active agent, and optionally is not administered any other treatment designed to treat CRS or neurotoxicity after administration of the cells and prior to the onset of grade 2 or higher CRS or severe CRS. The method of any one of embodiments 1 to 75. 77. The method of embodiment 76, wherein the increase or prolongation of proliferation and / or persistence is 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or 10-fold. 78. the therapy is a cell therapy comprising engineered cells and / or CAR-expressing cells; and At 30, 60, or 90 days following initiation of administration of the therapy, the concentration or number of engineered cells and / or CAR-expressing cells in the subject's blood is at least 10 or at least about 10 engineered cells or CAR-expressing cells per microliter, at least 50% of the total number of peripheral blood mononuclear cells (PBMCs), at least 1 x 10 5 or at least about 1 x 10 5engineered cells or CAR-expressing cells, and / or at least 5,000 copies of CAR-encoding DNA or engineered receptor-encoding DNA per microgram of DNA; and / or 30, 60, or 90 days following initiation of administration of the therapy, CAR-expressing cells and / or engineered cells are detectable in the blood or serum of the subject; and / or On the 30th, 60th, or 90th day following initiation of administration of the therapy, the subject's blood contains at least 20% CAR-expressing cells, at least 10 CAR-expressing cells per microliter, or at least 1 x 10 4 containing CAR-expressing cells; on the 30th, 60th, or 90th day following initiation of administration of the therapy, the subject's blood contains at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% of a biologically effective dose of the cells; At 30, 60, or 90 days following initiation of administration of the therapy, the subject's blood contains at least 20% engineered cells and / or CAR-expressing cells, at least 10 engineered cells and / or CAR-expressing cells per microliter, and / or at least 1 x 10 4 containing the engineered cells and / or CAR-expressing cells; At the 30th, 60th, or 90th day following initiation of administration of the therapy, the subject exhibits a reduction or sustained reduction in the burden of the disease or condition, which is a 50, 60, 70, or 80% peak reduction, or about a 50, about 60, about 70, or about 80% peak reduction, or at least a 50, at least a 60, at least a 70, or at least an 80% peak reduction, or at least about a 50, at least a 60, at least a 70, or at least an 80% peak reduction, or a reduction associated with an effective dose. The method of any one of embodiments 1 to 77. 79. At 30, 60, or 90 days following initiation of administration of said therapy, the subject does not and / or does not exhibit severe neurotoxicity, severe CRS, Grade 2 or higher CRS, Grade 2 or higher neurotoxicity, and / or does not exhibit seizures or other CNS outcomes; or The method of any of embodiments 1-78, wherein at 30, 60, or 90 days following initiation of administration of said therapy, less than or about 25%, less than or about 20%, less than or about 15%, or less than or about 10% of the subjects so treated do not exhibit and / or do not exhibit severe neurotoxicity, severe CRS, Grade 2 or higher CRS, Grade 2 or higher neurotoxicity, and / or do not exhibit seizures or other CNS outcomes. 80. the therapy is a cell therapy comprising engineered cells and / or CAR-expressing cells; and The method of any of embodiments 1-79, wherein the area under the curve (AUC) of blood concentrations of engineered cells and / or CAR-expressing cells over a period of time following administration of the therapy is greater than that obtained by a method comprising an alternative dosing regimen in which the therapy is administered to a subject and the active agent or other treatment is administered when the subject exhibits severe or Grade 2 or greater or Grade 3 or greater CRS or neurotoxicity. 81. 1. An active agent or other treatment for use in treating, preventing, delaying or reducing the onset of toxicity in a subject who has previously been administered a therapy, including immunotherapy and / or cell therapy, (a) administering the active substance or other treatment to: (i) less than 10, 7, 6, 5, 4, or 3 days after initiation of administration of the therapy to the subject; and / or, (ii) when the subject does not exhibit signs or symptoms of severe cytokine release syndrome (CRS) and / or does not exhibit CRS of grade 2 or higher; and / or (iii) When the subject does not exhibit signs or symptoms of severe neurotoxicity and / or does not exhibit grade 2 or higher neurotoxicity; administering to a subject; and / or (b) between the start of administration of the therapy to the subject and the administration of the active agent or other treatment; (i) the subject does not exhibit severe CRS and / or does not exhibit grade 2 or higher CRS, and / or (ii) the subject does not experience severe neurotoxicity and / or does not experience grade 2 or higher neurotoxicity; Active substances or other treatments. 82. The active agent or other treatment of embodiment 81, wherein the active agent or other treatment is administered when the subject shows signs or symptoms of CRS and / or shows grade 1 CRS, or is administered within 24 hours after the subject shows the first sign or symptom of grade 1 CRS following administration of the therapy. 83. Grade 1 signs or symptoms of CRS include fever; and / or The active agent or other treatment is administered within 24 hours after the first sign of fever following administration of the therapy; The active agent or other treatment of embodiment 81 or embodiment 82. 84. 1. An active agent or other treatment for use in treating, preventing, delaying or reducing the onset of toxicity in a subject previously administered a therapy, including immunotherapy and / or cell therapy, The active agent or other treatment is administered within 24 hours of the first symptom of fever following administration of the therapy; Active substances or other treatments. 85. 1. An active agent or other treatment for use as a pharmaceutical in treating, preventing, delaying, or reducing the onset of toxicity in a subject previously administered a therapy, including immunotherapy and / or cell therapy, (a) administering the active substance or other treatment to: (i) less than 10, 7, 6, 5, 4, or 3 days after initiation of administration of the therapy to the subject; and / or, (ii) when the subject does not exhibit signs or symptoms of severe cytokine release syndrome (CRS) and / or does not exhibit CRS of grade 2 or higher; and / or (iii) When the subject does not exhibit signs or symptoms of severe neurotoxicity and / or does not exhibit grade 2 or higher neurotoxicity; administering to a subject; and / or (b) between the start of administration of the therapy to the subject and the administration of the active agent or other treatment; (i) the subject does not exhibit severe CRS and / or does not exhibit grade 2 or higher CRS, and / or (ii) the subject does not experience severe neurotoxicity and / or does not experience grade 2 or higher neurotoxicity; Active substances or other treatments. 86. The active agent or other treatment of embodiment 85, which is administered when the subject shows signs or symptoms of CRS and / or shows grade 1 CRS, or is administered within 24 hours after the subject shows the first sign or symptom of grade 1 CRS following administration of said therapy. 87. Grade 1 signs or symptoms of CRS include fever; and / or The active agent or other treatment is administered within 24 hours after the first sign of fever following administration of the therapy; The active agent or other treatment of embodiment 85 or embodiment 86. 88. 1. An active agent or other treatment for use as a pharmaceutical in treating, preventing, delaying, or reducing the onset of toxicity in a subject previously administered a therapy, including immunotherapy and / or cell therapy, The active agent or other treatment is administered within 24 hours of the first symptom of fever following administration of the therapy; Active substances or other treatments. 89. 1. Use of an active agent or other treatment for the manufacture of a medicament for treating, preventing, delaying, or reducing the onset of toxicity in a subject previously administered a therapy, including immunotherapy and / or cell therapy, comprising: (a) administering the active substance or other treatment to: (i) less than 10, 7, 6, 5, 4, or 3 days after initiation of administration of the therapy to the subject; and / or, (ii) when the subject does not exhibit signs or symptoms of severe cytokine release syndrome (CRS) and / or does not exhibit CRS of grade 2 or higher; and / or (iii) When the subject does not exhibit signs or symptoms of severe neurotoxicity and / or does not exhibit grade 2 or higher neurotoxicity; administering to a subject; and / or (b) between the start of administration of the therapy to the subject and the administration of the active agent or other treatment; (i) the subject does not exhibit severe CRS and / or does not exhibit grade 2 or higher CRS, and / or (ii) the subject does not experience severe neurotoxicity and / or does not experience grade 2 or higher neurotoxicity; use. 90. The use of embodiment 89, wherein the active agent or other treatment is administered when the subject shows signs or symptoms of CRS and / or exhibits grade 1 CRS, or within 24 hours after the subject shows the first sign or symptom of grade 1 CRS following administration of the therapy. 91. Grade 1 signs or symptoms of CRS include fever; and / or The active agent or other treatment is administered within 24 hours after the first sign of fever following administration of the therapy; Use of embodiment 89 or embodiment 90. 92. 1. Use of an active agent or other treatment for the manufacture of a medicament for treating, preventing, delaying, or reducing the onset of toxicity in a subject previously administered a therapy, including immunotherapy and / or cell therapy, comprising: The active agent or other treatment is administered within 24 hours of the first symptom of fever following administration of the therapy; use. 93. The active agent or other treatment of any of embodiments 81-88 or the use of any of embodiments 89-92, wherein the active agent or other treatment is administered within about 16 hours, within about 12 hours, within about 8 hours, within about 2 hours, or within about 1 hour after the first sign of fever following administration of the therapy. 94. The active substance or other treatment or use of any of embodiments 83, 84, 87, 88 and 91-93, wherein the fever is persistent fever. 95. Fever that does not decrease after treatment with antipyretics or does not decrease by more than 1°C; and / or Fever has not decreased by more than 1°C following treatment of the subject with an antipyretic medication; The active substance or other treatment or use of any of embodiments 83, 84, 87, 88 and 91-94. 96. The active agent or other treatment or use of any of embodiments 83, 84, 87, 88 and 91-95, wherein the heat comprises a temperature of at least 38.0°C or at least about 38.0°C. 97. Fever includes a temperature between 38.0°C and 42.0°C, between 38.0°C and 39.0°C, between 39.0°C and 40.0°C, or between 40.0°C and 42.0°C, or between about 38.0°C and 42.0°C, between about 38.0°C and 39.0°C, between about 39.0°C and 40.0°C, or between about 40.0°C and 42.0°C, inclusive; or Fever includes temperatures greater than or equal to about 38.5°C, 39.0°C, 39.5°C, 40.0°C, 41.0°C, 42.0°C, or greater than or equal to about 38.5°C, 39.0°C, 39.5°C, 40.0°C, 41.0°C, 42.0°C, The active substance or other treatment or use of any of embodiments 83, 84, 87, 88 and 91-96. 98. 98. The active substance or other treatment or use of any of embodiments 81-97, wherein said active substance or other treatment is or comprises a steroid, or an antagonist or inhibitor of a cytokine receptor or cytokine selected from among IL-10, IL-10R, IL-6, IL-6 receptor, IFNγ, IFNGR, IL-2, IL-2R / CD25, MCP-1, CCR2, CCR4, MIP1β, CCR5, TNFα, TNFR1, IL-1, and IL-1Rα / IL-1β. 99. 99. The active agent or other treatment or use of embodiment 98, wherein said antagonist or inhibitor is or comprises an active agent selected from among an antibody or antigen-binding fragment, a small molecule, a protein or peptide, and a nucleic acid. 100. The active substance or other treatment or use of embodiment 98 or embodiment 99, wherein said active substance or other treatment is or comprises an active substance selected from among tocilizumab, cituximab, sarilumab, olokizumab (CDP6038), ersilimomab, ALD518 / BMS-945429, sirukumab (CNTO 136), CPSI-2634, ARGX-109, FE301, and FM101. 101. The active substance or other treatment or use of any of aspects 81 to 100, wherein the active substance or other treatment is or comprises tocilizumab. 102. Tocilizumab is administered at a dosage of 1 mg / kg to 10 mg / kg, 2 mg / kg to 8 mg / kg, 2 mg / kg to 6 mg / kg, 2 mg / kg to 4 mg / kg, or 6 mg / kg to 8 mg / kg, or about 1 mg / kg to 10 mg / kg, about 2 mg / kg to 8 mg / kg, about 2 mg / kg to 6 mg / kg, about 2 mg / kg to 4 mg / kg, or about 6 mg / kg to 8 mg / kg, inclusive; or Tocilizumab is administered at a dosage of at least 2 mg / kg, at least 4 mg / kg, at least 6 mg / kg, or at least 8 mg / kg, or at least about 2 mg / kg, at least about 4 mg / kg, at least about 6 mg / kg, or at least about 8 mg / kg, or about 2 mg / kg, about 4 mg / kg, about 6 mg / kg, or about 8 mg / kg; The active substance or other treatment or use of embodiment 101. 103. The active agent or other treatment or use of any of aspects 81-98, wherein the active agent is or comprises a steroid, which optionally is or comprises a corticosteroid, which optionally is a glucocorticoid. 104. The active substance or other treatment or use of embodiment 103, wherein the corticosteroid is or comprises dexamethasone or prednisone. 105. 105. The active substance or other treatment or use of any of embodiments 81-98, 103 and 104, wherein the steroid is administered in an equivalent dosage of 1.0 mg to 20 mg dexamethasone / day, 1.0 mg to 10 mg dexamethasone / day, or 2.0 mg to 6.0 mg dexamethasone / day, or about 1.0 mg to 20 mg dexamethasone / day, about 1.0 mg to 10 mg dexamethasone / day, or about 2.0 mg to 6.0 mg dexamethasone / day, inclusive. 106. The active substance or other treatment or use of any of embodiments 81-98 and 103-105, wherein the steroid is formulated for intravenous or oral administration. 107. The active substance or other treatment or use of any of aspects 81 to 106, wherein said therapy is or comprises a cell therapy. 108. The active substance or other treatment or use of embodiment 107, wherein said cell therapy is or comprises adoptive cell therapy. 109. The active substance or other treatment or use of any of aspects 81 to 108, wherein said therapy is or comprises tumor infiltrating lymphocyte (TIL) therapy, transgenic TCR therapy, or recombinant receptor-expressing cell therapy, which is optionally T cell therapy, optionally chimeric antigen receptor (CAR)-expressing cell therapy. 110. the therapy is a cell therapy comprising a dose of cells expressing a recombinant receptor; the recombinant receptor binds to, recognizes or targets an antigen associated with a disease or condition; and / or the recombinant receptor is a T cell receptor or a functional non-T cell receptor; and / or The recombinant receptor is a chimeric antigen receptor (CAR). The active substance or other treatment or use of any of embodiments 81 to 109. 111. The active agent or other treatment or use of embodiment 109 or embodiment 110, wherein the CAR comprises an extracellular antigen recognition domain that specifically binds to an antigen, and an intracellular signaling domain comprising an ITAM. 112. The active agent or other treatment or use of embodiment 111, wherein the antigen is CD19. 113. The active agent or other treatment or use of embodiment 111, wherein the intracellular signaling domain comprises the intracellular domain of the CD3 zeta (CD3ζ) chain. 114. The active agent or other treatment or use of any of embodiments 109-113, wherein the CAR further comprises a costimulatory signaling region. 115. The active agent or other treatment or use of embodiment 114, wherein the costimulatory signaling domain comprises the signaling domain of CD28 or 4-1BB. 116. The active agent or other treatment or use of any of aspects 81 to 115, wherein the therapy is a cell therapy comprising a dose of cells, including T cells. 117. The active substance or other treatment or use of embodiment 116, wherein the T cells are CD4+ or CD8+. 118. The active substance or other treatment or use of embodiment 116 or embodiment 117, wherein the T cells are autologous to the subject. 119. The active substance or other treatment or use of any of embodiments 110 to 118, wherein the disease or condition is a tumor or cancer. 120. The active substance or other treatment or use of any of embodiments 110-119, wherein the disease or condition is leukemia or lymphoma. 121. The active substance or other treatment or use of any of embodiments 110-120, wherein the disease or condition is non-Hodgkin's lymphoma (NHL) or acute lymphoblastic leukemia (ALL). 122. The active agent or other treatment or use of any of aspects 81-121, wherein the subject has been pre-treated with a chemotherapeutic agent prior to administration of said therapy. one two three. The active agent or other treatment or use of embodiment 122, wherein the chemotherapeutic agent comprises an active agent selected from the group consisting of cyclophosphamide, fludarabine, and / or combinations thereof.

[0332] IV. Definition Unless otherwise defined, all technical terms, annotations, and other technical and scientific terms or technical terms used herein are intended to have the same meaning as that commonly understood by those skilled in the art to which the claimed matter belongs.In some cases, for ease of understanding and / or easy reference, terms with commonly understood meanings are defined herein.The description of such definitions in this specification should not necessarily be interpreted as being significantly different from that commonly understood in the art.

[0333] The terms "polypeptide" and "protein" are used interchangeably to refer to a polymer of amino acid residues and are not limited to a minimum length. The polypeptides and other polypeptides, including the receptors provided, such as linkers or peptides, may contain amino acid residues, including natural and / or non-natural amino acid residues. The term also includes post-expression modifications of the polypeptide, such as glycosylation, sialylation, acetylation, and phosphorylation. In some aspects, the polypeptide may contain modifications to the native or natural sequence, so long as the protein maintains the desired activity. These modifications may be deliberate, such as modifications via site-directed mutagenesis, or accidental, such as modifications via mutations in the host that produces the protein or errors due to PCR amplification.

[0334] The term "pharmaceutical formulation" refers to a preparation in a form such that the biological activity of the active ingredient contained therein is effective, and which does not contain additional ingredients that are unacceptably toxic to the subject to which the formulation is administered.

[0335] "Pharmaceutically acceptable carrier" refers to an ingredient in a pharmaceutical formulation, other than an active ingredient, that is non-toxic to a subject. Pharmaceutically acceptable carriers include, but are not limited to, buffers, excipients, stabilizers, or preservatives.

[0336] As used herein, a "subject" is a mammal, such as a human or other animal, typically a human. In some embodiments, the subject, such as a patient, to which the active agent, cell, cell population, or composition is administered is a mammal, typically a primate, such as a human. In some embodiments, the primate is a monkey or an ape. The subject may be male or female and may be of any suitable age, including infants, juveniles, adolescents, adults, and geriatric subjects. In some embodiments, the subject is a non-primate mammal, such as a rodent.

[0337] As used herein, "treatment" (and its grammatical variants, e.g., "treat" or "treating") refers to the complete or partial improvement or reduction of a disease or condition or disorder, or its associated symptoms, adverse effects or outcomes, or phenotype. Desirable therapeutic effects of treatment include, but are not limited to, prevention of disease onset or recurrence, alleviation of symptoms, reduction of any direct or indirect pathological consequences of a disease, prevention of metastasis, reduction in the rate of disease progression, improvement or mitigation of the disease state, and remission or improvement of prognosis. The term does not imply complete cure of a disease, or complete elimination of any symptoms, or effect on all symptoms or outcomes.

[0338] As used herein, "delaying the onset of disease" means to prolong, hinder, slow, decelerate, stabilize, inhibit, and / or postpone the onset of a disease (e.g., cancer). This delay can be of various lengths of time depending on the history of the disease and / or the individual being treated. As will be apparent to those skilled in the art, a sufficient or significant delay actually includes prevention in that the individual does not develop the disease. For example, late-stage cancer, such as the onset of metastasis, can be delayed.

[0339] "Preventing" as used herein includes providing prophylaxis against the occurrence or recurrence of a disease in a subject who may be predisposed to the disease but has not yet been diagnosed with the disease. In some embodiments, the active agents, cells and compositions provided are used to delay the onset of a disease or to slow the progression of a disease.

[0340] As used herein, "inhibiting" a function or activity refers to reducing a function or activity when compared to the same conditions except for the condition or parameter of interest, or when compared to another condition, For example, a cell that inhibits tumor growth reduces the rate of tumor growth compared to the rate of tumor growth in the absence of the cell.

[0341] In the context of administration, an "effective amount" of an active agent, e.g., a pharmaceutical formulation, active agent, cell, or composition, refers to an amount effective, at dosages / amounts, and for periods of time necessary, to achieve a desired result, e.g., a therapeutic or prophylactic result.

[0342] A "therapeutically effective amount" of a composition, e.g., a pharmaceutical formulation comprising an active agent or cells, refers to an amount effective at the dosage and for the period of time necessary to achieve a desired therapeutic result, e.g., a desired therapeutic result for treating a disease, condition, or disorder, and / or a pharmacokinetic or pharmacodynamic effect of treatment. A therapeutically effective amount may vary depending on factors such as the disease state, age, sex, and weight of the subject, and the active agent or cell population administered. In some embodiments, the provided methods involve administering an effective amount, e.g., a therapeutically effective amount, of the active agent, cell, and / or composition.

[0343] A "prophylactically effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result. Typically, since a prophylactic dose is used in subjects prior to or at an earlier stage of disease, the prophylactically effective amount will be less than the therapeutically effective amount, but not necessarily less than the therapeutically effective amount. EXAMPLES

[0344] V. Working Examples The following examples are included for illustrative purposes only and are not intended to limit the scope of the invention.

[0345] Example 1 Early intervention methods to prevent or reduce toxicity in cancer patients treated with CAR-expressing autologous T cells A cohort of subjects (n=6) with pediatric acute lymphoblastic leukemia (ALL) was administered autologous T cells expressing anti-CD19 chimeric antigen receptor (CAR). The construct encoding the CAR also contained a nucleic acid encoding truncated EGFR (EGFRt) for use as a marker. Prior to administration of the cells, patients were leukapheresed and treated with a conditioning chemotherapy regimen including fludarabine and cyclophosphamide. To generate autologous CAR-expressing T cells, T cells were isolated from leukapheresed samples from each individual subject by immunoaffinity-based enrichment, activated, transduced with a viral vector encoding an anti-CD19 CAR, and subsequently expanded.

[0346] Prior to administration of CAR-expressing T cells, subjects were treated with 30 mg / m 2 Fludarabine daily for 3 days and 300 mg / m 2 Cyclophosphamide was administered daily for three days. At d=0, subjects were then randomized to 0.5–10 x 10 6 Treated with CAR-expressing T cells at cells / kg.

[0347] As an early or preemptive measure to prevent or ameliorate potential toxicity, subjects were administered an active agent capable of treating or preventing such toxicity prior to the appearance of severe toxicity and / or prior to signs or symptoms of neurotoxicity. At the first sign of persistent fever following administration of CAR-expressing T cells (e.g., fever not abated by administration of antipyretics), subjects were treated with either 4 mg / kg or 8 mg / kg of the anti-IL-6 receptor antibody tocilizumab. In subjects exhibiting hypotension, such as hypotension to an extent that indicates they should be treated with low-dose vasopressor therapy, subjects were administered the steroid dexamethasone starting at the time of such hypotension, such as at the time of administration of such vasopressor therapy. When applicable, such subjects were administered dexamethasone at 5-10 mg / day for 2 days.

[0348] Tumor burden was assessed in subjects at various time points throughout treatment. At day 63+, each of the subjects in this cohort demonstrated minimal residual disease (MRD)-negative complete response (CR) with CAR-T persistence at greater than 80% biologically effective dose (BED) as measured by levels of B-cell aplasia (BCA).

[0349] One of six subjects in this cohort developed hypotension requiring vasopressor therapy, and none of the subjects (0 / 6) developed signs or symptoms of severe neurotoxicity (CNS outcomes) or exhibited seizures. The results demonstrated the success of preemptive intervention with a toxicity targeting agent, showing that subjects preemptively treated (prior to the onset of severe CRS or neurotoxicity symptoms) with a regimen involving early intervention with an active agent commonly used to target toxic outcomes observed following CAR-T therapy showed an absence of CNS outcomes or neurotoxicity and severe CRS, while also demonstrating persistence and continued efficacy of CAR-T cells over time.

[0350] Example 2 Early intervention methods to prevent or reduce toxicity in cancer patients treated with CAR-expressing autologous T cells As an extension of the study, a cohort of subjects (total n=43) with pediatric acute lymphoblastic leukemia (ALL) were administered and evaluated autologous T cells expressing an anti-CD19 chimeric antigen receptor (CAR), as described in Example 1.

[0351] In this evaluation, subjects in the first cohort (n=20) were administered treatment for toxicity following evidence or signs of dose-limiting toxicity after CAR-T cell infusion, if applicable, and (2) subjects in the second cohort (n=23) were administered early intervention therapy to ameliorate or prevent toxicity or toxic outcomes before developing or exhibiting dose-limiting toxicity. Specifically, in the first cohort (n=20), subjects were treated with the anti-IL-6 receptor antibody tocilizumab 8 mg / kg with or without steroids in the event of dose-limiting toxicity. Subjects in the second cohort (n=23) were administered early or preemptive treatment with the anti-IL-6 receptor antibody tocilizumab and optionally dexamethasone following administration of CAR-expressing T cells if the subject exhibited persistent fever of 39°C or higher for 10 hours despite antipyretics, persistent or recurrent hypotension after the first fluid bolus, and / or initiation of supplemental oxygen. At various time points relative to treatment, CAR T cell engraftment and B cell aplasia were determined by flow cytometry, and tumor burden was assessed in subjects. The overall rate of minimal residual disease (MRD)-negative complete response (CR) was 93% (40 / 43) and was not affected by the use of tocilizumab or dexamethasone. The rates of MRD-negative CR in patients receiving tocilizumab without steroids, tocilizumab with steroids, or steroids alone were similar (89% vs. 100% vs. 100%, respectively). Continued peripheral blood proliferation of CAR T cells was seen in subjects receiving tocilizumab and / or steroids. The results demonstrate that early intervention treatment with tocilizumab or dexamethasone did not affect the efficacy of CAR T cell therapy, CAR T cell engraftment, or CAR T cell persistence. The overall rates of CRS observed in the two cohorts were 91% (21 / 23) and 95% (19 / 20), respectively. The rates of severe CRS were 30% (9 / 23) and 15% (3 / 20), respectively, p=0.3. The results of the early intervention strategy are shown in Table 5 below.

[0352] (Table 5) JPEG2024156736000005.jpg33153

[0353] Cell proliferation was evaluated in subjects who received intervention for severe toxicity. The results show that CAR T cell proliferation was not affected by the administration of tocilizumab, as shown in Figure 3. The peak number of CAR T cells per microliter of peripheral blood was significantly higher in patients with severe CRS (Figure 4A) and severe neurotoxicity (Figure 4B) compared to those without (p=0.002 and p=0.0015, respectively). The results show that patients with higher peak CAR T cell numbers may show increased risk for severe CRS and neurotoxicity.

[0354] Various biomarkers were evaluated at day 28 in subjects with and without severe CRS for each cohort. Figures 2A, 2B, 2C, and 2D show correlations of peak cytokine levels for IL-6, IFN-γ, Granzyme B, and IL-2, respectively. Some biomarkers showed statistically significant differences between subjects with (yes) and without (no) severe CRS within the same cohort.

[0355] Table 6 shows adverse event data for all subjects in both cohorts (N=43) that were possibly, probably, or definitely related to the study.

[0356] (Table 6) JPEG2024156736000006.jpg52153

[0357] Table 7 shows data on neurotoxicity events for all subjects in both cohorts (N=43) possibly, probably, or definitely related to the study.

[0358] (Table 7) JPEG2024156736000007.jpg38153

[0359] The present invention is not intended to be limited in scope to the specific disclosed embodiments provided, for example, to illustrate various aspects of the invention. From the description and teachings herein, various modifications to the described compositions and methods will become apparent. Such variations can be made without departing from the true scope and spirit of the present disclosure and are intended to be within the scope of the present disclosure.

[0360] array JPEG2024156736000008.jpg203153 JPEG2024156736000009.jpg122153

Claims

1. 1. A medicament for treating, preventing, delaying, or reducing the onset of toxicity in a subject administered adoptive cellular therapy (ACT), comprising: The medicament comprises a monoclonal antibody or an antigen-binding fragment thereof capable of binding to the IL-6 receptor or IL-6, and The medicament is administered to a subject within 24 hours after the first sign of fever following administration of the ACT.

2. The pharmaceutical of claim 1, wherein the subject is a subject determined to have an increased risk for developing said toxicity and has a higher peak number of adoptive cellular therapy (ACT) cells compared to a peak number of ACT cells of a subject having a lower risk for developing said toxicity.

3. The pharmaceutical of claim 1 or 2, wherein the toxicity includes cytokine release syndrome (CRS) or neurotoxicity.

4. The pharmaceutical composition of claim 3, wherein the toxicity is severe neurotoxicity or severe cytokine release syndrome (CRS).

5. The pharmaceutical composition according to any one of claims 1 to 4, wherein the monoclonal antibody or antigen-binding fragment thereof is selected from the group consisting of tocilizumab, sarilumab, siltuximab, olokizumab, elcilimomab, clazakizumab (ALD518 or BMS-945429), sirukumab, CPSI-2634, ARGX-109, FE301, and FM101.

6. The pharmaceutical according to any one of claims 1 to 5, wherein the monoclonal antibody or antigen-binding fragment thereof comprises tocilizumab.

7. The pharmaceutical composition of any one of claims 1 to 6, wherein the monoclonal antibody or antigen-binding fragment thereof is administered to the subject within about 16 hours after the first signs of fever.

8. The pharmaceutical composition according to any one of claims 1 to 7, wherein the monoclonal antibody or antigen-binding fragment thereof is administered less than 5 days after the start of administration of the adoptive cellular therapy (ACT).

9. (i) The fever is persistent; (ii) The fever does not subside after treatment with antipyretic medication; and / or (iii) the fever includes a temperature of at least 38.0°C; The pharmaceutical composition according to any one of claims 1 to 8.

10. The pharmaceutical composition according to any one of claims 1 to 10, which is administered to the subject in combination with a steroid.

11. The steroid is (i) within 9 days after initiation of administration of the adoptive cellular therapy (ACT); (ii) within 24 hours after the first sign of hypotension after initiation of administration of the ACT; (iii) when the subject exhibits grade 2 cytokine release syndrome (CRS) following initiation of administration of the ACT or within 24 hours after the subject exhibits the first signs of grade 2 CRS; and / or (iv) following initiation of administration of the ACT, when the subject exhibits grade 2 neurotoxicity or within 24 hours after the subject exhibits the first sign or symptom of grade 2 neurotoxicity. The pharmaceutical composition of claim 10 , which is administered to the subject.

12. The pharmaceutical according to claim 10 or 11, wherein the steroid comprises dexamethasone or prednisone.

13. The pharmaceutical composition according to any one of claims 1 to 12, wherein the adoptive cellular therapy (ACT) is performed to treat cancer.

14. The pharmaceutical composition of claim 13, wherein the cancer is leukemia or lymphoma.

15. The pharmaceutical composition of claim 13 or 14, wherein the cancer is non-Hodgkin's lymphoma (NHL) or acute lymphoblastic leukemia (ALL).

16. The pharmaceutical agent of any one of claims 1 to 15, wherein the adoptive cell therapy (ACT) comprises chimeric antigen receptor (CAR) T cells.

17. The pharmaceutical composition of claim 16, wherein the CAR T cell is a CD4+ T cell or a CD8+ T cell.

18. The pharmaceutical agent of claim 16 or 17, wherein the CAR T cells are autologous to the subject.

19. The pharmaceutical agent of any one of claims 16 to 18, wherein the CAR T cells comprise an anti-CD19 CAR.

Citation Information

Patent Citations

  • Toxicity management for the antitumor activity of CARs

    JP2015522081A

  • Early intervention to prevent or ameliorate toxicity

    JP2022088489A